0001892480true Hempacco Co., Inc. (the
“Company”) is filing this amendment on Form
10-Q/A for the quarter ended September 30, 2022, to amend the
Quarterly Report on Form 10-Q that was originally filed on November
15, 2022 (the "Original 10-Q") to provide the required interactive
data files in connection with the Company’s financial
statements and to make other minor changes to the Original 10-Q.
00001000000084780002337321300800000000000847800000000000196955320.7516803970200001293620000thirty
months56592one
year49445933330900018924802022-01-012022-09-300001892480hpco:HempaccoMember2022-02-090001892480hpco:StickItLabsLtdMember2022-01-012022-01-310001892480hpco:CheechAndChongsCannabisCompanyMember2022-01-012022-01-310001892480us-gaap:SubsequentEventMemberhpco:AlfalfaHoldingsLLCMember2022-10-012022-10-120001892480us-gaap:SubsequentEventMemberhpco:SonoraPaperCoIncMember2022-10-012022-10-120001892480us-gaap:SubsequentEventMemberhpco:HighSierraTechnologiesIncMember2022-10-012022-10-120001892480us-gaap:SubsequentEventMember2022-10-012022-10-040001892480us-gaap:SubsequentEventMember2022-10-012022-10-1200018924802022-01-060001892480hpco:GGIIAndRelatedEntitiesMember2022-09-300001892480hpco:NorthEquitiesCorpMember2022-09-012022-09-170001892480hpco:BousteadSecuritiesLLCMember2022-09-060001892480hpco:SeptemberOneTwoZeroTwentyTwoMemberhpco:BousteadSecuritiesLLCMember2022-09-300001892480hpco:SeptemberOneTwoZeroTwentyTwoMemberhpco:BousteadSecuritiesLLCMember2022-01-012022-09-300001892480hpco:SeptemberOneTwoZeroTwentyTwoMemberhpco:BousteadSecuritiesLLCMember2021-12-012021-12-1400018924802022-07-1500018924802022-07-012022-07-1500018924802021-04-070001892480hpco:FamilyTrustOfJerryHalamudaMember2021-12-012021-12-140001892480hpco:FamilyTrustOfJerryHalamudaMember2021-12-140001892480hpco:CFOAndDrStuartTitusMember2022-01-012022-09-300001892480hpco:CFOAndDrStuartTitusMember2021-12-060001892480hpco:CFOAndDrStuartTitusMember2021-12-012021-12-0600018924802021-08-012021-08-110001892480hpco:GGIIWarrantsMember2021-05-210001892480hpco:MexicoFranchiseOpportunitiesFundMember2021-05-012021-05-210001892480hpco:ConsultantMember2021-05-012021-05-2100018924802021-09-280001892480hpco:GGIICommonStockMemberhpco:ConsultantMember2021-05-012021-05-210001892480hpco:MexicoFranchiseOpportunitiesFundMember2021-05-200001892480hpco:MexicoFranchiseOpportunitiesFundMember2021-05-012021-05-200001892480hpco:HempaccoSeriesAPreferredSharesMember2021-05-012021-05-2000018924802021-04-012021-04-070001892480hpco:Cube17INCMember2020-12-310001892480hpco:USTMexicoIncMember2020-01-012020-12-310001892480hpco:USTMexicoIncMember2021-01-012021-12-310001892480hpco:GreenGlobeInternationalIncMember2022-01-012022-09-300001892480hpco:GreenGlobeInternationalIncMember2022-03-012022-09-300001892480hpco:LakeComoMember2021-12-310001892480hpco:LakeComoMember2022-09-300001892480hpco:USTMexicoIncMember2021-01-012021-09-300001892480hpco:USTMexicoIncMember2022-01-012022-09-300001892480hpco:StrategicGlobalPartnersIncMember2022-09-300001892480hpco:StrategicGlobalPartnersIncMember2021-12-310001892480hpco:StrategicGlobalPartnersIncMember2021-01-012021-09-300001892480hpco:StrategicGlobalPartnersIncMember2022-01-012022-09-300001892480hpco:StrategicGlobalPartnersIncMember2021-05-012021-05-210001892480hpco:StrategicGlobalPartnersIncMember2021-05-012021-05-310001892480hpco:PrimusLogisticsMember2021-05-210001892480hpco:PrimusLogisticsMember2021-05-012021-05-210001892480hpco:GreenGlobeInternationalIncMember2021-05-012021-05-210001892480hpco:Cube17INCMember2021-12-310001892480hpco:Cube17INCMember2022-03-310001892480hpco:Cube17INCMember2021-01-012021-03-310001892480hpco:Cube17INCMember2022-01-012022-03-310001892480hpco:Cube17INCMember2021-05-012021-05-210001892480hpco:Cube17INCMember2021-05-210001892480hpco:Cube17INCMember2021-05-012021-05-310001892480hpco:USTMexicoIncMember2020-12-310001892480hpco:PrimusLogisticsMember2020-12-310001892480hpco:GreenGlobeInternationalIncMember2022-09-300001892480hpco:PrimusLogisticsMember2021-12-310001892480hpco:PrimusLogisticsMember2022-09-300001892480hpco:USTMexicoIncMember2021-12-310001892480hpco:USTMexicoIncMember2022-09-300001892480hpco:ThirdPartyLoanAgreementMember2022-01-012022-09-300001892480hpco:ThirdPartyLoanAgreementMember2021-12-310001892480hpco:ThirdPartyLoanAgreementMember2022-09-300001892480hpco:ThirdPartyLoanAgreementMember2020-06-012020-06-150001892480hpco:ThirdPartyLoanAgreementMember2021-01-012021-01-150001892480hpco:BrockerRepresentationAgreementsMember2021-08-012021-08-110001892480hpco:GGIIWarrantsMember2021-08-012021-08-110001892480hpco:GGIIWarrantsMember2021-06-090001892480hpco:HempaccoWarrantsMember2021-03-012021-03-310001892480hpco:HempaccoWarrantsMember2021-02-280001892480hpco:BrockerRepresentationAgreementsMember2021-11-230001892480srt:MinimumMemberhpco:WarrantsMember2021-01-012021-12-310001892480srt:MaximumMemberhpco:WarrantsMember2021-12-310001892480srt:MinimumMemberhpco:WarrantsMember2022-01-012022-09-300001892480srt:MaximumMemberhpco:WarrantsMember2022-01-012022-09-300001892480srt:MaximumMemberhpco:WarrantsMember2022-09-300001892480srt:MinimumMemberhpco:WarrantsMember2022-09-300001892480srt:MinimumMemberhpco:WarrantsMember2021-12-310001892480hpco:WarrantsMember2022-01-012022-09-300001892480hpco:WarrantsMember2021-01-012021-12-310001892480srt:MaximumMemberhpco:WarrantsMember2021-01-012021-12-310001892480hpco:ConvertiblePromissoryNotesMember2020-06-012020-06-300001892480hpco:ConvertiblePromissoryNotesMember2022-06-012022-06-180001892480hpco:ConvertiblePromissoryNotesMember2022-03-012022-03-180001892480hpco:ConvertiblePromissoryNotesMember2022-03-180001892480hpco:ConvertiblePromissoryNotesMember2020-07-230001892480hpco:ConvertiblePromissoryNotesMember2020-12-310001892480hpco:ConvertiblePromissoryNotesMember2021-02-160001892480hpco:RelatedPartyMember2020-12-310001892480hpco:RelatedPartyMember2020-06-300001892480hpco:RelatedPartyMember2022-06-070001892480hpco:RelatedPartyMember2020-02-012020-02-170001892480hpco:RelatedPartyMember2020-02-170001892480hpco:ConvertiblePromissoryNotesMember2022-06-070001892480hpco:ConvertiblePromissoryNotesMember2021-01-012021-12-310001892480hpco:ConvertiblePromissoryNotesMember2021-05-210001892480hpco:ConvertiblePromissoryNotesMember2021-12-310001892480hpco:ConvertiblePromissoryNotesMember2021-05-012021-06-210001892480hpco:ConvertiblePromissoryNotesMember2020-07-012020-07-230001892480hpco:ConvertiblePromissoryNotesMember2021-02-012021-02-160001892480us-gaap:ShortTermDebtMember2020-01-012020-12-310001892480us-gaap:ShortTermDebtMember2020-12-310001892480us-gaap:ShortTermDebtMember2021-12-310001892480us-gaap:ShortTermDebtMember2022-09-012022-09-060001892480us-gaap:ShortTermDebtMember2022-01-012022-01-060001892480us-gaap:ShortTermDebtMember2021-01-012021-12-310001892480us-gaap:ShortTermDebtMember2022-09-300001892480us-gaap:ShortTermDebtMember2019-12-012019-12-110001892480us-gaap:ShortTermDebtMember2019-12-110001892480hpco:OperatingLeaseMember2020-01-012020-12-310001892480hpco:OperatingLeaseMember2021-01-012021-09-300001892480hpco:OperatingLeaseMember2022-09-300001892480hpco:OperatingLeaseMember2021-01-012021-12-310001892480hpco:OperatingLeaseMember2021-12-310001892480hpco:OperatingLeaseMember2020-12-310001892480hpco:OperatingLeaseMember2022-01-012022-09-300001892480hpco:KiosksPlusImprovementsMember2022-09-300001892480us-gaap:LeaseholdImprovementsMember2022-09-300001892480hpco:ProductionEquipmentMember2022-09-300001892480hpco:KiosksPlusImprovementsMember2020-12-310001892480us-gaap:LeaseholdImprovementsMember2020-12-310001892480hpco:KiosksPlusImprovementsMember2021-12-310001892480us-gaap:LeaseholdImprovementsMember2021-12-310001892480hpco:ProductionEquipmentMember2021-12-310001892480hpco:ProductionEquipmentMember2020-12-310001892480hpco:CustomerMember2021-12-310001892480hpco:Customer3Member2022-09-300001892480hpco:Customer3Member2021-12-310001892480hpco:Customer3Member2022-01-012022-09-300001892480hpco:Customer2Member2021-12-310001892480hpco:Customer2Member2022-09-300001892480hpco:CustomerMember2022-09-300001892480hpco:CustomerMember2022-01-012022-09-300001892480hpco:ProductionEquipmentMember2021-01-012021-12-310001892480us-gaap:LeaseholdImprovementsMember2021-01-012021-12-310001892480hpco:KiosksMember2021-01-012021-12-310001892480us-gaap:ConvertibleNotesPayableMember2020-01-012020-12-310001892480us-gaap:ConvertibleNotesPayableMember2021-01-012021-12-310001892480us-gaap:ConvertibleNotesPayableMember2021-01-012021-09-300001892480us-gaap:ConvertibleNotesPayableMember2022-01-012022-09-300001892480hpco:StickItUSSecondMember2022-09-120001892480hpco:StickItUSMember2022-09-012022-09-120001892480hpco:StickItUSFirstMember2022-09-120001892480hpco:StickItUSMember2022-09-120001892480hpco:StickItUSSecondMember2022-01-012022-09-300001892480hpco:StickItUSFirstMember2022-01-012022-09-300001892480hpco:SecondJVagreementMember2022-01-012022-09-300001892480hpco:FirstJVAgreementMember2022-01-012022-09-300001892480hpco:GreenGlobeInternationMember2022-01-012022-09-300001892480hpco:GreenGlobeInternationMember2022-09-3000018924802022-09-012022-09-1200018924802022-01-052022-01-1900018924802022-01-012022-01-2000018924802022-08-2900018924802022-01-032022-01-040001892480hpco:JointVentureAgreementMember2022-09-3000018924802022-08-012022-08-290001892480hpco:OneSeptemberTwoThousandTwentyTwoMember2022-01-012022-09-300001892480us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001892480us-gaap:RetainedEarningsMember2022-07-012022-09-300001892480us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001892480us-gaap:PreferredStockMember2022-07-012022-09-300001892480us-gaap:CommonStockMember2022-07-012022-09-3000018924802022-06-300001892480us-gaap:NoncontrollingInterestMember2022-06-300001892480us-gaap:RetainedEarningsMember2022-06-300001892480us-gaap:AdditionalPaidInCapitalMember2022-06-300001892480us-gaap:CommonStockMember2022-06-300001892480us-gaap:PreferredStockMember2022-06-300001892480us-gaap:NoncontrollingInterestMember2022-09-300001892480us-gaap:RetainedEarningsMember2022-09-300001892480us-gaap:AdditionalPaidInCapitalMember2022-09-300001892480us-gaap:CommonStockMember2022-09-300001892480us-gaap:PreferredStockMember2022-09-300001892480us-gaap:NoncontrollingInterestMember2022-01-012022-09-300001892480us-gaap:RetainedEarningsMember2022-01-012022-09-300001892480us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001892480us-gaap:CommonStockMember2022-01-012022-09-300001892480us-gaap:PreferredStockMember2022-01-012022-09-300001892480us-gaap:NoncontrollingInterestMember2021-07-012021-09-300001892480us-gaap:RetainedEarningsMember2021-07-012021-09-300001892480us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001892480us-gaap:CommonStockMember2021-07-012021-09-300001892480us-gaap:PreferredStockMember2021-07-012021-09-3000018924802021-06-300001892480us-gaap:NoncontrollingInterestMember2021-06-300001892480us-gaap:RetainedEarningsMember2021-06-300001892480us-gaap:AdditionalPaidInCapitalMember2021-06-300001892480us-gaap:CommonStockMember2021-06-300001892480us-gaap:PreferredStockMember2021-06-3000018924802021-09-300001892480us-gaap:NoncontrollingInterestMember2021-09-300001892480us-gaap:RetainedEarningsMember2021-09-300001892480us-gaap:AdditionalPaidInCapitalMember2021-09-300001892480us-gaap:CommonStockMember2021-09-300001892480us-gaap:PreferredStockMember2021-09-300001892480us-gaap:NoncontrollingInterestMember2021-01-012021-09-300001892480us-gaap:RetainedEarningsMember2021-01-012021-09-300001892480us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001892480us-gaap:CommonStockMember2021-01-012021-09-300001892480us-gaap:PreferredStockMember2021-01-012021-09-300001892480us-gaap:NoncontrollingInterestMember2021-12-310001892480us-gaap:RetainedEarningsMember2021-12-310001892480us-gaap:AdditionalPaidInCapitalMember2021-12-310001892480us-gaap:CommonStockMember2021-12-310001892480us-gaap:PreferredStockMember2021-12-310001892480us-gaap:NoncontrollingInterestMember2021-01-012021-12-310001892480us-gaap:RetainedEarningsMember2021-01-012021-12-310001892480us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001892480us-gaap:CommonStockMember2021-01-012021-12-310001892480us-gaap:PreferredStockMember2021-01-012021-12-310001892480us-gaap:NoncontrollingInterestMember2020-12-310001892480us-gaap:RetainedEarningsMember2020-12-310001892480us-gaap:AdditionalPaidInCapitalMember2020-12-310001892480us-gaap:CommonStockMember2020-12-310001892480us-gaap:PreferredStockMember2020-12-310001892480us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001892480us-gaap:RetainedEarningsMember2020-01-012020-12-310001892480us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001892480us-gaap:CommonStockMember2020-01-012020-12-310001892480us-gaap:PreferredStockMember2020-01-012020-12-3100018924802019-12-310001892480us-gaap:NoncontrollingInterestMember2019-12-310001892480us-gaap:RetainedEarningsMember2019-12-310001892480us-gaap:AdditionalPaidInCapitalMember2019-12-310001892480us-gaap:CommonStockMember2019-12-310001892480us-gaap:PreferredStockMember2019-12-3100018924802021-01-012021-09-3000018924802021-01-012021-12-3100018924802020-01-012020-12-3100018924802021-07-012021-09-3000018924802022-07-012022-09-300001892480us-gaap:SeriesAPreferredStockMember2021-12-310001892480us-gaap:SeriesAPreferredStockMember2020-12-310001892480us-gaap:SeriesAPreferredStockMember2022-09-3000018924802020-12-3100018924802021-12-3100018924802022-09-30iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureutr:sqftutr:acrehpco:integer
As filed with the Securities and Exchange Commission on February 3,
2023
Registration No. 333-_____
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF
1933
Hempacco Co.,
Inc.
|
(Exact name of registrant as specified in its
charter)
|
Nevada
|
|
2111
|
|
83-4231457
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Primary Standard Industrial
Classification Code Number)
|
|
(I.R.S. Employer
Identification Number)
|
9925 Airway Road,
San Diego, CA, 92154
(619)
779-0715
(Address, including zip code, and telephone number, including area
code, of registrant's principal executive offices)
Sandro Piancone
Chief Executive Officer
9925 Airway Road,
San Diego, CA, 92154
(619)
779-0715
(Names, address, including zip code, and telephone number,
including area code, of agent for service)
Copies to:
Lance Brunson, Esq.
Callie Tempest Jones, Esq.
Brunson Chandler & Jones, PLLC
Walker Center
175 S. Main Street, Suite 1410
Salt Lake City, UT 84111
(801) 303-5737
|
Louis A. Bevilacqua, Esq.
Bevilacqua PLLC
1050 Connecticut Avenue, NW, Suite 500
Washington, DC 20036
(202) 869-0888
|
Approximate date of commencement of proposed sale to the
public: As soon as practicable after this Registration
Statement becomes effective.
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box. ☐
If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration
statement number of the earlier effective registration statement
for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier
effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule
462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier
effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
smaller reporting company, or an emerging growth company. See the
definitions of "large accelerated filer," "accelerated filer,"
"smaller reporting company," and "emerging growth company" in Rule
12b-2 of the Exchange Act.
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
|
|
Emerging growth company
|
☐
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for comply with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
The registrant hereby amends this registration statement on
such date or dates as may be necessary to delay its effective date
until the registrant shall file a further amendment which
specifically states that this registration statement shall
thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the registration statement
shall become effective on such date as the Commission, acting
pursuant to such Section 8(a), may determine.
The information in this prospectus is not complete and may
be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is
effective. This prospectus is not an offer to sell these securities
and it is not soliciting offers to buy these securities in any
state where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED FEBRUARY 3, 2023
PRELIMINARY PROSPECTUS

Hempacco Co., Inc.
4,729,729 Shares of Common Stock
We
are offering up to 4,729,729 shares of our common stock in a
firm commitment public offering. We currently estimate that the
public offering price will be $1.11 per share.
Our common stock is listed on the Nasdaq Capital Market under the
symbol "HPCO." On February 2, 2023, the last reported sale price of
our common stock on the Nasdaq Capital Market was $1.11 per
share.
After completion of this offering, investors in the offering will
own approximately 16.8% of our outstanding shares of common
stock, other investors will own approximately 20.8% of our
outstanding shares of common stock, and approximately 62.4% of our
outstanding common stock will be owned by Green Globe
International, Inc., a Delaware corporation. Accordingly, we
are a “controlled company” under Nasdaq corporate governance rules
and are eligible for certain exemptions from these rules, though we
do not intend to rely on any such exemptions. See
“Risk Factors – We will be a ‘controlled company’ within the
meaning of the listing rules of Nasdaq and, as a result, can rely
on exemptions from certain corporate governance requirements that
provide protection to shareholders of other companies” on
page 24 for more information.
Investing in our common stock involves a high degree of
risk. See the section of this prospectus entitled "Risk Factors"
beginning on page 11 for a discussion of information that should be
considered in connection with an investment in our common
stock.
Neither the United States Securities and Exchange
Commission (the "SEC") nor any state securities commission has
approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the
contrary is a criminal offense.
|
|
PER SHARE
|
|
|
TOTAL (4)
|
|
Public offering price(1)
|
|
$ |
1.11
|
|
|
$ |
5,249,999
|
|
Underwriting discounts and commissions(2)
|
|
$ |
0.08
|
|
|
$ |
367,500
|
|
Proceeds, before expenses, to us(3)
|
|
$ |
1.03
|
|
|
$ |
4,882,449
|
|
(1)
|
The public offering price per share is estimated to be $1.11 per
share.
|
(2)
|
We have agreed to pay the underwriter a discount equal to (i) 7% of
the gross proceeds of the offering. We have agreed to sell to the
Representatives, on the applicable closing date of this offering,
warrants in an amount equal to 7% of the aggregate number of shares
of common stock sold by us in this offering (the "Representatives’
Warrants") (not including over-allotment shares). For a description
of other terms of the Representatives’ Warrants and a description
of the other compensation to be received by the Underwriter, see
"Underwriting" beginning on page 61.
|
(3)
|
Excludes fees and expenses payable to the Underwriter. The total
amount of Underwriter's expenses related to this offering is set
forth in the section entitled "Underwriting."
|
(4)
|
Assumes that the Underwriter does not exercise any portion of their
over-allotment option.
|
We expect our total cash expenses for this offering (including cash
expenses payable to our Underwriter for its out-of-pocket expenses)
to be approximately $188,712, exclusive of the above discounts. In
addition, we will pay additional items of value in connection with
this offering that are viewed by the Financial Industry Regulatory
Authority, or FINRA, as underwriting compensation. These payments
will further reduce proceeds available to us before expenses. See
"Underwriting" beginning on page 61.
This offering is being conducted on a firm commitment basis. The
underwriter, Boustead Securities, LLC (the "Underwriter"), is
obligated to take and pay for all of the shares of common stock if
any such shares of common stock are taken. We have granted the
Underwriter an option for a period of 45 days after the closing of
this offering to purchase up to 15% of the total number of our
shares of common stock to be offered by us pursuant to this
offering (excluding shares of common stock subject to this option),
solely for the purpose of covering over-allotments, at the public
offering price less the underwriting discounts and commissions. If
the underwriters exercise their option in full, the total
underwriting discounts and commissions payable will be $422,625
based on the estimated offering price of $1.11 per share, and
the total gross proceeds to us, before underwriting discounts and
commissions and expenses, will be $6,037,499. If we complete this
offering, net proceeds will be delivered to us on the applicable
closing date.
The Underwriter expects to deliver the shares of common stock
against payment as set forth under "Underwriting", on or about
_____________, 2023.
BOUSTEAD SECURITIES, LLC
|
|
EF HUTTON
|
|
|
Division of Benchmark Investments, LLC
|
Prospectus dated February 3, 2023.
TABLE OF
CONTENTS
Please read this prospectus carefully. It describes our
business, financial condition, results of operations and prospects,
among other things. We are responsible for the information
contained in this prospectus and in any free-writing prospectus we
have authorized. Neither we nor the underwriters have authorized
anyone to provide you with different information, and neither we
nor the underwriters take responsibility for any other information
others may give you. Neither we nor the underwriters are making an
offer to sell these securities in any jurisdiction where the offer
or sale is not permitted. The information contained in this
prospectus is accurate only as of the date on the front of this
prospectus, regardless of the time of delivery of this prospectus
or any sale of securities. You should not assume that the
information contained in this prospectus is accurate as of any date
other than its date.
TRADEMARKS, TRADE NAMES AND SERVICE MARKS
We use various trademarks, trade names and service marks in our
business, including "Disrupting Tobacco," "HempBox," "Hempbar,"
"The Real Stuff," "Solito," and "Cali Vibes D8." For convenience,
we may not include the SM, ® or ™ symbols, but such omission is not
meant to indicate that we would not protect our intellectual
property rights to the fullest extent allowed by law. Any other
trademarks, trade names or service marks referred to in this
prospectus are the property of their respective owners.
INDUSTRY AND MARKET DATA
This prospectus includes industry data and forecasts that we
obtained from industry publications and surveys including but not
limited to certain publications of Hemp Industry Daily - Sector
Snapshot - Smokable Hemp, as well as public filings and
internal company sources. Industry publications, surveys and
forecasts generally state that the information contained therein
has been obtained from sources believed to be reliable, but there
can be no assurance as to the accuracy or completeness of the
included information. Statements as to our ranking, market position
and market estimates are based on third-party forecasts,
management's estimates and assumptions about our markets and our
internal research. We have not independently verified such
third-party information, nor have we ascertained the underlying
economic assumptions relied upon in those sources, and we cannot
assure you of the accuracy or completeness of such information
contained in this prospectus. Such data involve risks and
uncertainties and is subject to change based on various factors,
including those discussed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements."
PROSPECTUS
SUMMARY
This summary highlights selected information contained
elsewhere in this prospectus. This summary is not complete and does
not contain all of the information that you should consider before
deciding whether to invest in our securities. You should carefully
read the entire prospectus, including the risks associated with an
investment in our company discussed in the "Risk Factors" section
of this prospectus, before making an investment decision. Some of
the statements in this prospectus are forward-looking statements.
See the section titled "Cautionary Statement Regarding
Forward-Looking Statements."
In this prospectus, "we," "us," "our," "our company" and
similar references refer to Hempacco Co., Inc., a Nevada
corporation formerly known as The Hempacco Co., Inc.
OUR COMPANY
Overview
We are focused on Disrupting Tobacco™ by manufacturing and selling
nicotine-free and tobacco-free alternatives to traditional
cigarettes. We utilize a proprietary, patented spraying technology
for terpene infusion and patent-pending flavored filter infusion
technology to manufacture hemp and herb-based smokable
alternatives.
We have conducted research and development in the smokables space
and are engaged in the manufacturing and sale of smokable hemp and
herb products, including The Real Stuff™ Hemp Smokables. Our
operational segments include private label manufacturing and sales,
intellectual property licensing, and the development and sales of
inhouse brands using patented counter displays. Our inhouse brands
are currently sold in over 200 retail locations located in the San
Diego, California, area, our private label customers include
well-known and established companies in the cannabis and
tobacco-alternatives industries, and we currently own approximately
600 kiosk vending machines which we plan to refurbish and use to
distribute our products in a wider fashion under our HempBox
Vending brand.
Our hemp cigarette production facility, located in San Diego,
California, has the capacity to produce up to 30 million cigarettes
monthly. From our facility, we can ship small-to-large quantities
of product—from single displays of product to targeted retail
locations to truckloads of product to private label customers—with
in-house processing, packing, and shipping capabilities.
We believe that our manufacturing technologies will be a critical
component of our success. We plan to continue to invest in research
and development, and we currently have one approved patent and one
patent pending with respect to our critical manufacturing
processes. Our approved patent is an exclusivity patent to spray
hemp with terpenes for flavoring or to add cannabidiol, which we
refer to as CBD, or cannabigerol, which we refer to as CBG, and our
pending patent relates to our flavored filter infusion technology.
We also have several ready-to-file patent applications with respect
to hemp manufacturing, hemp processing, design patents for hemp
machines and merchandisers, and customized manufacturing
equipment.
We believe that we are positioned to rapidly grow our customer and
product footprint through increasing marketing efforts, reaching
agreements with master distributors who will sell to a broad
network of retail establishments, and aggressively targeting
additional distributors throughout the United States. We plan to
drive and increase customer traffic with internet marketing to or
with the clients that carry our products.
We have experienced operating losses to date and negative cash
flows from operating activities. We expect to continue to incur
significant expenses related to our expanding operations and to
generate operating losses in the near future. The size of our
losses will depend, in part, on the rate of future expenditures and
our ability to generate revenues. We incurred a net loss of
$1,049,473 and $2,024,039 for the three and nine months ended
September 30, 2022, respectively, a net loss of $1,870,675 for the
year ended December 31, 2021, our accumulated deficit increased to
$5,490,216 as of September 30, 2022, we had a working capital
surplus of $3,558,716 as of September 30, 2022, and we had cash and
cash equivalents of $2,973,686 as of September 30, 2022.
Although our audited financial statements for the years ended
December 31, 2021 and 2020, were prepared under the assumption that
we would continue our operations as a going concern, the report of
our independent registered public accounting firm that accompanies
our financial statements for the years ended December 31, 2021 and
2020, contains a going concern qualification in which such firm
expressed substantial doubt about our ability to continue as a
going concern, based on our financial statements and results at
that time, including our net loss of $1,870,675 during the year
ended December 31, 2021, our accumulated deficit of $3,459,214 as
of December 31, 2021, and our working capital deficit of $2,050,626
as of December 31, 2021.
Our Products
We have launched the production and sale of our own in-house brand
of hemp-based cigarettes, The Real Stuff Smokables, in three
presentations: the twenty pack, the ten pack, and the Solito™
single pack, all of which are sold in our patented counter displays
in convenience stores through master distributors.
We have also entered into several joint ventures to launch multiple
smokables brands: Cali Vibes D8, a joint venture focused on Delta 8
smokable products; Hemp Hop Smokables, a joint venture with rapper
Rick Ross and Rap Snack's CEO James Lindsay; a joint venture with
StickIt Ltd., an Israeli corporation, to manufacture cannabinoid
sticks for insertion into other cigarettes; a joint venture to
launch Cheech & Chong-branded hemp smokables; Hempacco Paper
Co., Inc., a joint venture with Sonora Paper Co., Inc. focused on
rolling papers; Organipure, Inc., a joint venture with High Sierra
Technologies, Inc. focused on hemp smokables; and HPDG, LLC, a
joint venture to launch smokables products with Alfalfa Holdings,
LLC.
We have launched a brand of flavored hemp rolling papers, and we
also manufacture private label hemp rolling papers for third
parties. We are currently manufacturing hemp rolling papers for HBI
International, one of the leading smoking paper producers in the
world, and in the fall of 2021, we received our largest purchase
order to date for approximately $9.2 million from HBI
International's Skunk and Juicy brand to manufacture hemp
rolling papers for it.
|
Our products include the following:

Competitive Strengths
We believe our manufacturing technologies, manufacturing facility
manufacturing capacity, and management with extensive industry
experience are strengths that set us apart from our
competitors. Our manufacturing facility can quickly scale up
production volumes, our management team has extensive experience in
the cigarette and food and beverage industries, and because of our
manufacturing technologies, which allow us to spray hemp with
terpenes for flavoring or to add CBD or CBG, and add flavoring via
our filter infusion technology, we believe our smokables products
offer consistent and unique flavor and odor profiles to consumers,
which we believe sets our products apart from competing products,
which may lack flavor and odor consistency or smell like marijuana
when smoked.
Growth Strategy
We seek to become the leader in sales and distribution of
alternative smokable products. We aim to offer our products and
affiliate products in over 100,000 convenience and liquor stores in
the United States, and we also intend to build international sales
and distribution channels for our products and affiliate products.
Our goal is to build a portfolio of non-tobacco smokables brands,
become the United States market leader in the space, and
subsequently build exclusive master distribution relationships in
other countries. We plan to do this in four ways:
|
|
|
|
|
●
|
We intend to focus on growing our fast-moving consumer goods
brands, such as our "The Real Stuff" smokables and "Hempbar," our
line of "liquor flavored" infused hemp smokables for sale in liquor
stores and bars.
|
|
●
|
We plan to build a portfolio of patents and technologies, which
should allow us to protect and grow our competitive position in the
industry.
|
|
●
|
We intend to expand our manufacturing capabilities.
|
|
●
|
We plan to increase sales by focusing on master distributor
relationships, e-commerce sales, and distribution of our brands,
and joint venture brands.
|
|
|
|
Our Corporate History and Structure
We were incorporated in the State of Nevada on April 1, 2019, as
"The Hempacco Co., Inc.," and on April 23, 2021, changed our name
to "Hempacco Co., Inc." On May 21, 2021, we were acquired by Green
Globe International, Inc., a Delaware corporation (“Green Globe”),
and became a wholly owned subsidiary of it, and as of immediately
prior to this offering, we are a majority-owned subsidiary of Green
Globe International, Inc., with Green Globe International, Inc.
owning approximately 78.7% of our capital stock. Additional
information regarding our corporate history and transactions in
connection with our prior acquisition by Green Globe are discussed
more fully in the "Our Corporate History and Structure"
section of “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” beginning on page 31.
|
Impact of the COVID-19 Pandemic
In December 2019, a novel coronavirus disease ("COVID-19") was
reported to have surfaced in Wuhan, China, and on March 11, 2020,
the World Health Organization characterized COVID-19 as a pandemic.
The pandemic, which has continued to spread, and the related
adverse public health developments, including orders to
shelter-in-place, travel restrictions, and mandated business
closures, have adversely affected workforces, organizations,
customers, economies, and financial markets globally, leading to an
economic downturn and increased market volatility. It has also
disrupted the normal operations of many businesses, including
ours.
Our operations have been impacted by a range of external factors
related to the pandemic that are not within our control. For
example, many cities, counties, states, and even countries have
imposed or may impose a wide range of restrictions on the physical
movement of our employees, partners and customers to limit the
spread of the pandemic, including physical distancing, travel bans
and restrictions, closure of non-essential business, quarantines,
work-from-home directives, shelter-in-place orders, and limitations
on public gatherings. These measures have caused, and are
continuing to cause, business slowdowns or shutdowns in affected
areas, both regionally and worldwide. In 2020, we temporarily
scaled down sales efforts at trade shows and with customers and
potential customers in in-person meetings, and we were forced to
source ingredients for some of the components of our products from
alternative suppliers. These changes disrupted our business, and
similar changes in the future may disrupt the way we operate our
business. In addition, our management team has, and will likely
continue, to spend significant time, attention and resources
monitoring the pandemic and seeking to minimize the risk of the
virus and manage its effects on our business.
The duration and extent of the impact from the pandemic depends on
future developments that cannot be accurately predicted at this
time, such as the severity and transmission rate of the virus, the
extent and effectiveness of containment actions and the disruption
caused by such actions, the effectiveness of vaccines and other
treatments for COVID-19, and the impact of these and other factors
on our employees, customers, partners and vendors. If we are not
able to respond to and manage the impact of such events
effectively, our business will be harmed.
To the extent the pandemic adversely affects our business and
financial results, it may also have the effect of heightening many
of the other risks described in the "Risk Factors" section.
Corporate Information
We are currently incorporated and in good standing in the State of
Nevada. Our principal executive offices are located at 9925 Airway
Road, San Diego, California, 92154, and our telephone number is
(619) 779-0715. We maintain a website at https://hempaccoinc.com/.
Information available on our website is not incorporated by
reference in and is not deemed a part of this prospectus, and you
should not consider any information contained on, or that can be
accessed through, our website as part of this prospectus or in
deciding whether to purchase our common stock.
|
THE OFFERING
|
|
|
|
Shares being offered:
|
|
Up
to 4,729,729 shares of common stock (or 5,439,188 shares if
the underwriter exercises the over-allotment option in full).
|
|
|
|
Offering price:
|
|
We
currently estimate that the public offering price will be $1.11 per
share.
|
|
|
|
Shares outstanding immediately before the offering:
|
|
23,477,999 shares of common stock.
|
|
|
|
Shares outstanding after the offering:
|
|
28,207,728 shares of common stock (or 28,917,187 shares if the
underwriters exercise the over-allotment option in full).
|
|
|
|
Over-allotment option:
|
|
We
have granted to the underwriters a 45-day option to purchase from
us up to an additional 15% of the shares sold in the offering
(709,459 additional shares) at the public offering price, less the
underwriting discounts and commissions.
|
|
|
|
Representatives’ warrants:
|
|
We have agreed to issue to the representatives of the underwriter
(the "Representatives") warrants to purchase a number of shares of
common stock equal in the aggregate to 7% of the total number of
shares issued in this offering. The Representatives’ warrants will
be exercisable at a per share exercise price equal to 100% of the
public offering price per share of common stock sold in this
offering. The Representatives’ warrants will be exercised at any
time, and from time to time, in whole or in part, commencing from
the closing of the offering and expiring five (5) years from the
effectiveness of the offering. The registration statement of which
this prospectus forms a part also registers the issuance of the
shares of common stock issuable upon exercise of the
Representatives’ warrants. See the "Underwriting" section
for more information.
|
|
|
|
Use of proceeds:
|
|
We
expect to receive net proceeds of approximately $4,641,287 from
this offering (or approximately $5,365,787 if the underwriters
exercise their over-allotment option in full), based on the
estimated public offering price of $1.11 per share and no
exercise of the underwriters' over-allotment option, and after
deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. We plan to use the net
proceeds of this offering for sales, marketing and advertising
initiatives; acquisitions of companies and technologies aligned and
synergistic with our manufacturing technologies and growth
objectives; expansion and upgrades to our existing manufacturing
facility; research and development; hiring sales and other
employees; expenses associated with being a public company; and
general corporate and working capital purposes. See "Use of
Proceeds" section for more information on the use of
proceeds.
|
|
|
|
Risk factors:
|
|
Investing in our common stock involves a high degree of risk. As an
investor, you should be able to bear a complete loss of your
investment. You should carefully consider the information set forth
in the "Risk Factors" section beginning on page 11 before
deciding to invest in our common stock.
|
|
|
|
Lock-up:
|
|
Our executive officers, directors and our majority shareholder have
agreed not to offer, sell, agree to sell, directly or indirectly,
or otherwise dispose of any shares of our common stock for a
lock-up period through August 30, 2023, and we have agreed not to
offer or sell any shares of stock until September 1, 2023. See
"Underwriting" for more information.
|
|
|
|
Trading market and symbol:
|
|
Our common stock is listed on the Nasdaq Capital Market under the
symbol "HPCO."
|
|
|
|
The number of shares of common stock outstanding immediately
following this offering is based on 23,477,999 shares outstanding
as of February 3, 2023.
|
SUMMARY FINANCIAL INFORMATION
The following tables summarize certain financial data regarding our
business and should be read in conjunction with our financial
statements and related notes contained elsewhere in this prospectus
and the information under "Management's Discussion and Analysis
of Financial Condition and Results of Operations."
Our summary financial data as of December 31, 2021 and 2020, are
derived from our audited financial statements included elsewhere in
this prospectus. Our summary financial data as of September
30, 2022 and 2021, are derived from our unaudited financial
statements included elsewhere in this prospectus. All financial
statements included in this prospectus are prepared and presented
in accordance with generally accepted accounting principles in the
United States ("GAAP"). The summary financial information is only a
summary and should be read in conjunction with the historical
financial statements and related notes contained elsewhere herein.
The financial statements contained elsewhere fully represent our
financial condition and operations; however, they are not
indicative of our future performance.
Although our audited financial statements for the years ended
December 31, 2021 and 2020, were prepared under the assumption that
we would continue our operations as a going concern, the report of
our independent registered public accounting firm that accompanies
our financial statements for the years ended December 31, 2021 and
2020, contains a going concern qualification in which such firm
expressed substantial doubt about our ability to continue as a
going concern, based on our financial statements and results at
that time, including our net loss of $1,870,675 during the year
ended December 31, 2021, our accumulated deficit of $3,459,214 as
of December 31, 2021, and our working capital deficit of $2,050,626
as of December 31, 2021.
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
|
Years Ended
December 31,
|
|
|
|
2022
|
|
|
2021
|
|
|
2022
|
|
|
2021
|
|
|
2021
|
|
|
2020
|
|
|
|
(unaudited)
|
|
|
(unaudited)
|
|
|
(unaudited)
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
Statements of Operations Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$ |
592,235 |
|
|
$ |
425,171 |
|
|
$ |
3,438,458 |
|
|
$ |
911,008 |
|
|
$ |
1,187,273 |
|
|
$ |
345,989 |
|
Cost of Sales
|
|
|
598,627 |
|
|
|
315,281 |
|
|
|
2,795,661 |
|
|
|
613,784 |
|
|
|
850,901 |
|
|
|
899,699 |
|
Gross Profit (Loss) from Operations
|
|
|
(6,392 |
) |
|
|
109,890 |
|
|
|
642,797 |
|
|
|
297,224 |
|
|
|
336,372 |
|
|
|
(553,710 |
) |
Operating Expenses
|
|
|
1,037,538 |
|
|
|
423,679 |
|
|
|
2,638,647 |
|
|
|
1,237,423 |
|
|
|
1,995,705 |
|
|
|
751,279 |
|
Operating Loss
|
|
|
(1,043,930 |
) |
|
|
(313,789 |
) |
|
|
(1,995,850 |
) |
|
|
(940,199 |
) |
|
|
(1,659,333 |
) |
|
|
(1,304,989 |
) |
Other Income / (Expense)
|
|
|
(5,543 |
) |
|
|
(53,514 |
) |
|
|
(28,189 |
) |
|
|
(256,504 |
) |
|
|
(211,342 |
) |
|
|
(160,455 |
) |
Net Loss
|
|
|
(1,049,473 |
) |
|
|
(367,303 |
) |
|
|
(2,024,039 |
) |
|
|
(1,196,703 |
) |
|
|
(1,870,675 |
) |
|
|
(1,465,444 |
) |
Net Loss Attributable to Non-Controlling Interests
|
|
|
617 |
|
|
|
- |
|
|
|
2,200 |
|
|
|
- |
|
|
|
14,250 |
|
|
|
- |
|
Net Loss Attributable to Hempacco Co., Inc.
|
|
|
(1,048,856 |
) |
|
|
(367,303 |
) |
|
|
(2,021,839 |
) |
|
|
(1,196,703 |
) |
|
|
(1,856,425 |
) |
|
|
(1,465,444 |
) |
Dividend Issued to Preferred Stockholders
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(757,479 |
) |
|
|
- |
|
Net Loss Attributable to Common Stockholders
|
|
|
(1,048,856 |
) |
|
|
(367,303 |
) |
|
|
(2,021,839 |
) |
|
|
(1,196,703 |
) |
|
|
(2,613,904 |
) |
|
|
(1,465,444 |
) |
|
|
As of
September 30,
|
|
|
As of
December 31
|
|
|
|
2022
|
|
|
2021
|
|
|
2020
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
Balance Sheet Data
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents
|
|
$ |
2,973,686 |
|
|
$ |
933,469 |
|
|
$ |
500 |
|
Total Current Assets
|
|
|
5,197,591 |
|
|
|
2,117,638 |
|
|
|
101,462 |
|
Total Assets
|
|
|
14,664,060 |
|
|
|
7,570,523 |
|
|
|
5,657,894 |
|
Total Current Liabilities
|
|
|
1,638,875 |
|
|
|
4,168,264 |
|
|
|
2,931,761 |
|
Total Liabilities
|
|
|
2,083,505 |
|
|
|
4,702,863 |
|
|
|
3,435,326 |
|
Accumulated Deficit
|
|
|
(5,490,216 |
) |
|
|
(3,459,214 |
) |
|
|
(1,602,789 |
) |
Total Stockholder's Equity
|
|
|
12,587,842 |
|
|
|
2,881,910 |
|
|
|
2,222,568 |
|
Non-Controlling Interests
|
|
|
(7,287 |
) |
|
|
(14,250 |
) |
|
|
- |
|
Total Equity for Hempacco Co., Inc.
|
|
|
12,580,555 |
|
|
|
2,867,660 |
|
|
|
2,222,568 |
|
Total Liabilities and Stockholder's Equity
|
|
|
14,664,060 |
|
|
|
7,570,523 |
|
|
|
5,657,894 |
|
SUMMARY OF RISK FACTORS
An investment in our common stock involves a high degree of risk.
You should carefully consider the risks summarized below. These
risks are discussed more fully in the "Risk Factors"
section immediately following this Prospectus Summary. These risks
include, but are not limited to, the following:
|
|
|
|
|
·
|
Since inception, we have experienced operating losses and negative
cash flows from operating activities and anticipate that we will
continue to incur operating losses in the near future.
|
|
|
|
|
·
|
If we are not able to successfully execute on our future operating
plans, our financial condition and results of operation may be
materially adversely affected, and we may not be able to continue
as a going concern.
|
|
|
|
|
·
|
We may be unable to effectively manage future growth. We will need
additional financing in the future, which may not be available when
needed or may be costly and dilutive.
|
|
|
|
|
·
|
If we are unable to continue as a going concern, our securities
will have little or no value.
|
|
|
|
|
·
|
We have a limited operating history, and we may not be able to
successfully operate our business or execute our business plan.
|
|
|
|
|
·
|
We may incur significant debt to finance our operations.
|
|
|
|
|
·
|
We compete in an industry that is brand-conscious, so brand name
recognition and acceptance of our products are critical to our
success.
|
|
|
|
|
·
|
Our brand and image are keys to our business and any inability to
maintain a positive brand image could have a material adverse
effect on our results of operations.
|
|
|
|
|
·
|
Competition from traditional and large, well-financed tobacco or
nicotine cigarette manufacturers or distributors may adversely
affect our distribution relationships and may hinder development of
our existing markets, as well as prevent us from expanding our
markets.
|
|
|
|
|
·
|
We compete in an industry characterized by rapid changes in
consumer preferences and public perception, so our ability to
continue developing new products to satisfy our consumers' changing
preferences will determine our long-term success.
|
|
|
|
|
·
|
We may be unable to respond effectively to technological changes in
our industry, which could reduce the demand for our products.
|
|
|
|
|
·
|
We may experience a reduced demand for some of our products due to
health concerns and legislative initiatives against smokables
products.
|
|
|
|
|
·
|
Legislative or regulatory changes that affect our products,
including new taxes, could reduce demand for products or increase
our costs.
|
|
|
|
|
·
|
Our ability to develop, commercialize and distribute hemp smokables
products and comply with laws and regulations governing cannabis,
hemp or related products will affect our operational results.
|
|
|
|
|
·
|
International expansion efforts would likely significantly increase
our operational expenses.
|
|
|
|
|
·
|
Our reliance on distributors, retailers and brokers could affect
our ability to efficiently and profitably distribute and market our
products, maintain our existing markets and expand our business
into other geographic markets.
|
|
|
|
|
·
|
We incur significant time and expense in attracting and maintaining
key distributors, and loss of distributors or retails accounts
would harm our business.
|
|
|
|
|
·
|
We rely on suppliers, manufacturers and contractors, and events
adversely affecting them would adversely affect us.
|
|
|
|
|
·
|
We have a single customer that accounts for a substantial portion
of our revenues, and our business would be harmed were we to lose
this customer.
|
|
|
|
|
·
|
Wholesale price volatility may adversely affect operations.
|
|
·
|
The Company may sustain losses that cannot be recovered through
insurance or other preventative measures.
|
|
|
|
|
·
|
The Company may be subject to product liability claims and other
claims of our customers and partners.
|
|
|
|
|
·
|
If we encounter product recalls or other product quality issues,
our business may suffer.
|
|
|
|
|
·
|
It is difficult to predict the timing and amount of our sales, and
as a result our sales forecasts are uncertain.
|
|
|
|
|
·
|
If we do not adequately manage our inventory levels, our operating
results could be adversely affected.
|
|
|
|
|
·
|
Increases in costs or shortages of raw materials could harm our
business and financial results.
|
|
|
|
|
·
|
Increases in costs of energy and increased regulations may have an
adverse impact on our gross margin.
|
|
|
|
|
·
|
Disruption within our supply chain, contract manufacturing or
distribution channels could have an adverse effect on our business,
financial condition and results of operations.
|
|
|
|
|
·
|
If we are unable to attract and retain key personnel, our
efficiency and operations would be adversely affected; in addition,
staff turnover causes uncertainties and could harm our
business.
|
|
|
|
|
·
|
If we lose the services of our Chief Executive Officer, our future
operations could be impaired until such time as a qualified
replacement can be found.
|
|
|
|
|
·
|
If we fail to protect our trademarks and trade secrets, we may be
unable to successfully market our products and compete
effectively.
|
|
|
|
|
·
|
Disruptions to our information technology systems due to
cyber-attacks or our failure to upgrade and adjust our information
technology systems, may materially impair our operations, hinder
our growth and materially and adversely affect our business and
results of operations.
|
|
|
|
|
·
|
Our business is subject to many regulations and noncompliance is
costly.
|
|
|
|
|
·
|
Significant additional labeling or warning requirements may inhibit
sales of affected products.
|
|
|
|
|
·
|
Our industry may become subject to expanded regulation and
increased enforcement by the Food and Drug Administration (FDA) and
the Federal Trade Commission (FTC)
|
|
|
|
|
·
|
Our business and operations would be adversely impacted in the
event of a failure or interruption of our information technology
infrastructure or as a result of a cybersecurity attack.
|
|
|
|
|
·
|
Our results of operations may fluctuate from quarter to quarter for
many reasons, including seasonality.
|
|
|
|
|
·
|
Global economic, political, social and other conditions, including
the COVID-19 pandemic, may continue to adversely impact our
business and results of operations.
|
|
|
|
|
·
|
We may not be able to satisfy the continued listing requirements of
Nasdaq and maintain a listing of our common stock on Nasdaq.
|
|
|
|
|
·
|
We are majority-owned by Green Globe International, Inc. ("GGII"),
a small group of Company officers and directors hold a majority of
the control of GGII, those officers and directors are able to
control the election of members of GGII’s Board of Directors as
well as the election of members of our Board of Directors, and they
are able to generally exercise control over our affairs.
|
|
|
|
|
·
|
Our executive officers and the majority of our directors are also
officers and directors of GGII, and conflicts of interest may arise
as a result.
|
|
|
|
|
·
|
We are a “controlled company” within the meaning of the listing
rules of Nasdaq and, as a result, can rely on exemptions from
certain corporate governance requirements that provide protection
to shareholders of other companies.
|
|
|
|
|
·
|
During the nine months ended September 30, 2022, GGII advanced
$621,755 in funding to us, and we may need additional funding
from GGII in the future, which may not be available when
needed.
|
RISK FACTORS
An investment in our securities involves a high degree of risk.
You should carefully consider the following risk factors, together
with the other information contained in this prospectus, before
purchasing our securities. We have listed below (not necessarily in
order of importance or probability of occurrence) what we believe
to be the most significant risk factors applicable to us, but they
do not constitute all of the risks that may be applicable to us.
Any of the following factors could harm our business, financial
condition, results of operations or prospects, and could result in
a partial or complete loss of your investment. Some statements in
this prospectus, including statements in the following risk
factors, constitute forward-looking statements. Please refer to the
section titled "Cautionary Statement Regarding Forward-Looking
Statements".
We may not be successful in preventing the material adverse
effects that any of the following risks and uncertainties may
cause. These potential risks and uncertainties may not be a
complete list of the risks and uncertainties facing us. There may
be additional risks and uncertainties that we are presently unaware
of, or presently consider immaterial, that may become material in
the future and have a material adverse effect on us. You could lose
all or a significant portion of your investment due to any of these
risks and uncertainties.
Risks Related to our Financial Condition and Capital
Requirements
Since inception, we have experienced operating losses
and negative cash flows from operating
activities and anticipate
that we will continue to incur operating losses in the near
future.
We have experienced operating losses to date and negative cash
flows from operating activities. We expect to continue to incur
significant expenses related to our expanding operations and to
generate operating losses in the near future. The size of our
losses will depend, in part, on the rate of future expenditures and
our ability to generate revenues. We incurred a net loss of
$1,049,473 and $2,024,039 for the three and nine months ended
September 30, 2022, respectively, a net loss of $1,870,675 for
the year ended December 31, 2021, and our accumulated deficit
increased to $5,490,216 as of September 30, 2022.
We may encounter unforeseen expenses, difficulties, complications,
delays, and other unknown factors that may adversely affect our
financial condition. Our prior losses and expected future losses
have had, and will continue to have, an adverse effect on our
financial condition. If our products do not achieve sufficient
market acceptance and our revenues do not increase significantly,
we may never become profitable. Even if we achieve profitability in
the future, we may not be able to sustain profitability in
subsequent periods. Our failure to become and remain profitable
would decrease the value of our company and could impair our
ability to raise capital, expand our business, diversify our
product offerings or continue our operations. A decline in the
value of our company could cause you to lose all or part of your
investment.
If we are not able to successfully execute on our
future operating plans, our financial condition and results of
operation may be materially adversely affected, and we may not be
able to continue as a going concern.
It is critical that we meet our sales goals and increase sales
going forward as our operating plan already reflects prior
significant cost containment measures and may make it difficult to
achieve top-line growth if further significant reductions become
necessary. If we do not meet our sales goals, our available cash
and working capital will decrease and our financial condition will
be negatively impacted.
We may be unable to effectively manage future
growth.
We may be subject to growth-related risks, including capacity
constraints and pressure on our internal systems and controls. Our
ability to manage growth effectively will require us to continue to
implement and improve our operational and financial systems and to
expand, train and manage our employee base. Rapid growth of our
business may significantly strain our management, operations and
technical resources. If we are successful in obtaining large orders
for its products, we will be required to deliver large volumes of
products to our customers on a timely basis and at a reasonable
cost. We may not obtain large-scale orders for our products and if
we do, we may not be able to satisfy large-scale production
requirements on a timely and cost-effective basis. Our inability to
deal with this growth may have a material adverse effect on our
business, financial condition, results of operations and
prospects.
We will need additional financing in the future, which
may not be available when needed or may be costly and
dilutive.
We will require additional financing to support our working capital
needs in the future. The amount of additional capital we may
require, the timing of our capital needs and the availability of
financing to fund those needs will depend on a number of factors,
including our strategic initiatives and operating plans, the
performance of our business and the market conditions for debt or
equity financing. Additionally, the amount of capital required will
depend on our ability to meet our sales goals and otherwise
successfully execute our operating plan. We believe it is
imperative that we meet these sales objectives in order to lessen
our reliance on external financing in the future. We intend to
continually monitor and adjust our operating plan as necessary to
respond to developments in our business, our markets and the
broader economy. Although we believe various debt and equity
financing alternatives will be available to us to support our
working capital needs, financing arrangements on acceptable terms
may not be available to us when needed. Additionally, these
alternatives may require significant cash payments for interest and
other costs or could be highly dilutive to our existing
shareholders. Any such financing alternatives may not provide us
with sufficient funds to meet our long-term capital requirements.
If necessary, we may explore strategic transactions that we
consider to be in the best interest of the Company and our
shareholders, which may include, without limitation, public or
private offerings of debt or equity securities, a rights offering,
and other strategic alternatives; however, these options may not
ultimately be available or feasible when needed.
If we are unable to continue as a going concern, our
securities will have little or no value.
Although our financial statements have been prepared under the
assumption that we would continue our operations as a going
concern, there is substantial doubt about our ability to continue
as a going concern, based on our financial statements and results
of operations at that time. Specifically, as noted above, we have
experienced losses from operations and negative cash flows from
operating activities due primarily to relatively high general and
administrative expenses associated with launching our business, as
well as an inventory obsolescence allowance expense. An inventory
obsolescence allowance was created as a precautionary measure with
regard to a large quantity of hemp biomass that is currently being
used in production of our products, which we expect will be
consumed within 6 to 12 months. All or a portion the allowance is
expected to be credited back as other income as the biomass is
used, but there is no guarantee that the biomass will be used, and
that the allowance will be credited back as other income.
Although our audited financial statements for the years ended
December 31, 2021 and 2020, were prepared under the assumption that
we would continue our operations as a going concern, the report of
our independent registered public accounting firm that accompanies
our financial statements for the years ended December 31, 2021 and
2020, contains a going concern qualification in which such firm
expressed substantial doubt about our ability to continue as a
going concern, based on our financial statements and results at
that time, including our net loss of $1,870,675 during the year
ended December 31, 2021, our accumulated deficit of $3,459,214 as
of December 31, 2021, and our working capital deficit of $2,050,626
as of December 31, 2021.
We expect to continue to incur significant expenses and operating
losses for the foreseeable future. These prior losses and expected
future losses have had, and will continue to have, an adverse
effect on our financial condition. In addition, as noted above,
continued operations and our ability to continue as a going concern
may be dependent on our ability to obtain additional financing in
the near future and thereafter, and there are no assurances that
such financing will be available to us at all or will be available
in sufficient amounts or on reasonable terms. Our financial
statements do not include any adjustments that may result from the
outcome of this uncertainty. If we are unable to generate
additional funds in the future through sales of our products,
financings or from other sources or transactions, we will exhaust
our resources and will be unable to continue operations. If we
cannot continue as a going concern, our shareholders would likely
lose most or all of their investment in us.
We have a limited operating history, and we may not be
able to successfully operate our business or execute our business
plan.
The Company was formed on April 1, 2019, and it is still in its
development stage. We are therefore subject to many of the risks
common to early-stage enterprises, including under-capitalization,
cash shortages, limitations with respect to personnel, financial,
and other resources and lack of revenues. Given our limited
operating history, it is hard to evaluate our proposed business and
prospects. Our proposed business operations will be subject to
numerous risks, uncertainties, expenses and difficulties associated
with early- stage enterprises. There is no assurance that we will
be successful in achieving a return on shareholders' investment,
and the likelihood of success must be considered in light of the
early stage of our hemp smokables operations.
We may incur significant debt to finance our
operations.
There is no assurance that we will not incur debt in the future,
that we will have sufficient funds to repay our indebtedness, or
that we will not default on our debt, jeopardizing our business
viability. Furthermore, we may not be able to borrow or raise
additional capital in the future to meet the Company's needs or to
otherwise provide the capital necessary to conduct our
business.
Risk Factors Relating to Our Business and
Industry
We compete in an industry that is brand-conscious, so
brand name recognition and acceptance of our products are critical
to our success.
Our business is substantially dependent upon awareness and market
acceptance of our products and brands by our target market: trendy,
young consumers looking for a distinctive product tonality and/or
the perceived benefits of hemp, CBD and CBG in their smokables as
compared to nicotine or tobacco-based smokables. In addition, our
business depends on acceptance by our independent distributors and
retailers of our brands that have the potential to provide
incremental sales growth. If we are not successful in the growth of
our brand and product offerings, we may not achieve and maintain
satisfactory levels of acceptance by independent distributors and
retail consumers. In addition, we may not be able to effectively
execute our marketing strategies in light of the various closures
and cancellations caused by the COVID-19 pandemic. Any failure of
our brands to maintain or increase acceptance or market penetration
would likely have a material adverse effect on our revenues and
financial results.
Our brand and image are keys to our business and any
inability to maintain a positive brand image could have a material
adverse effect on our results of operations.
Our success depends on our ability to maintain brand image for our
existing products and effectively build up brand image for new
products and brand extensions. We cannot predict whether our
advertising, marketing and promotional programs will have the
desired impact on our products' branding and on consumer
preferences. In addition, negative public relations and product
quality issues, including negative perceptions regarding the hemp
industry, whether real or imagined, could tarnish our reputation
and image of the affected brands and could cause consumers to
choose other products. Our brand image can also be adversely
affected by unfavorable reports, studies and articles, litigation,
or regulatory or other governmental action, whether involving our
products or those of our competitors.
Competition from traditional and large, well-financed
tobacco or nicotine cigarette manufacturers or distributors may
adversely affect our distribution relationships and may hinder
development of our existing markets, as well as prevent us from
expanding our markets.
The smokables industry is highly competitive. We compete with other
smokables companies, including with "Big Tobacco" manufacturers and
distributors, not only for consumer acceptance but also for shelf
space in retail outlets and for marketing focus by our
distributors, many of whom also distribute other smokables brands.
Our products compete with both tobacco-based and hemp-based
smokables, many of which are marketed by companies with
substantially greater financial resources than ours. Some of these
competitors are placing severe pressure on independent distributors
not to carry competitive hemp brands such as ours. We also compete
with regional hemp smokables producers and "private label"
smokables suppliers.
Our direct competitors in the smokables industry include large
domestic and international traditional tobacco companies and
distributors as well as regional or niche smokables companies.
These national and international competitors have advantages such
as lower production costs, larger marketing budgets, greater
financial and other resources and more developed and extensive
distribution networks than ours. We may not be able to grow our
volumes or maintain our selling prices, whether in existing markets
or as we enter new markets.
Increased competitor consolidations, market-place competition,
particularly among branded hemp smokables products, and competitive
product and pricing pressures could impact our earnings, market
share and volume growth. If, due to such pressure or other
competitive threats, we are unable to sufficiently maintain or
develop our distribution channels, we may be unable to achieve our
current revenue and financial targets. As a means of maintaining
and expanding our distribution network, we intend to introduce
additional brands. We may not be successful in doing this, or it
may take us longer than anticipated to achieve market acceptance of
these new products and brands, if at all. Other companies may be
more successful in this regard over the long term. Competition,
particularly from companies with greater financial and marketing
resources than ours, could have a material adverse effect on our
existing markets, as well as on our ability to expand the market
for our products.
We compete in an industry characterized by rapid
changes in consumer preferences and public perception, so our
ability to continue developing new products to satisfy our
consumers' changing preferences will determine our long-term
success.
Failure to introduce new brands, products or product extensions
into the marketplace as current ones mature and to meet our
consumers' changing preferences could prevent us from gaining
market share and achieving long-term profitability. Product
lifecycles can vary, and consumers' preferences and loyalties
change over time. We may not succeed at innovating new products to
introduce to our consumers. Customer preferences also are affected
by factors other than taste, such as health and nutrition
considerations and obesity concerns, shifting consumer needs,
changes in consumer lifestyles, increased consumer information and
competitive product and pricing pressures. Sales of our products
may be adversely affected by the negative publicity associated with
these issues. In addition, there may be a decreased demand for our
products as a result of the COVID-19 pandemic. If we do not
adequately anticipate or adjust to respond to these and other
changes in customer preferences, we may not be able to maintain and
grow our brand image and our sales may be adversely affected.
We may be unable to respond effectively to
technological changes in our industry, which could reduce the
demand for our products.
Our future business success will depend upon our ability to
maintain and enhance our product portfolio with respect to advances
in technological improvements for certain products and market
products that meet customer needs and market conditions in a
cost-effective and timely manner. Maintaining and enhancing our
product portfolio may require significant investments in licensing
fees and royalties. We may not be successful in gaining access to
new products that successfully compete or are able to anticipate
customer needs and preferences, and our customers may not accept
one or more of our products. If we fail to keep pace with evolving
technological innovations or fail to modify our products and
services in response to customers' needs or preferences, then our
business, financial condition and results of operations could be
adversely affected.
We may experience a reduced demand for some of our
products due to health concerns and legislative initiatives against
smokables products.
Consumers are concerned about health and wellness; public health
officials and government officials are increasingly vocal about
smoking, vaping, and their adverse consequences. There has been a
trend among many public health advocates to pursue generalized
reduction in consumption of smokables products, as well as
increased public scrutiny, new taxes on smokables products, and
additional governmental regulations concerning the marketing and
labeling/packing of smokable products. Additional or revised
regulatory requirements, whether labeling, tax or otherwise, could
have a material adverse effect on our financial condition and
results of operations. Further, increasing public concern with
respect to smokables could reduce demand for our hemp smokables
products.
Legislative or regulatory changes that affect our
products, including new
taxes, could reduce demand for products
or increase our costs.
Taxes imposed on the sale of certain of our products by federal,
state, and local governments in the United States, or other
countries in which we operate could cause consumers to shift away
from purchasing our hemp smokables products. These taxes could
materially affect our business and financial results.
Our ability to develop, commercialize and distribute
hemp smokables products and comply with laws and regulations
governing cannabis, hemp or related
products will affect our operational results.
As of December 31, 2021, more than 40 states had enacted
legislation to establish hemp production programs pursuant to the
2018 farm bill (the Agricultural Improvement Act of 2018, the "2018
Farm Bill"), which legalized the regulated production of hemp.
The 2018 Farm Bill was signed into law on December 20, 2018. The
2018 Farm Bill removed hemp from the U.S. Controlled Substances Act
(the "CSA") and established a federal regulatory framework for hemp
production in the United States. Among other provisions, the 2018
Farm Bill: (a) explicitly amends the CSA to exclude all parts of
the cannabis plant (including its cannabinoids, derivatives, and
extracts) containing a delta-9 THC concentration of not more than
0.3% on a dry weight basis from the CSA's definition of
"marihuana"; (b) permits the commercial production and sale of
hemp; (c) precludes states, territories, and Indian tribes from
prohibiting the interstate transport of lawfully-produced hemp
through their borders; and (d) establishes the USDA as the primary
federal agency regulating the cultivation of hemp in the United
States, while allowing states, territories, and Indian tribes to
obtain (or retain) primary regulatory authority over hemp
activities within their borders after receiving approval of their
proposed hemp production plan from the USDA. Any such plan
submitted by a state, territory, or Indian tribe to the USDA must
meet or exceed minimum federal standards and receive USDA approval.
Any state, territory, or Indian tribe that does not submit a plan
to the USDA, or whose plan is not approved by the USDA, will be
regulated by the USDA; provided that, states retain the ability to
prohibit hemp production within their borders.
Marijuana continues to be classified as a Schedule I substance
under the CSA. As a result, any cannabinoids (including CBD)
derived from marijuana, as opposed to hemp, or any products derived
from hemp containing in excess of 0.3% THC on a dry-weight basis,
remain Schedule I substances under U.S. federal law. Cannabinoids
derived from hemp are indistinguishable from those derived from
marijuana, and confusion surrounding the nature of our smokables
products containing hemp or CBD, inconsistent interpretations of
the definition of "hemp", inaccurate or incomplete testing, farming
practices and law enforcement vigilance or lack of education could
result in our products being intercepted by federal and state law
enforcement as marijuana and could interrupt and/or have a material
adverse impact on the Company's business. The Company could be
required to undertake processes that could delay shipments, impede
sales or result in seizures, proper or improper, that would be
costly to rectify or remove and which could have a material adverse
effect on the business, prospects, results of operations or
financial condition of the Company. If the Company makes mistakes
in processing or labeling, and THC in excess of 0.3% on a
dry-weight basis is found in our products, the Company could be
subject to enforcement and prosecution under local, state, and
federal laws which would have a negative impact on the Company's
business and operations.
Under the 2018 Farm Bill, states have authority to adopt their own
regulatory regimes, and as such, regulations will likely continue
to vary on a state-by-state basis. States take varying approaches
to regulating the production and sale of hemp and hemp-derived
products under state food and drug laws. The variance in state law
and that state laws governing hemp production are rapidly changing
may increase the chance of unfavorable law enforcement
interpretation of the legality of Company's operations as they
relate to the cultivation of hemp. Further, such variance in state
laws that may frequently change increases the Company's compliance
costs and risk of error.
While some states explicitly authorize and regulate the production
and sale of hemp products or otherwise provide legal protection for
authorized individuals to engage in commercial hemp activities,
other states maintain outdated drug laws that do not distinguish
between marijuana, hemp and/or hemp-derived CBD, resulting in hemp
being classified as a controlled substance under state law. In
these states, sale of CBD, notwithstanding origin, is either
restricted to state medical or adult-use marijuana program
licensees or remains otherwise unlawful under state criminal laws.
Variance in hemp regulation across jurisdictions is likely to
persist. This patchwork of state laws may, for the foreseeable
future, materially impact the Company's business and financial
condition, limit the accessibility of certain state markets, cause
confusion amongst regulators, and increase legal and compliance
costs.
There are no express protections in the United States under
applicable federal or state law for possessing or processing hemp
biomass derived from lawful hemp not exceeding 0.3% THC on a dry
weight basis and intended for use in finished product, but that may
temporarily exceed 0.3% THC during the interim processing stages.
While it is a common occurrence for hemp biomass to have variance
in THC content during interim processing stages after cultivation
but prior to use in finished products, there is risk that state or
federal regulators or law enforcement could take the position that
such hemp biomass is a Schedule I controlled substance in violation
of the CSA and similar state laws. Further, there is a risk that
state regulators and/or law enforcement may interpret provisions of
state law prohibiting unlawful marijuana activity to apply to
in-process hemp at any facility where we manufacture our hemp
smokables products so that such activity is considered unlawful
under state law.
In the event that the Company's operations are deemed to violate
any laws or if we are deemed to be assisting others to violate a
state or federal law, the Company could be subject to enforcement
actions and penalties, and any resulting liability could cause the
Company to modify or cease its operations.
Continued development of the industrial hemp and cannabis
industries will be dependent upon new legislative authorization of
industrial hemp and cannabis at the state level, and further
amendment or supplementation of legislation at the federal level.
Any number of events or occurrences could slow or halt progress all
together in this space. While progress within the industrial hemp
and cannabis industries is currently encouraging, growth is not
assured. While there appears to be ample public support for
favorable legislative action, numerous factors may impact or
negatively affect the legislative process(es) within the various
states where we have business interests. Any one of these factors
could slow or halt use of industrial hemp and cannabis, which could
negatively impact our business and financial results.
In addition, the general manufacture, labeling and distribution of
our hemp smokables products is regulated by various federal, state,
and local agencies. These governmental authorities may commence
regulatory or legal proceedings, which could restrict the
permissible scope of our product claims or the ability to sell
products in the future.
The shifting compliance environment and the need to build and
maintain robust systems to comply with different compliance in
multiple jurisdictions increases the possibility that we may
violate one or more of the requirements. If our operations are
found to be in violation of any of such laws or any other
governmental regulations that apply to our business, we may be
subject to penalties, including, without limitation, civil and
criminal penalties, damages, fines, the curtailment or
restructuring of our operations, any of which could adversely
affect the ability to operate our business and its financial
results.
International expansion efforts would likely
significantly increase our operational expenses.
We may in the future expand into other geographic areas, which
could increase our operational, regulatory, compliance,
reputational and foreign exchange rate risks. The failure of our
operating infrastructure to support such expansion could result in
operational failures and regulatory fines or sanctions. Future
international expansion could require us to incur a number of
up-front expenses, including those associated with obtaining
regulatory approvals, as well as additional ongoing expenses,
including those associated with infrastructure, staff and
regulatory compliance. We may not be able to successfully identify
suitable acquisition and expansion opportunities or integrate such
operations successfully with our existing operations.
Our reliance on distributors, retailers and brokers
could affect our ability to efficiently and profitably distribute
and market our products, maintain our existing markets and expand
our business into other geographic markets.
Our ability to maintain and expand our existing markets for our
products, and to establish markets in new geographic distribution
areas, is dependent on our ability to establish and maintain
successful relationships with reliable distributors, retailers and
brokers strategically positioned to serve those areas. Most of our
distributors, retailers and brokers sell and distribute competing
products, including tobacco-based or nicotine-based smokables
products, and our products may represent a small portion of their
businesses. The success of our distribution network will depend on
the performance of the distributors, retailers, and brokers in our
network. There is a risk they may not adequately perform their
functions within the network by, without limitation, failing to
distribute to sufficient retailers or positioning our products in
localities that may not be receptive to our product. Our ability to
incentivize and motivate distributors to manage and sell our
products is affected by competition from other hemp smokables
companies who have greater resources than we do. To the extent that
our distributors, retailers and brokers are distracted from selling
our products or do not employ sufficient efforts in managing and
selling our products, including re-stocking the retail shelves with
our products, our sales and results of operations could be
adversely affected. Furthermore, such third parties' financial
position or market share may deteriorate, which could adversely
affect our distribution, marketing and sales activities.
Our ability to maintain and expand our distribution network and
attract additional distributors, retailers and brokers will depend
on a number of factors, some of which are outside our control. Some
of these factors include:
|
·
|
the level of demand for our brands and products in a particular
distribution area;
|
|
·
|
our ability to price our products at levels competitive with those
of competing products; and
|
|
·
|
our ability to deliver products in the quantity and at the time
ordered by distributors, retailers and brokers.
|
We may not be able to successfully manage all or any of these
factors in any of our current or prospective geographic areas of
distribution. Our inability to achieve success with regards to any
of these factors in a geographic distribution area will have a
material adverse effect on our relationships in that particular
geographic area, thus limiting our ability to maintain or expand
our market, which will likely adversely affect our revenues and
financial results.
We incur significant time and expense in attracting and
maintaining key distributors, and loss of distributors or retails
accounts would harm our business.
Our marketing and sales strategy depends in large part on the
availability and performance of our independent distributors. We
currently do not have, nor do we anticipate in the future that we
will be able to establish, long-term contractual commitments from
some of our distributors. We may not be able to maintain our
current distribution relationships or establish and maintain
successful relationships with distributors in new geographic
distribution areas. Moreover, there is the additional possibility
that we may have to incur additional expenditures to attract and
maintain key distributors in one or more of our geographic
distribution areas in order to profitably exploit our geographic
markets.
We currently have approximately ten distributors who service
numerous retail accounts. If we were to lose any of our
distributors, or if they were to lose national, regional or larger
retail accounts, our financial condition and results of operations
could be adversely affected. While we continually seek to expand
and upgrade our distributor network, we may not be able to maintain
our distributor or retailer base. The loss of any of our
distributors, or their significant retail accounts, could have
adverse effects on our revenues, liquidity and financial results,
could negatively impact our ability to retain our relationships
with our other distributors and our ability to expand our market,
and would place increased dependence on our other independent
distributors and national accounts.
The COVID-19 pandemic has and could continue to
negatively affect various aspects of our business, make it more
difficult for us to meet our obligations to our customers, and
result in reduced demand for our products and services, which could
have a material adverse effect on our business, financial
condition, results of operations, or cash flows.
In December 2019, a novel strain of coronavirus was reported to
have surfaced in Wuhan, China, and it has since spread throughout
other parts of the world, including the United States. Any outbreak
of contagious diseases or other adverse public health developments
could have a material adverse effect on our business operations.
These impacts to our operations have included, and could again in
the future include, disruptions or restrictions on the ability of
our employees and customers to travel or our ability to pursue
collaborations and other business transactions, travel to customers
and/or promote our products at conferences or other live events,
oversee the activities of our third-party manufacturers and
suppliers. We may also be impacted by the temporary closure of the
facilities of suppliers, manufacturers or customers.
In an effort to halt the outbreak of COVID-19, a number of
countries, including the United States, placed significant
restrictions on travel and many businesses announced extended
closures. These travel restrictions and business closures have and
may in the future adversely impact our operations locally and
worldwide, including our ability to manufacture, market, sell or
distribute our products. Such restrictions and closure have caused
or may cause temporary closures of the facilities of our suppliers,
manufacturers or customers. A disruption in the operations of our
employees, suppliers, customers, manufacturers or access to
customers would likely impact our sales and operating results. We
are continuing to monitor and assess the effects of the COVID-19
pandemic on our commercial operations; however, we cannot at this
time accurately predict what effects these conditions will
ultimately have on our operations due to uncertainties relating to
the ultimate geographic spread of the virus, the severity of the
disease, the duration of the outbreak and speed of vaccinations,
and the length of the travel restrictions and business closures
imposed by the governments of impacted countries. In addition, a
significant outbreak of contagious diseases in the human population
could result in a widespread health crisis that could adversely
affect the economies and financial markets of many countries,
resulting in an economic downturn that could affect demand for our
products and likely impact our operating results.
We rely on suppliers, manufacturers and contractors,
and events adversely affecting them would adversely affect
us.
The Company intends to maintain a full supply chain for the
provision of its hemp-based smokables products. Due to the novel
and variable regulatory landscape for hemp and CBD production in
the United States, the Company's third-party hemp and hemp
smokables suppliers, manufacturers and contractors may elect, at
any time, to decline or withdraw services necessary for the
Company's operations. Loss of these suppliers, manufacturers and
contractors, including for non-hemp-based ingredients in the
Company's hemp smokables products, may have a material adverse
effect on the Company's business, financial condition, results of
operations and prospects.
In addition, any significant interruption, negative change in the
availability or economics of the supply chain or increase in the
prices for the ingredients in the Company's products provided by
any such third-party suppliers, manufacturers and contractors could
materially impact the Company's business, financial condition,
results of operations and prospects. Any inability to secure
required supplies or to do so on appropriate terms could have a
materially adverse impact on the Company's business, financial
condition, results of operations and prospects.
We have a single customer that accounts for a
substantial portion of our revenues, and our business would be
harmed were we to lose this customer.
Sales to one of our customers, HBI International, made up
approximately 81.5% and 81.3% of our revenues for the three and
nine months ended September 30, 2022, respectively, and
approximately 41% of our revenues for the year ended December 31,
2021, and the balance receivable from HBI International at
September 30, 2022, and December 31, 2021, represents approximately
46.5% of our total accounts receivable balance as of September 30,
2022, and approximately 37% of our total accounts receivable
balances as of December 31, 2021, respectively. We do not have
a binding purchase agreement with this customer, and were we to
lose this customer, our revenues would significantly decline, and
our business would be harmed.
Wholesale price volatility may adversely affect
operations.
The hemp smokables industry is margin-based with gross profits
typically dependent on the excess of sales prices over costs.
Consequently, profitability is sensitive to fluctuations in
wholesale and retail prices caused by changes in supply (which
itself depends on other factors such as weather, fuel, equipment
and labor costs, shipping costs, economic situation and demand),
taxes, government programs and policies for the hemp smokables and
hemp industries (including price controls and wholesale price
restrictions that may be imposed by government agencies responsible
for the regulation of hemp and/or smokables products), and other
market conditions, all of which are factors beyond the control of
the Company. The Company's operating income will be sensitive to
changes in the price of hemp and other product ingredients, and the
overall condition of the hemp and smokables industries, as the
Company's profitability is directly related to the price of hemp
and our other smokables ingredients. There is currently not an
established market price for hemp, and the price of hemp is
affected by numerous factors beyond the Company's control.
Ingredient price volatility may have a material adverse effect on
the Company's business, financial condition, and results of
operations.
The Company may sustain losses that cannot be recovered
through insurance or other preventative measures.
There is no assurance that the Company will not incur uninsured
liabilities and losses as a result of the conduct of its business.
While the Company currently has some liability insurance coverage,
it does not have broad coverage at high levels. The Company plans
to continue to review its liability coverage in the light of its
expanding operations in order to insure against potential major
insurable liabilities. Should uninsured losses occur, shareholders
could lose their invested capital.
The Company may be subject to product liability claims
and other claims of our customers and partners.
The sale of hemp smokables products to consumers involves a certain
level of risk of product liability claims and the associated
adverse publicity. Because use of the Company's hemp smokables
products could cause injury to consumers if packaging or
ingredients are defective, we are subject to a risk of claims for
such injuries and damages. We could also be named as co-parties in
product liability suits that are brought against manufacturing
partners that produce our hemp smokables products, packaging for
those products, or the ingredients in those products.
In addition, our customers and partners may bring suits against us
alleging damages for the failure of our products to meet stated
specifications or other requirements. Any such suits, even if not
successful, could be costly, disrupt the attention of our
management and damage our negotiations with distributors and/or
customers. Any attempt by us to limit our product liability in our
contracts may not be enforceable or may be subject to exceptions.
While we do have product liability insurance, our amounts of
coverage may be inadequate to cover all potential liability claims.
Insurance coverage, particularly as it relates to products relating
to the hemp industry, is expensive, and additional coverage may be
difficult to obtain. Also, additional insurance coverage may not be
available in the future on acceptable terms and may not be
sufficient to cover potential claims. We cannot be sure that our
contract manufacturers or manufacturing partners who produce our
hemp smokables products, packaging and ingredients will have
adequate insurance coverage themselves to cover against potential
claims. If we experience a large insured loss, it may exceed any
insurance coverage limits we have at that time, or our insurance
carrier may decline to cover us or may raise our insurance rates to
unacceptable levels, any of which could impair our financial
position and potentially cause us to go out of business.
If we encounter product recalls or other product
quality issues, our business may suffer.
Product quality issues, real or imagined, or allegations of product
contamination, even when false or unfounded, could tarnish our
image and could cause consumers to choose other products. In
addition, because of changing government regulations or
implementation thereof, or allegations of product contamination, we
may be required from time to time to recall products entirely or
from specific markets. Product recalls could affect our
profitability and could negatively affect brand image.
It is difficult to predict the timing and amount of our
sales, and as a result our sales forecasts are
uncertain.
Many of our white label clients (clients who we manufacture product
for, and which product is labeled with the clients' own branding
and then sold by the clients) are required to place minimum orders
with us, but we cannot accurately predict what our sales will be.
As to our own brand of smokables, The Real Stuff, the number of
stores where our product is available continues to increase each
month, providing a major indicator of future product demand.
However, such an indicator is not dispositive, and our sales
forecasts are uncertain.
Our independent distributors and national accounts are not
generally required to place minimum monthly orders for our
products. In order to reduce their inventory costs, independent
distributors typically order products from us on a "just in time"
basis in quantities and at such times based on the demand for the
products in a particular distribution area. Accordingly, we cannot
accurately predict the timing or quantity of purchases by any of
our independent distributors or whether any of our distributors
will continue to purchase products from us in the same frequencies
and volumes as they may have done in the past. Additionally, our
larger distributors and regional partners may make orders that are
larger than we have historically been required to fill. Shortages
in inventory levels, supply of raw materials or other key supplies
could also negatively affect us.
If we do not adequately manage our inventory levels,
our operating results could be adversely
affected.
We need to maintain adequate inventory levels to be able to deliver
products to distributors on a timely basis. Our inventory supply
depends on our ability to correctly estimate demand for our
products. Our ability to estimate demand for our products is
imprecise, particularly for new products, seasonal promotions and
new markets. If we materially underestimate demand for our products
or are unable to maintain sufficient inventory of raw materials, we
might not be able to satisfy demand on a short-term basis. If we
overestimate distributor or retailer demand for our products, we
may end up with too much inventory, resulting in higher storage
costs, increased trade spend and the risk of inventory spoilage. If
we fail to manage our inventory to meet demand, we could damage our
relationships with our distributors and retailers and could delay
or lose sales opportunities, which would unfavorably impact our
future sales and adversely affect our operating results. In
addition, if the inventory of our products held by our distributors
and retailers is too high, they will not place orders for
additional products, which would also unfavorably impact our sales
and adversely affect our operating results.
Increases in costs or shortages of raw materials could
harm our business and financial results.
In addition to the primary ingredient, the hemp blend, other
principal ingredients we use include (but are not limited to) paper
wrappers, filters, glue, terpenes, labels and cardboard cartons.
These manufacturing and ingredient costs are subject to
fluctuation. Substantial increases in the prices of ingredients,
raw materials and packaging materials, used to produce our
products, to the extent that they cannot be recouped through
increases in the prices of finished hemp smokables products, would
increase our operating costs and could reduce our profitability. If
the supply of these raw materials is impaired or if prices increase
significantly, it could affect the affordability of our products
and reduce sales.
If we or any contract manufacturers we may use are unable to secure
sufficient ingredients or raw materials including hemp, the various
paper products and filters, and other key supplies, we might not be
able to satisfy demand for our hemp smokables products on a
short-term basis. Moreover, in the past there have been
industry-wide shortages of hemp, papers and other ingredients in
our products, and these shortages could occur again from time to
time in the future, which could interfere with and delay production
of our products and could have a material adverse effect on our
business and financial results.
In addition, suppliers could fail to provide ingredients or raw
materials on a timely basis, or fail to meet our performance
expectations, for a number of reasons, including, for example,
disruption to the global supply chain as a result of the COVID-19
pandemic, which could cause a serious disruption to our business,
increase our costs, decrease our operating efficiencies and have a
material adverse effect on our business, results of operations and
financial condition.
Increases in costs of energy
and increased regulations may have an adverse impact on our gross
margin.
Over the past few years, volatility in the global oil markets has
resulted in high fuel prices, which many shipping companies have
passed on to their customers by way of higher base pricing and
increased fuel surcharges. If fuel prices increase, we expect to
experience higher shipping rates and fuel surcharges, as well as
energy surcharges on our raw materials. It is hard to predict what
will happen in the fuel markets in 2022 and beyond. Due to the
price sensitivity of our products, we may not be able to pass such
increases on to our customers.
Disruption within our supply chain, contract
manufacturing or distribution channels could have an adverse effect
on our business, financial condition and results of
operations.
Our ability, through our suppliers, business partners, contract
manufacturers, independent distributors and retailers, to make,
move and sell products is critical to our success. Damage or
disruption to our suppliers or to manufacturing or distribution
capabilities due to weather, natural disaster, fire or explosion,
terrorism, pandemics such as COVID-19, influenza, and other
viruses, labor strikes or other reasons, could impair the
manufacture, distribution and sale of our products. Many of these
events are outside of our control. Failure to take adequate steps
to protect against or mitigate the likelihood or potential impact
of such events, or to effectively manage such events if they occur,
could adversely affect our business, financial condition and
results of operations.
If we are unable to attract and retain key personnel,
our efficiency and operations would be adversely affected; in
addition, staff turnover causes uncertainties and could harm our
business.
Our success depends on our ability to attract and retain highly
qualified employees in such areas as finance, sales, marketing and
product development and distribution. We compete to hire new
employees, and, in some cases, must train them and develop their
skills and competencies. We may not be able to provide our
employees with competitive salaries, and our operating results
could be adversely affected by increased costs due to increased
competition for employees, higher employee turnover or increased
employee benefit costs.
Recently, we have experienced significant changes in our sales
personnel, and more could occur in the future. Changes to
operations, policies and procedures, which can often occur with the
appointment of new personnel, can create uncertainty, may
negatively impact our ability to execute quickly and effectively,
and may ultimately be unsuccessful. In addition, transition periods
are often difficult as the new Company personnel gain detailed
knowledge of our operations, and friction can result from changes
in strategy and management style. Employee turnover inherently
causes some loss of institutional knowledge, which can negatively
affect strategy and execution. Until we integrate new personnel,
and unless they are able to succeed in their positions, we may be
unable to successfully manage and grow our business, and our
financial condition and profitability may suffer.
Further, to the extent we experience additional personnel turnover,
our operations, financial condition and employee morale could be
negatively impacted. If we are unable to attract and retain
qualified management and sales personnel, our business could
suffer. Moreover, our operations could be negatively affected if
employees are quarantined as the result of exposure to a contagious
illness such as COVID-19.
If we lose the services of
our Chief Executive Officer, our future
operations could be impaired until such time as a qualified
replacement can be found.
Our business plan relies significantly on the continued services of
Sandro Piancone, our Chief Executive Officer. If we were to lose
the services of Mr. Piancone, our ability to obtain new business
and new strategic partners, as well as our ability to manage our
operations, could be materially impaired.
We are required to indemnify our directors and
officers.
Our Articles of Incorporation and Bylaws provide that we will
indemnify our officers and directors to the maximum extent
permitted by Nevada law, provided that the officer or director did
not act in bad faith or breach his or her duty to us or our
stockholders, or that it is more likely than not that it will
ultimately be determined that the officer or director has met the
standards of conduct which make it permissible for under Nevada law
for the Company to indemnify the officer or director. If we were
called upon to indemnify an officer or director, then the portion
of its assets expended for such purpose would reduce the amount
otherwise available for the Company's business.
If we fail to protect our trademarks and trade secrets,
we may be unable to successfully market our products and compete
effectively.
We rely on a combination of trademark and trade secrecy laws,
confidentiality procedures and contractual provisions to protect
our intellectual property rights. Failure to protect our
intellectual property could harm our brand and our reputation, and
adversely affect our ability to compete effectively. Further,
enforcing or defending our intellectual property rights, including
our trademarks and trade secrets, could result in the expenditure
of significant financial and managerial resources. We regard our
intellectual property, particularly our trademarks and trade
secrets, as crucial to our business and our success. However, the
steps taken by us to protect these proprietary rights may not be
adequate and may not prevent third parties from infringing or
misappropriating our trademarks, trade secrets or similar
proprietary rights. In addition, other parties may seek to assert
infringement claims against us, and we may have to pursue
litigation against other parties to assert our rights. Any such
claim or litigation could be costly. In addition, any event that
would jeopardize our proprietary rights or any claims of
infringement by third parties could have a material adverse effect
on our ability to market or sell our brands, profitably exploit our
products or recoup our associated research and development
costs.
Disruptions to our information technology systems due
to cyber-attacks or our failure to upgrade and adjust our
information technology systems, may materially impair our
operations, hinder our growth and materially and adversely affect
our business and results of operations.
We believe that an appropriate information technology, or IT,
infrastructure is important in order to support our daily
operations and the growth of our business. If we experience
difficulties in implementing new or upgraded information systems or
experience significant system failures, or if we are unable to
successfully modify our management information systems or respond
to changes in our business needs, we may not be able to effectively
manage our business, and we may fail to meet our reporting
obligations. Additionally, if our current arrangements and plans
are not operated as planned, we may not be able to effectively
recover our information system in the event of a crisis, which may
materially and adversely affect our business and results of
operations.
In the current environment, there are numerous and evolving risks
to cybersecurity and privacy, including criminal hackers,
hacktivists, state-sponsored intrusions, industrial espionage,
employee malfeasance and human or technological error. High-profile
security breaches at other companies and in government agencies
have increased in recent years, and security industry experts and
government officials have warned about the risks of hackers and
cyber-attacks targeting businesses such as ours. Computer hackers
and others routinely attempt to breach the security of technology
products, services and systems, and to fraudulently induce
employees, customers, or others to disclose information or
unwittingly provide access to systems or data. We can provide no
assurance that our current IT system or any updates or upgrades
thereto and the current or future IT systems of our potential
distributors use or may use in the future, are fully protected
against third-party intrusions, viruses, hacker attacks,
information or data theft or other similar threats. Legislative or
regulatory action in these areas is also evolving, and we may be
unable to adapt our IT systems or to manage the IT systems of third
parties to accommodate these changes. We have experienced and
expect to continue to experience actual or attempted cyber-attacks
of our IT networks. Although none of these actual or attempted
cyber-attacks has had a material adverse impact on our operations
or financial condition, we cannot guarantee that any such incidents
will not have such an impact in the future.
Our business is subject to many regulations and
noncompliance is costly.
The production, marketing and sale of our hemp smokables products,
including contents, labels, and containers, are subject to the
rules and regulations of various federal, provincial, state and
local health agencies. If a regulatory authority finds that a
current or future product or production batch or "run" is not in
compliance with any of these regulations, we may be fined, or
production may be stopped, which would adversely affect our
financial condition and results of operations. Similarly, any
adverse publicity associated with any noncompliance may damage our
reputation and our ability to successfully market our products.
Furthermore, the rules and regulations are subject to change from
time to time and while we closely monitor developments in this
area, we cannot anticipate whether changes in these rules and
regulations will impact our business adversely. Additional or
revised regulatory requirements, whether labeling, environmental,
tax or otherwise, could have a material adverse effect on our
financial condition and results of operations.
Significant additional labeling or warning requirements
may inhibit sales of affected products.
Various jurisdictions may seek to adopt significant additional
product labeling or warning requirements relating to the chemical
content or perceived adverse health consequences of our hemp
smokables products. These types of requirements, if they become
applicable to one or more of our products under current or future
environmental or health laws or regulations, may inhibit sales of
such products. In California, a law requires that a specific
warning appear on any product that contains a component listed by
the state as having been found to cause cancer or birth defects.
This law recognizes no generally applicable quantitative thresholds
below which a warning is not required. If a component found in one
of our products is added to the list, or if the increasing
sensitivity of detection methodology that may become available
under this law and related regulations as they currently exist, or
as they may be amended, results in the detection of an
infinitesimal quantity of a listed substance in one of our hemp
smokables products produced for sale in California, the resulting
warning requirements or adverse publicity could affect our
sales.
Our industry may become subject to expanded regulation
and increased enforcement by the Food and Drug Administration (FDA)
and the Federal Trade Commission (FTC).
The FDA under the Federal Food, Drug, and Cosmetic Act regulates
the formulation, manufacturing, packaging, labeling, and
distribution of food, dietary supplements, drugs, cosmetic, medical
devices, biologics, and tobacco products. Our products are subject
to law and regulation by the FDA. Moreover, the regulatory status
of our products are currently in a state of flux as the FDA
attempts to determine the appropriate manner in which to regulate
these products. Thus, the regulatory approach is still evolving,
and we may be required to seek the FDA's approval to market our
products. It is also possible that the FDA may simply issue a
regulation setting forth the conditions in which such products may
be marketed, or it may simply prohibit these products. However,
because the FDA's regulatory process is subject to change, we
cannot predict the likely outcome. In addition, the FTC under the
Federal Trade Commission Act ("FTC Act") requires that product
advertising be truthful, substantiated and not misleading. We
believe that our advertising meets these requirements. However, the
FTC may bring a challenge at any time to evaluate our compliance
with the FTC Act. In addition, most states where our products are
legal provide their own regulatory guidelines and regulations in
connection with cigarette or other smokable product sales. Any
failure by us to remain current on state regulatory changes could
negatively affect our ability to operate our business.
Litigation or legal proceedings could expose us to
significant liabilities and damage our
reputation.
We may become party to litigation claims and legal proceedings.
Litigation involves significant risks, uncertainties and costs,
including distraction of management attention away from our
business operations. We evaluate litigation claims and legal
proceedings to assess the likelihood of unfavorable outcomes and to
estimate, if possible, the amount of potential losses. Based on
these assessments and estimates, we establish reserves and disclose
the relevant litigation claims or legal proceedings, as
appropriate. These assessments and estimates are based on the
information available to management at the time and involve a
significant amount of management judgment. Actual outcomes or
losses may differ materially from those envisioned by our current
assessments and estimates. Our policies and procedures require
strict compliance by our employees and agents with all U.S. and
local laws and regulations applicable to our business operations,
including those prohibiting improper payments to government
officials. Nonetheless, our policies and procedures may not ensure
full compliance by our employees and agents with all applicable
legal requirements. Improper conduct by our employees or agents
could damage our reputation or lead to litigation or legal
proceedings that could result in civil or criminal penalties,
including substantial monetary fines, as well as disgorgement of
profits.
Climate change may negatively affect our
business.
There is growing concern that a gradual increase in global average
temperatures may cause an adverse change in weather patterns around
the globe resulting in an increase in the frequency and severity of
natural disasters. Changing weather patterns could have a negative
impact on agricultural productivity, which may limit availability
or increase the cost of certain key ingredients such as hemp,
natural flavors and other ingredients used in our products. Also,
increased frequency or duration of extreme weather conditions may
disrupt the productivity of our facilities, the operation of our
supply chain or impact demand for our products. In addition, the
increasing concern over climate change may result in more regional,
federal and global legal and regulatory requirements and could
result in increased production, transportation and raw material
costs. As a result, the effects of climate change could have a
long-term adverse impact on our business and results of
operations.
Our business and operations would be adversely impacted
in the event of a failure or interruption of our information
technology infrastructure or as a result of a cybersecurity
attack.
The proper functioning of our own information technology (IT)
infrastructure is critical to the efficient operation and
management of our business. We may not have the necessary financial
resources to update and maintain our IT infrastructure, and any
failure or interruption of our IT system could adversely impact our
operations. In addition, our IT is vulnerable to cyberattacks,
computer viruses, worms and other malicious software programs,
physical and electronic break-ins, sabotage and similar disruptions
from unauthorized tampering with our computer systems. We believe
that we have adopted appropriate measures to mitigate potential
risks to our technology infrastructure and our operations from
these IT-related and other potential disruptions. However, given
the unpredictability of the timing, nature and scope of any such IT
failures or disruptions, we could potentially be subject to
downtimes, transactional errors, processing inefficiencies,
operational delays, other detrimental impacts on our operations or
ability to provide products to our customers, the compromising of
confidential or personal information, destruction or corruption of
data, security breaches, other manipulation or improper use of our
systems and networks, financial losses from remedial actions, loss
of business or potential liability, and/or damage to our
reputation, any of which could have a material adverse effect on
our cash flows, competitive position, financial condition or
results of operations.
Our results of operations may fluctuate from quarter to
quarter for many reasons, including seasonality.
Our sales may be seasonal, and we experience fluctuations in
quarterly results as a result of many factors. We expect to
generate a greater percentage of our revenues during the warm
weather months of April through September. Timing of customer
purchases will vary each year, and sales can be expected to shift
from one quarter to another. As a result, management believes that
period-to-period comparisons of results of operations are not
necessarily meaningful and should not be relied upon as any
indication of future performance or results expected for the fiscal
year.
In addition, our operating results may fluctuate due to a number of
other factors including, but not limited to:
|
•
|
Our ability to maintain, develop and expand distribution channels
for current and new products, develop favorable arrangements with
third party distributors of our products and minimize or reduce
issues associated with engaging new distributors and retailers,
including, but not limited to, transition costs and expenses and
down time resulting from the initial deployment of our products in
each new distributor's network;
|
|
•
|
Unilateral decisions by distributors, grocery store chains,
specialty chain stores, club stores, mass merchandisers and other
customers to discontinue carrying all or any of our products that
they are carrying at any time;
|
|
•
|
Our ability to manage our resources to sufficiently support general
operating activities, promotion allowances and slotting fees,
promotion and selling activities, and capital expansion, and our
ability to sustain profitability;
|
|
•
|
Our ability to meet the competitive response by much larger,
well-funded and established companies currently operating in the
hemp smokables industry, as we introduce new competitive products,
and our hemp smokables products; and
|
|
•
|
Competitive products and pricing pressures and our ability to gain
or maintain share of sales in the marketplace as a result of
actions by competitors.
|
Due to these and other factors, our results of operations have
fluctuated from period to period and may continue to do so in the
future, which could cause our operating results in a particular
quarter to fail to meet market expectations.
Changes in our effective tax rate may impact our
results of operations.
We are subject to taxes in the U.S. and other jurisdictions. Tax
rates in these jurisdictions may be subject to significant change
due to economic and/or political conditions. A number of other
factors may also impact our future effective tax rate
including:
|
•
|
the jurisdictions in which profits are determined to be earned and
taxed;
|
|
•
|
the resolution of issues arising from tax audits with various tax
authorities;
|
|
•
|
changes in valuation of our deferred tax assets and
liabilities;
|
|
•
|
increases in expenses not deductible for tax purposes, including
write-offs of acquired intangibles and impairment of goodwill in
connection with acquisitions;
|
|
•
|
changes in availability of tax credits, tax holidays, and tax
deductions;
|
|
•
|
changes in share-based compensation; and
|
|
•
|
changes in tax laws or the interpretation of such tax laws and
changes in generally accepted accounting principles.
|
Although we believe our income tax liabilities are reasonably
estimated and accounted for in accordance with applicable laws and
principles, an adverse resolution by one or more taxing authorities
could have a material impact on the results of our operations.
Further, we may be unable to utilize our net operating losses in
the event a change in control is determined to have occurred.
Global economic, political, social and other
conditions, including the COVID-19 pandemic, may continue to
adversely impact our business and results of
operations.
The hemp smokables industry can be affected by macro-economic
factors, including changes in national, regional, and local
economic conditions, unemployment levels and consumer spending
patterns, which together may impact the willingness of consumers to
purchase our products as they adjust their discretionary spending.
Adverse economic conditions may adversely affect the ability of our
distributors to obtain the credit necessary to fund their working
capital needs, which could negatively impact their ability or
desire to continue to purchase products from us in the same
frequencies and volumes as they have done in the past. If we
experience similar adverse economic conditions in the future, sales
of our products could be adversely affected, collectability of
accounts receivable may be compromised, and we may face
obsolescence issues with our inventory, any of which could have a
material adverse impact on our operating results and financial
condition.
Additionally, while the extent of the continued impact on our
business and financial condition is unknown at this time, we may
continue to be negatively affected by COVID-19 and actions taken to
address and limit the spread of COVID-19, such as travel
restrictions, event cancellations, and limitations affecting the
supply of labor and the movement of raw materials and finished
products. If available manufacturing capacity is reduced as a
result of COVID-19, it could negatively affect the timely supply,
pricing and availability of finished products. Moreover, we will
also be negatively impacted by current and future closures of
restaurants, independent accounts, convenience chains, and retail
store chains resulting from the COVID-19 outbreak. The current
closures of restaurants and independent accounts will negatively
affect our revenues and cash flows. Although the current status of
retail and convenience chains remains unknown at this time, the
future closure of these types of establishments will also adversely
impact our business and financial condition.
Overall, the Company does not yet know the full extent of potential
delays or impacts on its business, financing activities, or the
global economy as a whole. However, these effects could have a
material impact on the Company's liquidity, capital resources,
operations and business and those of third parties on which we
rely.
We are currently operating in a period of economic
uncertainty and capital markets disruption, which has been
significantly impacted by geopolitical instability due to the
ongoing military conflict between Russia and Ukraine. Our business
may be materially adversely affected by any negative impact on the
global economy and capital markets resulting from the conflict in
Ukraine or any other geopolitical tensions.
U.S. and global markets are experiencing volatility and disruption
following the escalation of geopolitical tensions and the start of
the military conflict between Russia and Ukraine. On February 24,
2022, a full-scale military invasion of Ukraine by Russian troops
was reported. Although the length and impact of the ongoing
military conflict is highly unpredictable, the conflict in Ukraine
could lead to market disruptions, including significant volatility
in commodity prices, credit and capital markets, as well as supply
chain interruptions. We are continuing to monitor the situation in
Ukraine and globally and assessing its potential impact on our
business.
Additionally, Russia's prior annexation of Crimea, recent
recognition of two separatist republics in the Donetsk and Luhansk
regions of Ukraine and subsequent military interventions in Ukraine
have led to sanctions and other penalties being levied by the
United States, European Union and other countries against Russia,
Belarus, the Crimea Region of Ukraine, the so-called Donetsk
People’s Republic, and the so-called Luhansk People's Republic,
including agreement to remove certain Russian financial
institutions from the Society for Worldwide Interbank Financial
Telecommunication (“SWIFT”) payment system, expansive ban on
imports and exports of products to and from Russia and ban on
exportation of U.S denominated banknotes to Russia or persons
located there. Additional potential sanctions and penalties have
also been proposed and/or threatened. Russian military actions and
the resulting sanctions could adversely affect the global economy
and financial markets and lead to instability and lack of liquidity
in capital markets, potentially making it more difficult for us to
obtain additional funds and sell the shares we are offering. The
extent and duration of the military action, sanctions and resulting
market disruptions are impossible to predict, but could be
substantial. Any such disruptions may also magnify the impact of
other risks described in this prospectus.
Changes in accounting standards and subjective
assumptions, estimates and judgments by management related to
complex accounting matters could significantly affect our financial
results.
The United States generally accepted accounting principles and
related pronouncements, implementation guidelines and
interpretations with regard to a wide variety of matters that are
relevant to our business, such as, but not limited to, stock-based
compensation, inventory, revenue recognition, trade spend and
promotions, and income taxes are highly complex and involve many
subjective assumptions, estimates and judgments by our management.
Changes to these rules or their interpretation or changes in
underlying assumptions, estimates or judgments by our management
could adversely affect our reported financial results.
Risks Related to This Offering and Ownership of Our Common
Stock
We may not be able to satisfy the continued listing
requirements of Nasdaq or obtain or maintain a listing of our
common stock on Nasdaq.
We must meet certain financial and liquidity criteria to maintain
the listing of our common stock on the Nasdaq Capital Market. If we
violate Nasdaq's listing requirements, or if we fail to meet any of
Nasdaq's listing standards, our common stock may be delisted. In
addition, our board of directors may determine that the cost of
maintaining our listing on a national securities exchange outweighs
the benefits of such listing. A delisting of our common stock from
Nasdaq may materially impair our shareholders' ability to buy and
sell our common stock and could have an adverse effect on the
market price of, and the efficiency of the trading market for, our
common stock. The delisting of our common stock could significantly
impair our ability to raise capital and the value of your
investment.
The recent listing our common stock on Nasdaq has
increased our regulatory burden.
Our common stock was listed on the Nasdaq Capital Market under the
symbol "HPCO" on August 30, 2022, and we became subject to the
continuous and timely disclosure requirements of Nasdaq’s exchange
rules, regulations and policies. We are working with our legal,
accounting and financial advisors to identify those areas in which
changes should be made to our financial management control systems
to manage our obligations as a public company listed on Nasdaq.
These areas include corporate governance, corporate controls,
disclosure controls and procedures and financial reporting and
accounting systems. We have made, and will continue to make,
changes in these and other areas, including our internal controls
over financial reporting. However, we cannot assure holders of our
shares that these and other measures that we might take will be
sufficient to allow us to satisfy our obligations as a public
company listed on Nasdaq on a timely basis and that we will be able
to maintain compliance with applicable listing requirements. In
addition, compliance with reporting and other requirements
applicable to public companies listed on Nasdaq increases our
operational costs and requires the time and attention of
management. We cannot predict the amount of the additional costs
that we will incur as a result of being a publicly traded company,
the timing of such costs or the effects that management's attention
to these matters will have on our business.
The market price of our common stock may fluctuate, and
you could lose all or part of your investment.
After this offering, the market price for our common stock is
likely to be volatile. The market price of our common stock may
fluctuate significantly in response to several factors, most of
which we cannot control, including:
|
•
|
actual or anticipated variations in our periodic operating
results;
|
|
•
|
increases in market interest rates that lead investors of our
common stock to demand a higher investment return;
|
|
•
|
changes in earnings estimates;
|
|
•
|
changes in market valuations of similar companies;
|
|
•
|
actions or announcements by our competitors;
|
|
•
|
adverse market reaction to any increased indebtedness we may incur
in the future;
|
|
•
|
additions or departures of key personnel;
|
|
•
|
actions by shareholders;
|
|
•
|
speculation in the media, online forums, or investment community;
and
|
|
•
|
our intentions and ability to list our common stock on Nasdaq and
our subsequent ability to maintain such listing.
|
The public offering price of our common stock has been determined
by negotiations between us and the underwriters based upon many
factors and may not be indicative of prices that will prevail
following the closing of this offering. Volatility in the market
price of our common stock may prevent investors from being able to
sell their common stock at or above the initial public offering
price. As a result, you may suffer a loss on your investment.
You will experience immediate and substantial dilution
as a result of this offering.
As
of September 30, 2022, our net tangible book value was
approximately $11,930,656, or approximately $0.51 per share.
Since the effective price per share of our common stock being
offered in this offering is substantially higher than the net
tangible book value per share of our common stock, you will suffer
substantial dilution with respect to the net tangible book value of
the common stock you purchase in this offering. Based on the
estimated public offering price of $1.11 per share of common
stock being sold in this offering, and our net tangible book value
per share as of September 30, 2022, if you purchase shares of
common stock in this offering, you will suffer immediate and
substantial dilution of approximately $0.52 per share (or
$0.51 per share if the underwriters exercise the
over-allotment option in full) with respect to the net tangible
book value of the common stock. See the section titled
"Dilution" for a more detailed discussion of the dilution
you will incur if you purchase securities in this offering.
We have considerable discretion as to the use of the
net proceeds from this offering, and we may use these proceeds in
ways with which you may not agree.
We intend to use the proceeds from this offering for sales,
marketing and advertising initiatives, acquisitions of companies
and technologies aligned and synergistic with our manufacturing
technologies and growth objectives, expansion and upgrades to our
existing manufacturing facility, research and development, hiring
sales and other employees, expenses associated with becoming a
public company, and general corporate and working capital purposes.
However, we have considerable discretion in the application of the
proceeds. Because of the number and variability of factors that
will determine our use of our net proceeds from this offering,
their ultimate use may vary substantially from their currently
intended use. You will not have the opportunity, as part of your
investment decision, to assess whether the proceeds are being used
appropriately. You must rely on the judgment of our management
regarding the application of the net proceeds of this offering. The
net proceeds may be used for corporate or other purposes with which
you do not agree or that do not improve our profitability or
increase our share price. The net proceeds from this offering may
also be placed in investments that do not produce income or that
lose value. Please see the "Use of Proceeds" section below
for more information.
We do not intend to pay any cash dividends on our
shares of common stock in the near future, so our shareholders will
not be able to receive a return on their shares unless they sell
their shares.
We intend to retain any future earnings to finance the development
and expansion of our business. We do not anticipate paying any cash
dividends on our common stock in the foreseeable future. There is
no assurance that future dividends will ever be paid, and if
dividends are paid, there is no assurance with respect to the
amount of any such dividend. Unless we pay dividends, our
shareholders will not be able to receive a return on their shares
unless they sell their shares, and they may be unable to sell their
shares on favorable terms or at all.
We are majority-owned by Green Globe International,
Inc. ("GGII"), and a small group of Company officers and directors
hold a majority of the control of GGII.
As of immediately prior to the commencement of this offering, the
Company was a majority-owned subsidiary of GGII with GGII owning
approximately 75% of our outstanding shares of common stock. The
Company's key officers and directors beneficially owned
approximately 30% of GGII's outstanding common stock and a majority
of GGII's outstanding preferred stock. By virtue of such stock
ownership, those principal GGII shareholders are able to control
the election of the members of GGII's Board of Directors. In turn,
GGII, by virtue of its majority ownership of the Company, is able
to control the election of the members of our Board of Directors.
As a result, those principal GGII shareholders can generally
exercise control over the affairs of the Company, including the
election and removal of members of our board of directors, amending
our Articles of Incorporation and Bylaws, and adopting measures
that could delay or prevent a change of control.
Such concentration of ownership and control could have the effect
of delaying, deterring or preventing a change in control of the
Company that might otherwise be beneficial to stockholders. There
can be no assurance that conflicts of interest will not arise with
respect to our key officers and directors, or that such conflicts
will be resolved in a manner favorable to the Company.
Our executive officers and the majority of our
directors are also officers and directors of our majority owner,
GGII, and conflicts of interest may arise as a
result.
Because our executive officers and a majority of our directors are
also officers and directors of GGII, conflicts of interest between
us and GGII may arise, including with respect to how our management
evaluates acquisition and other business development opportunities,
hiring opportunities, and financing opportunities. There can be no
assurance that conflicts of interest will be resolved in a manner
favorable to the Company.
We are a “controlled company” within the meaning of the
listing rules of Nasdaq and, as a result, can rely on exemptions
from certain corporate governance requirements that provide
protection to shareholders of other companies.
Because GGII owns a majority of our common stock and will own a
majority of our common stock after this offering, we are and will
continue to be after the offering a “controlled company” as defined
under the listing rules of Nasdaq. Under Nasdaq listing rules,
controlled companies are companies of which more than 50% of the
voting power for the election of directors is held by an
individual, a group, or another company. For as long as we remain a
controlled company, we are permitted to elect to rely on certain
exemptions from Nasdaq’s corporate governance rules, including the
following:
|
•
|
an exemption from the rule that a majority of our board of
directors must be independent directors;
|
|
•
|
an exemption from the rule that our compensation committee be
composed entirely of independent directors;
|
|
•
|
an exemption from the rule that our director nominees must be
selected or recommended solely by independent directors or a
nominating committee composed solely of independent directors;
|
Although we do not intend to rely on the “controlled company”
exemptions to Nasdaq’s corporate governance rules, we could elect
to rely on these exemptions in the future. If we elected to rely on
the “controlled company” exemptions, a majority of the members of
our board of directors might not be independent directors, our
nominating and corporate governance and compensation committees
might not consist entirely of independent directors upon closing of
the offering, and you would not have the same protection afforded
to shareholders of companies that are subject to Nasdaq’s corporate
governance rules.
We may need funding from GGII in the future, which may
not be available when needed.
During the nine months ended September 30, 2022, GGII advanced
$621,755 in funding to us. We may need additional funding from GGII
in the future, which may not be available when needed depending on
a number of factors, including GGII’s operating plans and results,
GGII’s business performance, the status and cost of litigation GGII
may be involved in, and other factors affecting the financial
condition of GGII which we cannot control.
We have broad discretion in how we use the proceeds of
this offering and may not use these proceeds effectively, which
could affect our results of operations.
We will have considerable discretion in the application of the net
proceeds of this Offering. We intend to use the net proceeds from
this offering for working capital and general corporate purposes.
As a result, investors will be relying upon management's judgment
with only limited information about our specific intentions for the
use of the net proceeds of this Offering. We may use the net
proceeds for purposes that do not yield a significant return or any
return at all for our shareholders. In addition, pending their use,
we may invest the net proceeds from this offering in a manner that
does not produce income or that loses value.
There has been no independent valuation of our stock,
which means that our common stock may be worth less than the
offering price in the offering.
The per share purchase price in the offering has been determined by
us without independent valuation of our shares of common stock. The
public offering price for our common stock has been determined by
negotiation between us and the underwriters based upon several
factors, including prevailing market conditions, our historical
performance, the historical market price of our common stock,
estimates of our business potential and earnings prospects, and the
market valuations of similar companies. There is no relation to the
market value, book value, or any other established criteria. We did
not obtain an independent appraisal opinion on the valuation of our
shares.
Additionally, the offering price is substantially higher than the
prices at which the selling stockholders acquired their shares
($1.00 and $2.00 per share), and we recently sold stock at prices
($1.00 and $2.00 per share) substantially less than the primary
offering price. Our recent share issuances at prices substantially
less than the primary offering price occurred while we were a
non-public company, and the shares we issued were subject to
transfer restrictions imposed by the Securities Act of 1933, as
amended, and by lock-up restrictions, whereas shares issued in the
offering will be issued after we became a public company and will
be issued without restriction.
Nevertheless, our shares of common stock may have a value
significantly less than the offering price, and the shares may
never obtain a value equal to or greater than the offering
price.
Additionally, if securities industry analysts do not publish
research reports on us, or publish unfavorable reports on us, then
the market price and market trading volume of our common stock
could be negatively affected.
Any trading market for our common stock may be influenced in part
by any research reports that securities industry analysts publish
about us. We do not currently have and may never obtain research
coverage by securities industry analysts. If no securities industry
analysts commence coverage of us, the market price and market
trading volume of our common stock could be negatively affected. In
the event we are covered by analysts, and one or more of such
analysts downgrade our securities, or otherwise reports on us
unfavorably, or discontinues coverage of us, the market price and
market trading volume of our common stock could be negatively
affected.
Future issuances of our common stock or securities
convertible into, or exercisable or exchangeable for, our common
stock, or the expiration of lock-up agreements that restrict the
issuance of new common stock or the trading of outstanding common
stock, could cause the market price of our common stock to decline
and would result in the dilution of your
holdings.
Future issuances of our common stock or securities convertible
into, or exercisable or exchangeable for, our common stock, or the
expiration of lock-up agreements that restrict the issuance of new
common stock or the trading of outstanding common stock, could
cause the market price of our common stock to decline. We cannot
predict the effect, if any, of future issuances of our securities,
or the future expirations of lock-up agreements, on the price of
our common stock. In all events, future issuances of our common
stock would result in the dilution of your holdings. In addition,
the perception that new issuances of our securities could occur, or
the perception that locked-up parties will sell their securities
when the lock-ups expire, could adversely affect the market price
of our common stock. In connection with this offering, we will
enter into a lock-up agreement that prevents us, subject to certain
exceptions, from offering additional shares of capital stock for up
to six months after the closing of this offering, as further
described in the section titled "Underwriting." In
addition to any adverse effects that may arise upon the expiration
of these lock-up agreements, the lock-up provisions in these
agreements may be waived, at any time and without notice. If the
restrictions under the lock-up agreements are waived, our common
stock may become available for resale, subject to applicable law,
including without notice, which could reduce the market price for
our common stock.
Future issuances of debt securities, which would rank
senior to our common stock upon our bankruptcy or liquidation, and
future issuances of preferred stock, which could rank senior to our
common stock for the purposes of dividends and liquidating
distributions, may adversely affect the level of return you may be
able to achieve from an investment in our common
stock.
In the future, we may attempt to increase our capital resources by
offering debt securities. Upon bankruptcy or liquidation, holders
of our debt securities, and lenders with respect to other
borrowings we may make, would receive distributions of our
available assets prior to any distributions being made to holders
of our common stock. Moreover, if we issue preferred stock, the
holders of such preferred stock could be entitled to preferences
over holders of common stock in respect of the payment of dividends
and the payment of liquidating distributions. Because our decision
to issue debt or preferred stock in any future offering, or borrow
money from lenders, will depend in part on market conditions and
other factors beyond our control, we cannot predict or estimate the
amount, timing or nature of any such future offerings or
borrowings. Holders of our common stock must bear the risk that any
future offerings we conduct or borrowings we make may adversely
affect the level of return, if any, they may be able to achieve
from an investment in our common stock.
We are authorized to issue "blank check" preferred
stock without stockholder approval, which could adversely impact
the rights of holders of our common stock.
Our articles of incorporation authorize us to issue up to
50,000,000 shares of "blank check" preferred stock, meaning our
board of directors can designate the rights and preferences of
classes or series of such preferred stock without shareholder
approval. Any preferred stock that we issue in the future may rank
ahead of our common stock in terms of dividend priority or
liquidation premiums and may have greater voting rights than our
common stock. In addition, such preferred stock may contain
provisions allowing those shares to be converted into shares of
common stock, which could dilute the value of common stock to
current stockholders and could adversely affect the market price,
if any, of our common stock. In addition, the preferred stock could
be utilized, under certain circumstances, as a method of
discouraging, delaying or preventing a change in control of our
company. Although we have no present intention to issue any shares
of authorized preferred stock, there can be no assurance that we
will not do so in the future.
If our shares of common stock become subject to the
penny stock rules, it would become more difficult to trade our
shares.
The Securities and Exchange Commission, or the SEC, has adopted
rules that regulate broker-dealer practices in connection with
transactions in penny stocks. Penny stocks are generally equity
securities with a price of less than $5.00, other than securities
registered on certain national securities exchanges or authorized
for quotation on certain automated quotation systems, provided that
current price and volume information with respect to transactions
in such securities is provided by the exchange or system. If we do
not retain a listing on Nasdaq or another national securities
exchange and if the price of our common stock is less than $5.00,
our common stock could be deemed a penny stock. The penny stock
rules require a broker-dealer, before a transaction in a penny
stock not otherwise exempt from those rules, to deliver a
standardized risk disclosure document containing specified
information. In addition, the penny stock rules require that before
effecting any transaction in a penny stock not otherwise exempt
from those rules, a broker-dealer must make a special written
determination that the penny stock is a suitable investment for the
purchaser and receive (i) the purchaser's written acknowledgment of
the receipt of a risk disclosure statement; (ii) a written
agreement to transactions involving penny stocks; and (iii) a
signed and dated copy of a written suitability statement. These
disclosure requirements may have the effect of reducing the trading
activity in the secondary market for our common stock, and
therefore shareholders may have difficulty selling their
shares.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus contains forward-looking statements that are based
on our management's beliefs, expectations, and assumptions and on
information currently available to us. All statements other than
statements of historical facts are forward-looking statements. The
forward-looking statements are contained principally in, but not
limited to, the sections entitled "Prospectus Summary,"
"Risk Factors," "Management's Discussion and Analysis
of Financial Condition and Results of Operations" and
"Business." These statements relate to future events or to
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity,
performance or achievements expressed or implied by these
forward-looking statements. Forward-looking statements include, but
are not limited to, statements about:
|
·
|
our goal and strategies;
|
|
·
|
our future business development, financial condition and results of
operations;
|
|
·
|
expected changes in our revenue, costs or expenditures;
|
|
·
|
growth of and competition trends in our industry;
|
|
·
|
our expectations regarding demand for, and market acceptance of,
our products;
|
|
·
|
our expectations regarding our relationships with investors,
institutional funding partners and other parties with whom we
collaborate;
|
|
·
|
our expectation regarding the use of proceeds from this
offering;
|
|
·
|
fluctuations in general economic and business conditions in the
markets in which we operate; and
|
|
·
|
relevant government policies and regulations relating to our
industry.
|
In some cases, you can identify forward-looking statements by terms
such as "may," "could," "will," "should," "would," "expect,"
"plan," "intend," "anticipate," "believe," "estimate," "predict,"
"potential," "project" or "continue" or the negative of these terms
or other comparable terminology. These statements are only
predictions. You should not place undue reliance on forward-looking
statements because they involve known and unknown risks,
uncertainties and other factors, which are, in some cases, beyond
our control and which could materially affect results. Factors that
may cause actual results to differ materially from current
expectations include, among other things, those listed under the
heading "Risk Factors" and elsewhere in this prospectus.
If one or more of these risks or uncertainties occur, or if our
underlying assumptions prove to be incorrect, actual events or
results may vary significantly from those implied or projected by
the forward-looking statements. No forward-looking statement is a
guarantee of future performance.
The forward-looking statements made in this prospectus relate only
to events or information as of the date on which the statements are
made in this prospectus. Although we will become a public company
after this offering and have ongoing disclosure obligations under
United States federal securities laws, except as required by
applicable law, we do not intend to update or otherwise revise the
forward-looking statements in this prospectus, whether as a result
of new information, future events or otherwise.
USE OF PROCEEDS
After deducting the estimated underwriters' discounts and
commissions and estimated offering expenses payable by us, we
expect to receive net proceeds of approximately $4,641,287 from
this offering (or approximately $5,365,787 if the underwriters
exercise the over-allotment option in full), based on the
estimated public offering price of $1.11 per share.
We plan to use the net proceeds of this offering as follows:
|
·
|
25% of the net proceeds (approximately $1,160,322) for sales,
marketing and advertising initiatives;
|
|
|
|
|
·
|
25% of the net proceeds (approximately $1,160,322) for acquisitions
of companies and technologies aligned and synergistic with our
manufacturing technologies and growth objectives;
|
|
|
|
|
·
|
15% of the net proceeds (approximately $696,193) for expansion and
upgrades to our existing manufacturing facility;
|
|
|
|
|
·
|
10% of the net proceeds (approximately $464,129) for research and
development;
|
|
|
|
|
·
|
10% of the net proceeds (approximately $464,129) for hiring of a
national sales team and general employee staffing;
|
|
|
|
|
·
|
5% of the net proceeds (approximately $232,064) for legal,
accounting, and other professional fees associated with being a
public company;
|
|
|
|
|
·
|
5% of the net proceeds (approximately $232,064) for general and
administrative expenses associated with increased operations;
and
|
|
|
|
|
·
|
5% of the net proceeds (approximately $232,064) for general working
capital.
|
With regard to our plan to use approximately 25% of the net
proceeds of this offering for potential acquisitions, we have been
introduced to several potential acquisition targets, but we do not
have any current plans, arrangements or agreements in connection
with any potential acquisition targets. We do not plan to use any
of the net proceeds of this offering to repay amounts owed to our
officers and directors.
The foregoing represents our current intentions to use and allocate
the net proceeds of this offering based upon our present plans and
business conditions. Our management, however, will have broad
discretion in the way that we use the net proceeds of this
offering. See "Risk Factors—Risks Related to This Offering and
Ownership of Our Common Stock—We have considerable discretion as to
the use of the net proceeds from this offering and we may use these
proceeds in ways with which you may not agree."
DIVIDEND POLICY
We have never declared or paid cash dividends on our common stock.
We currently intend to retain all available funds and any future
earnings for use in the operation of our business and do not
anticipate paying any cash dividends on our common stock in the
near future. We may also enter into credit agreements or other
borrowing arrangements in the future that will restrict our ability
to declare or pay cash dividends on our common stock. Any future
determination to declare dividends will be made at the discretion
of our board of directors and will depend on our financial
condition, operating results, capital requirements, contractual
restrictions, general business conditions and other factors that
our board of directors may deem relevant. See also "Risk
Factors—Risks Related to This Offering and Ownership of Our Common
Stock—We do not intend to pay any cash dividends on our shares of
common stock in the near future, so our shareholders will not be
able to receive a return on their shares unless they sell their
shares."
CAPITALIZATION
The following table sets forth our capitalization as of September
30, 2022:
|
·
|
on an actual basis;
|
|
·
|
on
a pro forma basis to reflect the sale of 4,729,729 shares
by us in this offering at the estimated price to the public of
$1.11 per share, resulting in net proceeds to us of $4,641,287
after deducting (i) underwriter commissions and non-accountable
expenses of $420,000, and (ii) our estimated other offering
expenses of $188,712; and
|
|
·
|
on
a pro forma basis to reflect the sale of 5,439,188 shares by
us in this offering, assuming the underwriters elect to exercise
the over-allotment option in full, at the estimated price to the
public of $1.11 per share, resulting in net proceeds to us of
$5,365,787 after deducting (i) underwriter commissions and
non-accountable expenses of $483,000, and (ii) our estimated other
offering expenses of $188,712.
|
The pro forma information below is illustrative only and our
capitalization following the completion of this offering is subject
to adjustment based on the initial public offering price of our
common stock and other terms of this offering determined at
pricing. You should read this table together with our financial
statements and the related notes included elsewhere in this
prospectus and the information under "
Management's Discussion and Analysis of Financial Condition and
Results of Operations."
|
|
As of September 30, 2022:
|
|
|
|
Actual
|
|
|
Post-Offering Pro Forma without
Over-
Allotment Option
|
|
|
Post-Offering Pro Forma with
Over-
Allotment Option
|
|
Cash and cash equivalents
|
|
$ |
2,973,686 |
|
|
$ |
7,614,973 |
|
|
$ |
8,339,473 |
|
Total long-term liabilities
|
|
$ |
444,630 |
|
|
$ |
444,630 |
|
|
$ |
444,630 |
|
Total liabilities
|
|
$ |
2,083,505 |
|
|
$ |
2,083,505 |
|
|
$ |
2,083,505 |
|
Shareholders’ equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value, 50,000,000 shares
authorized and no shares issued and outstanding on an actual
and pro forma basis (prior to this offering)
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
Common stock, $0.001 par value, 200,000,000 shares authorized and
23,373,213 shares issued and outstanding on an actual and pro forma
basis (prior to this offering)
|
|
$ |
23,373 |
|
|
$ |
28,103 |
|
|
$ |
28,812 |
|
Additional Paid in Capital
|
|
$ |
18,054,685 |
|
|
$ |
22,691,243 |
|
|
$ |
23,415,033 |
|
Accumulated Deficit
|
|
$ |
(5,490,216 |
) |
|
$ |
(5,490,216 |
) |
|
$ |
(5,490,216 |
) |
Total shareholders’ equity
|
|
$ |
12,587,842 |
|
|
$ |
17,229,129 |
|
|
$ |
17,953,629 |
|
Non-controlling interests
|
|
$ |
(7,287 |
) |
|
$ |
(7,287 |
) |
|
$ |
(7,287 |
) |
Total liabilities and shareholders’ equity
|
|
$ |
14,664,060 |
|
|
$ |
19,305,347 |
|
|
$ |
20,029,847 |
|
DILUTION
Dilution in net tangible book value per share to new investors in
our securities, is the amount by which the offering price paid by
the purchasers of the shares of our common stock sold in this
offering exceeds the pro forma net tangible book value per share of
common stock immediately after this offering. Net tangible book
value per share is determined at any date by subtracting our total
liabilities from the total book value of our tangible assets and
dividing the difference by the number of shares of common stock
deemed to be outstanding at that date.
The net tangible book value of our common stock as of September 30,
2022, was approximately $11,930,656, or approximately $0.51 per
share.
Pro forma as adjusted net tangible book value dilution per share to
new investors represents the difference between the amount per
share paid by purchasers of our common stock in this offering and
the pro forma as adjusted net tangible book value per share of our
common stock immediately after completion of this offering.
Investors participating in this offering will incur immediate,
substantial dilution. After giving effect to our sale
of 4,729,729 shares of our common stock in this offering
at the estimated public offering price of $1.11 per share, and
after deducting estimated underwriting discounts and commissions
and estimated offering expenses, our pro forma as adjusted net
tangible book value as of September 30, 2022, would have been
approximately $16,571,943, or approximately $0.59 per share. This
amount represents an immediate increase in pro forma net tangible
book value of $0.08 per share to existing shareholders and an
immediate dilution in pro forma net tangible book value of
$0.52 per share to purchasers of our common stock in this
offering, as illustrated in the following table.
Assumed public offering price per share
|
|
$ |
1.11 |
|
Net tangible book value per share at September 30, 2022
|
|
$ |
0.51 |
|
Pro forma net tangible book value per share after this offering
|
|
$ |
0.59 |
|
Increase in net tangible book value per share to the existing
shareholders
|
|
$ |
0.08 |
|
Dilution in net tangible book value per share to new investors in
this offering
|
|
$ |
0.52 |
|
If
the underwriters exercise their over-allotment option in full, the
pro forma as adjusted net tangible book value per share of our
common stock, as adjusted to give effect to this offering, would be
approximately $0.60 per share, and the dilution in pro forma net
tangible book value per share to new investors purchasing shares of
common stock in this offering would be approximately $0.51 per
share.
The following table sets forth, assuming the sale
of 4,729,729 shares of our common stock in this offering
at the estimated public offering price of $1.11 per share as of
September 30, 2022, the total number of shares of common stock
previously issued and sold by us to existing investors, the total
consideration paid for the foregoing and the average price per
share, before deducting underwriter commissions and estimated
offering expenses (assuming no exercise of the over-allotment
option to purchase additional shares of common stock and assuming
no exercise of the Representatives’ warrants), in each case payable
by us. As the table shows, new investors purchasing shares of our
common stock in this offering may in certain circumstances pay an
average price per share substantially higher than the average price
per share paid by our existing shareholders.
|
|
Shares Purchased
|
|
|
Total Consideration
|
|
|
Average Price
|
|
|
|
Number
|
|
|
Percent
|
|
|
Amount
|
|
|
Percent
|
|
|
Per Share
|
|
Existing shareholders(1)
|
|
|
23,373,213 |
|
|
|
83.2 |
% |
|
$ |
20,186,489 |
|
|
|
79.4 |
% |
|
$ |
0.86 |
|
New investors
|
|
|
4,729,729 |
|
|
|
16.8 |
% |
|
$ |
5,249,999 |
|
|
|
20.6 |
% |
|
$ |
1.11 |
|
Total
|
|
|
28,102,942 |
|
|
|
100.0 |
% |
|
$ |
25,436,488 |
|
|
|
100.0 |
% |
|
$ |
0.91 |
|
|
(1)
|
During the nine months ended September 30, 2022, the Company issued
shares of common stock as follows: (i) on or about April 7,
2022, the Company sold 208,000 shares of Company common stock at
$2.00 per share to 9 investors; (ii) on or about June 10, 2022, the
Company issued 56,592 shares of Company common stock to a lender in
conversion of $50,000 in principal and $6,592 of accrued interest;
(iii) on or about July 15, 2022, the Company issued 2,000,000
shares of Company common stock to Nery’s Logistics, Inc. in
consideration of the acquisition of two cigarette production
equipment lines and multiple trademarks from it; (iv) on or about
July 15, 2022, the Company settled two vendor accounts payable
balances totaling $100,000 by issuing 50,000 shares of Company
common stock (25,000 shares issued to each of the vendors) to the
vendors; (v) on or about September 1, 2022, the Company sold
1,000,000 shares of Company common stock in the Company’s initial
public offering (the “IPO”) at a price to the public of $6.00 per
share; (vi) on or about September 6, 2022, the Company issued
Boustead Securities, LLC (“Boustead”), the Company’s underwriter in
the IPO, 54,928 shares of Company common stock upon Boustead’s
exercise of warrants it received as partial compensation for
underwriting the IPO; (vii) on September 6, 2022, the Company
entered into a settlement agreement with Titan General Agency Ltd.
(“Titan”), the Company’s creditor equipment financier which was
owed $1,432,681 by the Company (the “Titan Debt”), pursuant
to which the Company agreed to pay Titan $250,000 in cash and issue
Titan 266,667 shares of Company common stock (the “Settlement
Shares”), in full satisfaction of the remaining balance, the
Company issued Titan the Settlement Shares on or about September 8,
2022, and (viii) on or about October 4, 2022, the Company issued
North Equities USA Ltd. (“North”) 41,494 shares of Company common
stock for six months of marketing services valued at $100,000, to
be rendered by North to the Company, commencing on September 19,
2022. During the year ended December 31, 2021, the Company issued
shares of common stock as follows: (i) on May 21, 2021, the
Company issued 9,917,532 shares for conversion of Series A
Preferred Shares into common stock and payment of dividends due
thereon, as well as for conversion of outstanding debt, and for
payment of past services rendered; and (ii) in December of 2021,
the Company sold 1,300,000 shares of common stock at $1.00 per
share to 24 investors. During the year ended December 31, 2020, the
Company issued shares of common stock as follows: (i) on February
17, 2020, the Company issued 25,000 shares for conversion of debt
of $25,000; (ii) on May 17, 2020, the Company issued 25,000 shares
to induce a note extension; and (iii) on November 21, 2020, the
Company issued 28,000 shares for conversion of debt of $28,000.
During the year ended December 31, 2019, the Company issued shares
of common stock as follows: (i) on April 1, 2019, the Company
issued 8,000,000 of founder shares, and (ii) on November 6, 2019,
the Company issued 400,000 of founder shares. On May 21, 2021, all
the Company's outstanding shares (18,395,532 shares of common
stock) were acquired by Green Globe International, Inc.
|
The pro forma as adjusted information discussed above is
illustrative only. Our net tangible book value following
the completion of this offering is subject to adjustment
based on the actual net tangible book value per share of our common
stock at the time of the offering and the public offering price of
our common stock and other terms of this offering determined at
pricing.
To the extent that any outstanding options or warrants are
exercised, new options, restricted stock units or other securities
are issued under our stock-based compensation plans, or new shares
of preferred stock are issued, or we issue additional shares of
common stock or warrants in the future, there will be further
dilution to investors participating in this offering.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis summarizes the
significant factors affecting our operating results, financial
condition, liquidity and cash flows of our company as of and for
the periods presented below. The following discussion and analysis
should be read in conjunction with our financial statements and the
related notes thereto included elsewhere in this prospectus. The
discussion contains forward-looking statements that are based on
the beliefs of management, as well as assumptions made by, and
information currently available to, our management. Actual results
could differ materially from those discussed in or implied by
forward-looking statements as a result of various factors,
including those discussed below and elsewhere in this prospectus,
particularly in the sections titled "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements".
Overview
We are focused on Disrupting Tobacco™ by manufacturing and selling
nicotine-free and tobacco-free alternatives to traditional
cigarettes. We utilize a proprietary, patented spraying technology
for terpene infusion and patent-pending flavored filter infusion
technology to manufacture hemp- and herb-based smokable
alternatives.
We have conducted research and development in the smokables space
and are engaged in the manufacturing and sale of smokable hemp and
herb products, including The Real Stuff™ Hemp Smokables. Our
operational segments include private label manufacturing and sales,
intellectual property licensing, and the development and sales of
inhouse brands using patented counter displays. Our inhouse brands
are currently sold in over 200 retail locations located in the San
Diego, California, area, our private label customers include
well-known and established companies in the cannabis and
tobacco-alternatives industries, and we currently own approximately
600 kiosk vending machines which we plan to refurbish and use to
distribute our products in a wider fashion under our HempBox
Vending brand.
Our hemp cigarette production facility, located in San Diego,
California, has the capacity to produce up to 30 million cigarettes
monthly. From our facility, we can small-to-large quantities of
product—from single displays of product to targeted retail
locations to truckloads of product to private label customers—with
in-house processing, packing, and shipping capabilities.
We believe that our manufacturing technologies will be a critical
component of our success. We plan to continue to invest in research
and development, and we currently have one approved patent and one
patent pending with respect our critical manufacturing processes.
Our approved patent is an exclusivity patent to spray hemp with
terpenes for flavoring or to add cannabidiol, which we refer to as
CBD, or cannabigerol, which we refer to as CBG, and our pending
patent relates to our flavored filter infusion technology. We also
have several ready-to-file patent applications with respect to hemp
manufacturing, hemp processing, design patents for hemp machines
and merchandisers, and customized manufacturing equipment.
We believe that we are positioned to rapidly grow our customer and
product footprint through increasing marketing efforts, reaching
agreements with master distributors who will sell to a broad
network of retail establishments, and aggressively targeting
additional distributors throughout the United States. We plan to
drive and increase customer traffic with internet marketing to or
with the clients that carry our products.
Our Corporate History and
Structure
We were incorporated in the State of Nevada on April 1, 2019, as
"The Hempacco Co., Inc.," and on April 23, 2021, changed our name
to "Hempacco Co., Inc." As further described below, on May 21,
2021, we were acquired by Green Globe International, Inc., a
Delaware corporation, and became a wholly owned subsidiary of it.
Subsequently, we issued additional shares of common stock, and as
of immediately prior to this offering, we are a majority-owned
subsidiary of Green Globe International, Inc., with Green Globe
International, Inc. owning approximately 78.7% of our capital
stock. Green Globe International, Inc. operates exclusively in the
fast-moving consumer goods space, focusing on products such as
nutraceuticals and CBD edible gummies, but it does not compete with
us, and it does not have operations in the smokables space separate
from us.
In February 2021, we negotiated the acquisition from an unrelated
third party of 100 shares of super-voting Series A Preferred Stock
(the “Control Block”) of Green Globe International, Inc., a
Delaware corporation (“Green Globe”), for a purchase price of
$50,000, with the understanding that the officers and directors of
Green Globe at the time would resign and our officers and directors
and nominees would be appointed as the officers and directors of
Green Globe upon payment of the $50,000 acquisition purchase price.
The Control Block was entitled to approximately 80% of the voting
rights of the capital stock of Green Globe, and there were
approximately 3,700,640,356 shares of Green Globe common stock
outstanding at the time. As of February 2021, Green Globe had not
filed any quarterly or annual reports with OTCMarkets.com since May
16, 2019, and we viewed Green Globe as insolvent because, at that
time, its liabilities exceeded its assets, it had no current assets
and had a working capital deficit, it was not generating revenues,
and it was not generating any cash flows from operations, investing
activities, or financing activities. Subsequent reports filed by
Green Globe with OTCMarkets.com indicated that it was a shell
company (i.e., a company with no or nominal non-cash assets and no
or nominal operations) at that time. We also determined that upon
acquiring control of Green Globe, we would cancel the Control Block
and have Green Globe acquire Hempacco in a share exchange
transaction by issuing 70,312,160,174 shares of Green Globe common
stock in exchange for all outstanding shares of Hempacco, such that
(i) Hempacco would become a wholly-owned subsidiary of Green Globe,
(ii) Hempacco’s shareholders immediately prior to acquiring
Hempacco would receive 95% of the common stock of Green Globe
(70,312,160,174 shares out of 74,012,800,530 that would be
outstanding following the share exchange), and (iii) Green Globe’s
common shareholders immediately prior to acquiring Hempacco would
retain 5% of Green Globe’s common stock (3,700,640,356 shares out
of 74,012,800,530 shares that would be outstanding following the
share exchange). We also determined at the time that we did not
want to effect the share exchange with Green Globe until we had
resolved as many of our outstanding liabilities as practicable. We
did not obtain any fairness opinion or other valuation of either
Green Globe or Hempacco at the time, and the 70,312,160,174-share
number (the number of shares of Green Globe we determined would be
issued to Hempacco’s shareholders in the share exchange
transaction) was arbitrarily determined by us without reference to
any particular valuation or book value.
On or about March 22, 2021, we paid the $50,000 purchase price for
the Control Block and acquired it, the officers and directors of
Green Globe resigned, and our officers, our sole director at the
time, and two other director nominees selected by us were appointed
as the officers and directors of Green Globe as follows: (i) our
CEO and sole director, Sandro Piancone, was appointed as CEO and
director of Green Globe; (ii) Neville Pearson, our Chief Financial
Officer, was appointed as the Chief Financial Officer, Secretary
and Treasurer of Green Globe; (iii) Jorge Olson, our Chief
Marketing Officer, was appointed as the Chief Marketing Officer of
Green Globe; and (iv) Jerry Halamuda and Dr. Stuart Titus, who at
the time had no positions with us, were appointed as directors of
Green Globe at our direction.
As of March 22, 2021, we had outstanding approximately 8,478,000
shares of common stock and 8,000,000 Series A Preferred Shares.
Between March 22, 2021, and May 21, 2021, we negotiated with
counterparties owed funds by us, including the related parties
described below, with the goal of resolving as much of our
outstanding obligations as possible prior to effecting the share
exchange with Green Globe. We then issued 9,917,532 shares of our
common stock, and then closed the share exchange with Green Globe
on May 21, 2021, with all 18,395,532 shares of our outstanding
common stock transferred to Green Globe in consideration of Green
Globe’s issuance of an aggregate of 70,312,160,174 shares to our
shareholders. The 9,917,532 shares of common stock we issued on May
21, 2021, are described below. Between March 22, 2021, and May 21,
2021, Mr. Piancone was our CEO and sole director, he was the CEO
and one of the directors of Green Globe, he was the officer and
control person of several of the related party entities described
below, and he functionally controlled both us and Green
Globe.
On October 22, 2019, we had entered into a Kiosk Acquisition
Agreement with Mexico Franchise Opportunity Fund LP ("MFOF") (a
related party entity of which approximately 31% is owned by our
founder and CEO, Sandro Piancone, and approximately 25% is owned by
our founder and CMO, Jorge Olson) to purchase 600 vending kiosks
for total consideration of $3,638,357, payable by the issuance of
8,000,000 shares of our Series A Preferred Shares to MFOF. On May
21, 2021, we issued 8,757,479 shares of common stock to MFOF upon
conversion of the 8,000,000 shares of Series A Preferred Shares
into common stock at $1.00 per share, and payment of 757,479 shares
of common stock for accrued dividends of $757,479, due on the
preferred shares, at $1.00 per share.
On May 21, 2021, we issued 357,006 shares of common stock to eight
third-party lenders shares for conversion of debt owed to the
lenders at $1.00 per share, with 336,500 of such shares issued upon
conversion of principal of $336,500, and 20,506 of such shares
issued upon conversion of accrued interest of $20,506.
On May 21, 2021, we issued 127,016 shares of common stock to Mr.
Halamuda (now considered a related party as he was appointed as a
member of our Board of Directors in July 2021) for conversion of
debt owed to Mr. Halamuda at $1.00 per share, with 125,000 of such
shares issued upon conversion of principal of $125,000, and 2,016
of such shares issued upon conversion of accrued interest of
$2,016.
On May 21, 2021, we issued 51,030 shares of common stock to a
lender (Dr. Stuart Titus, now considered a related party as he was
appointed as our Chairman of the Board of Directors in July 2021)
for conversion of debt owed to Dr. Titus at $1.00 per share, with
50,000 of such shares issued upon conversion of principal of
$50,000, and 1,030 of such shares issued upon conversion of accrued
interest of $1,030.
On May 21, 2021, we issued 170,000 shares of common stock to an
entity (Strategic Global Partners, Inc.) controlled by our founder
and CEO, Mr. Piancone, in satisfaction of $170,000 of accrued fees
for management services owed to the entity by us.
On May 21, 2021, we issued 185,000 shares of common stock to an
entity (Cube17, Inc.) controlled by our founder and CMO, Mr. Olson,
in satisfaction of $185,000 of accrued fees for management services
owed to the entity by us.
On May 21, 2021, we issued 170,000 shares of common stock to an
entity (Primus Logistics) controlled by our founder and CEO, Mr.
Piancone, for rent of our manufacturing and office facility from
January 1, 2020, to May 31, 2021, valued at $170,000.
On May 21, 2021, we issued 100,000 shares of common stock to a
third party for information technology, software development, and
kiosk technical services provided by them to us valued at
$100,000.
Our Products
We have launched the production and sale of our own in-house brand
of hemp-based cigarettes, The Real Stuff Smokables, in three
presentations: the twenty pack, the ten pack, and the Solito™
single pack, all of which are sold in our patented counter displays
in convenience stores through master distributors.
We have also entered into several joint ventures to launch multiple
smokables brands: Cali Vibes D8, a joint venture focused on Delta 8
smokable products; Hemp Hop Smokables, a joint venture with rapper
Rick Ross and Rap Snack's CEO James Lindsay; a joint venture with
StickIt Ltd., an Israeli corporation, to manufacture cannabinoid
sticks for insertion into other cigarettes; a joint venture to
launch Cheech & Chong-branded hemp smokables; Hempacco Paper
Co., Inc., a joint venture with Sonora Paper Co., Inc. focused on
rolling papers; Organipure, Inc., a joint venture with High Sierra
Technologies, Inc. focused on hemp smokables; and HPDG, LLC, a
joint venture to launch smokables products with Alfalfa Holdings,
LLC.
We have launched a brand of flavored hemp rolling papers, and we
also private label manufacture hemp rolling papers for third
parties. We are currently manufacturing hemp rolling papers for HBI
International, one of the leading smoking paper producers in the
world.
Recent Developments
In the fall of 2021, we received our largest purchase order to date
for approximately $9.2 million from HBI International's Skunk and
Juicy brand to manufacture hemp rolling papers for it. This
purchase order is non-binding (we are not obligated to produce any
product for HBI International under it), and we are currently
negotiating a supply and manufacturing agreement with HBI
International, the terms of which have not yet been
finalized. Our sales to HBI International constituted
approximately 41% of our revenues for the year ended December 31,
2021, the balance receivable from HBI International at
December 31, 2021, represents approximately 37% of our total
accounts receivable balances as of that date, and were we to lose
HBI International as a customer, our revenues would significantly
decline, and our business would be harmed.
In December 2021, we sold 1,300,000 shares of common stock at $1.00
per share to 24 investors, and in April 2022, we sold 208,000
shares of common stock at $2.00 per share to 9 investors.
On or about March 18, 2022, we borrowed $50,000 from Jerry
Halamuda, one of our directors, and issued Mr. Halamuda a $50,000
promissory note, accruing interest at 8% per annum, which
originally matured on June 18, 2022, and was extended to mature on
September 18, 2022. The note is secured by 50,000 shares of our
common stock.
In July 2022, we launched sales of our Hemp Hop Smokables joint
venture products, as well as our Cheech & Chong-branded joint
venture products.
On or about June 10, 2022, we issued 56,592 shares of common stock
to our lender, Mario Taverna, in conversion of $50,000 in principal
and $6,592 of accrued interest due to Mr. Taverna under a
convertible promissory note.
On July 15, 2022, we settled two vendor accounts payable balances
totaling $100,000 by issuing 50,000 shares of common stock to the
vendors.
On or about July 15, 2022, we acquired two cigarette equipment and
machinery lines, as well as a suite of trademarks described below,
aggregate value $4,000,000, from the seller, Nery’s Logistics,
Inc., in consideration of the issuance of 2,000,000 shares of our
common stock to the seller. The trademarks we acquired include
multiple smokables product trademarks in Mexico for smokable brands
including “Tijuana,” “Gladiator,” “Anchor,” “Black Cat,” and
“Solitos.” The acquired equipment and trademarks will be used in
connection with our hemp smokables products and will not be used
for tobacco smokables products.
On August 29, 2022, we entered into an underwriting agreement with
Boustead Securities, LLC (“Boustead”), in connection with the
initial public offering of our common stock (the “IPO”), pursuant
to which we agreed to (i) sell 1,000,000 shares of our common stock
at a price to the public of $6.00 per share, (ii) issue Boustead
warrants to purchase 70,000 shares of common stock, exercisable
from September 1, 2022, through August 29, 2027, and initially
exercisable at $9.00 per share (the “Boustead Warrants”), and (iii)
grant Boustead an option for a period of 45 days to purchase up to
an additional 150,000 shares of common stock solely for the purpose
of covering over-allotments in the IPO.
On August 30, 2022, our common stock was listed and began trading
on the Nasdaq Capital Market, and on September 1, 2022, the IPO
closed. At the closing, we (i) issued 1,000,000 shares of common
stock for total gross proceeds of $6,000,000, and (ii) issued
Boustead the Boustead Warrants. After deducting underwriting
commission and expenses, we received net proceeds of $5,484,015
from the IPO. On September 6, 2022, Boustead exercised the Boustead
Warrants, which were part of Boustead’s compensation as underwriter
in the IPO, in full on a cashless basis, pursuant to which, on
September 7, 2022, we issued 54,928 shares of common stock to
Boustead.
On September 6, 2022, we entered into a settlement agreement with
Titan General Agency Ltd. (“Titan”), our creditor equipment
financier which was owed $1,432,681 by us as of September 6,
2022 (the “Titan Debt”), pursuant to our prior purchase of
cigarette manufacturing machinery and equipment, pursuant to which
we agreed to pay Titan $250,000 in cash (the “Settlement Cash
Payment”) and issue Titan 266,667 shares of our common stock (the
“Settlement Shares”), in full satisfaction of the remaining
balance. On or about September 8, 2022, we made the Settlement
Payment to Titan and issued Titan the Settlement Shares,
extinguishing the Titan Debt.
On October 4, 2022, we issued North Equities USA Ltd. (“North”)
41,494 shares of Company common stock as compensation for $100,000
worth of marketing services to be rendered by North to us over a
period of six months, commencing on September 19, 2022, and
including content management for our YouTube channel, establishment
of a brand ambassador, and social media services.
On October 12, 2022, we entered a Broadcasting and Billboard
Agreement with FMW Media Works LLC (“FMW”) of Hauppauge, New York,
for a period of three months. FMW will produce an informative TV
show which will discuss the Company and its business, and as
compensation, FMW was issued 63,292 shares of Company common
stock.
In October 2022, we entered into a joint venture agreement with
Sonora Paper Co., Inc., a California corporation (“Sonora”), to
form a joint venture entity in Delaware, Hempacco Paper Co., Inc.,
which will market and sell hemp rolling papers. Pursuant to the
agreement, the joint venture entity will be owned 80% by us and 20%
by Sonora, we are required to manufacture and package joint venture
product and provide accounting, inventory management, staff
training, and trade show and marketing services for the joint
venture entity, and Sonora is required to provide its patented and
patent-pending technologies for the joint venture’s use, with the
joint venture obligated to pay royalties of $0.0025 per paper cone
manufactured by the joint venture entity and provide lodging for
Sonora’s director, Daniel Kempton.
In November 2022, we entered into a joint venture agreement with
High Sierra Technologies, Inc. (“High Sierra”), a Nevada
corporation and subsidiary of High Sierra Technologies, Inc., a
Colorado corporation, to form a joint venture entity in Nevada,
Organipure, Inc., which will market and sell hemp smokables
products. Pursuant to the agreement, the joint venture entity will
be owned will be owned 50% by each of us and High Sierra, with each
of us contributing $1,000 to the joint venture initially, we are
required to manufacture joint venture product, High Sierra is
required to process raw hemp biomass initially, and each of us is
required to provide joint accounting, inventory management, staff
training, and trade show and marketing services for the joint
venture entity.
In January 2023, we entered into a joint venture agreement with
Alfalfa Holdings, LLC (“Alfalfa”), a California limited liability
company, to operate a joint venture entity in California, HPDG, LLC
(the “Joint Venture”), which will market and sell hemp smokables
products. Pursuant to the agreement, the Joint Venture will be
owned 50% by each of us and Alfalfa, we are required to fund
$10,000 to the Joint Venture, we are required to manufacture Joint
Venture product and provide accounting, inventory management, staff
training, and trade show and marketing services for the Joint
Venture, and Alfalfa is required to provide online marketing and
promotion, design and branding, and brand management and
development services to the Joint Venture, as well as Snoop Dogg
attendance and appearances at Joint Venture events subject to
professional availability, and subject to a services agreement
between Alfalfa, the Joint Venture, and Spanky’s Clothing, Inc.,
and Calvin Broadus, Jr. p/k/a “Snoop Dogg” (collectively
“Talent”).
Impact of the COVID-19 Pandemic
In December 2019, a novel coronavirus disease ("COVID-19") was
reported to have surfaced in Wuhan, China, and on March 11, 2020,
the World Health Organization characterized COVID-19 as a pandemic.
The pandemic, which has continued to spread, and the related
adverse public health developments, including orders to
shelter-in-place, travel restrictions, and mandated business
closures, have adversely affected workforces, organizations,
customers, economies, and financial markets globally, leading to an
economic downturn and increased market volatility. It has also
disrupted the normal operations of many businesses, including
ours.
Our operations have been impacted by a range of external factors
related to the pandemic that are not within our control. For
example, many cities, counties, states, and even countries have
imposed or may impose a wide range of restrictions on the physical
movement of our employees, partners, and customers to limit the
spread of the pandemic, including physical distancing, travel bans
and restrictions, closure of non-essential business, quarantines,
work-from-home directives, shelter-in-place orders, and limitations
on public gatherings. These measures have caused, and are
continuing to cause, business slowdowns or shutdowns in affected
areas, both regionally and worldwide. In 2020, we temporarily
scaled down sales efforts at trade shows and with customers and
potential customers in in-person meetings, and we were forced to
source ingredients for some of the components of our products from
alternative suppliers. These changes disrupted our business, and
similar changes in the future may disrupt the way we operate our
business. In addition, our management team has, and will likely
continue, to spend significant time, attention and resources
monitoring the pandemic and seeking to minimize the risk of the
virus and manage its effects on our business.
The duration and extent of the impact from the pandemic depends on
future developments that cannot be accurately predicted at this
time, such as the severity and transmission rate of the virus, the
extent and effectiveness of containment actions and the disruption
caused by such actions, the effectiveness of vaccines and other
treatments for COVID-19, and the impact of these and other factors
on our employees, customers, partners, and vendors. If we are not
able to respond to and manage the impact of such events
effectively, our business will be harmed.
To the extent the pandemic adversely affects our business and
financial results, it may also have the effect of heightening many
of the other risks described in the "Risk Factors" section.
Principal Factors Affecting Our Financial
Performance
Our operating results are primarily affected by the following
factors:
|
●
|
our ability to acquire new customers or retain existing
customers;
|
|
●
|
our ability to offer competitive product pricing;
|
|
●
|
our ability to broaden product offerings;
|
|
●
|
industry demand and competition;
|
|
●
|
our ability to leverage technology and use and develop efficient
manufacturing processes;
|
|
●
|
our ability to attract and retain talented employees and sales
personnel and distributors; and
|
|
●
|
market conditions and our market position.
|
Results of Operations
For the Year Ended December 31, 2021, Compared to the
Year Ended December 31, 2020
Revenue
During the year ended December 31, 2021, the Company generated
$1,187,273 in revenue compared to $345,989 in revenue in 2020.
$805,969 of such revenue during 2021 was from sales of our own
product brands to third parties, $139,114 was from sales to related
parties (entities controlled by Sandro Piancone, as well as the
Cali Vibes D8 joint venture), and $242,190 was from product sales
to white label clients. $135,867 of such revenue during 2020 was
from sales of our own product brands to third parties, $64,290 was
from sales to related parties (entities controlled by Sandro
Piancone, the Company’s CEO, as well as the Cali Vibes D8
joint venture), and $145,832 was from product sales to white label
clients. The increase in revenues during 2021, as compared to 2020,
was as a result of us launching sales of our products in 2020 and
increasing sales efforts during 2021.
Operating Costs and Expenses
The Company had total cost of goods sold of $850,901 for the year
ended December 31, 2021, compared to $899,699 in cost of goods sold
in 2020, which included an inventory obsolescence allowance expense
of $623,375 in 2020 incurred in the year ended December 31, 2020,
as a result of the creation of a potential loss allowance provision
on a quantity of hemp biomass that was acquired shortly after the
Company was formed. The inventory obsolescence allowance was
created as a precautionary measure with regard to a large quantity
of hemp biomass that is currently being used in production of our
products, which we expect will be consumed within 6 to 12 months.
All or a portion of the allowance is expected to be credited back
as other income as the biomass is used, but there is no guarantee
that it will be. The other increase in costs of sales in 2021 as
compared to 2020 was due to expanding sales efforts in 2021 after
launching product sales in 2020.
The Company incurred general and administrative expenses totaling
$981,676 for the year ended December 31, 2021, compared to $303,682
in 2020. The increase was due to us expanding operations in 2021 as
compared to 2020, and incurring increased expenses associated with
raising capital in 2021, including new accounting, legal and broker
expenses incurred in 2021. The Company also incurred related party
general and administrative expenses of $469,259 during 2021 and
$420,000 during 2020, consisting of senior management consulting
fees and rent payable on our premises leased in San Diego,
California. The landlord, Primus Logistics, is 90%-owned by Sandro
Piancone, the Company's CEO.
The Company's sales and marketing expenses increased to $542,680
during the year ended December 31, 2021, compared to sales and
marketing expenses of $27,597 during 2020, as a result of us
expanding operations during 2021 and increasing sales efforts in
2021 as compared to 2020. While the Company incurred no research
and development expenses in 2020, during 2021, the Company incurred
research and development expenses of $2,090 associated with
laboratory testing of the Company's products.
Net Loss
The Company had a net loss of $1,870,675 for the year ended
December 31, 2021, compared to a net loss of $1,465,444 for the
2020 fiscal year. This increase was due to increasing sales and
expanding operations in 2021 as compared to 2020, and the
corresponding increase in general and administrative expenses
described above, and an increase in interest expense to $209,676
during the year ended December 31, 2021, compared to interest
expense of $160,423 during 2020, resulting from the sale of
additional interest-bearing promissory notes to private investors
for the purposes of raising seed capital in 2021. Additionally,
during May of 2021, the Company paid dividends to its then-holder
of preferred stock in shares of common stock rather than cash,
which shares were valued at $757,479. As a result, the Company’s
net loss attributable to the Company’s common stockholders during
2021 was $2,613,904, after a reduction of net loss of $14,250 for
the Company’s non-controlling interests in its joint ventures
subsidiaries. The Company had no comparable dividend and had no
non-controlling interests net loss reduction during
2020.
Assets & Liabilities
The following table sets forth key components of our balance sheet
as of December 31, 2021 and 2020.
|
|
As of December 31,
|
|
|
|
2021
|
|
|
2020
|
|
|
|
|
|
|
|
|
Current Assets
|
|
$ |
2,117,638 |
|
|
$ |
101,462 |
|
Property and Equipment
|
|
|
4,998,771 |
|
|
|
5,005,309 |
|
Total Assets
|
|
|
7,570,523 |
|
|
|
5,657,894 |
|
Current Liabilities
|
|
|
4,168,264 |
|
|
|
2,931,761 |
|
Total Liabilities
|
|
|
4,702,863 |
|
|
|
3,435,326 |
|
Stockholder's Equity (for Hempacco)
|
|
|
2,867,660 |
|
|
|
2,222,568 |
|
Total Liabilities and Equity
|
|
$ |
7,570,523 |
|
|
$ |
5,657,894 |
|
As of December 31, 2021, current assets increased to $2,117,638
from $101,462 as of December 31, 2020. This increase was primarily
due to increase in accounts receivable, deposits and prepayments as
of December 31, 2021, as compared to December 31, 2020, and the
Company’s sales of 1,300,000 shares of common stock to 24 investors
during December of 2021 at $1.00 per share, for gross proceeds of
$1,300,000. As of December 31, 2021, current liabilities increased
to $4,168,264 from $2,931,761 as of December 31, 2020, primarily
due to increases in accounts payable and accrued expenses,
long-term promissory note payables, prepaid invoices and deferred
revenue, partially offset by a decrease in related party accounts
payable.
At December 31, 2021, the Company had cash funds of $933,469.
Liquidity and Capital Resources
The table below, for the periods indicated, provides selected cash
flow information:
|
|
Year Ended December 31,
2021
|
|
|
Year Ended December 31,
2020
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
$ |
(730,961 |
) |
|
|
(69,686 |
) |
Net cash used in investing activities
|
|
|
(79,963 |
) |
|
|
(51,431 |
) |
Net cash provided by financing activities
|
|
|
1,743,893 |
|
|
|
121,500 |
|
Net change in cash
|
|
$ |
932,969 |
|
|
|
383 |
|
Cash Flows from
Operating Activities
We had cash used in operating activities of $730,961 in the year
ended December 31, 2021, as compared to cash used in operating
activities of $69,686 during the year ended December 31, 2020. The
increase in cash used in operating activities for the year ended
December 31, 2021, is primarily attributable to increases in 2021
in prepaid expenses, accounts receivable and inventory partially
offset by increases in deferred revenues, accounts payable and the
inventory obsolescence allowance expense (which allowance was
incurred in 2020 but not 2021).
Cash Flows from
Investing Activities
We had cash used in investing activities of $79,963 for the year
ended December 31, 2021, as compared to $51,431 in cash used in
investing activities in 2021. This cash was used to make
improvements to our manufacturing facility and purchase
equipment.
Cash Flows from
Financing Activities
We had cash provided by financing activities of $1,743,893 in the
year ended December 31, 2021, as compared to cash provided by
financing activities of $121,500 in 2020, due to increased
borrowing and sales of equity during 2021 as compared to 2020.
For the Three and Nine Months Ended September 30, 2022,
Compared to the Three and Nine Months Ended September 30,
2021
Revenue
During the three and nine months ended September 30, 2022, the
Company generated $592,235 and $3,438,438, respectively, in
revenue, compared to $377,221 and $911,007, respectively, in
revenue during the three and nine months ended September 30, 2021.
During the three and nine months ended September 30,
2022, $575,295 and $3,415,518, respectively, of our revenue
was from product sales to third parties, $16,940 and $22,940,
respectively, was from product sales to related parties, $6,653 and
$33,248, respectively, was from consulting and manufacturing
services, and $6,824 and $8,890, respectively, was from kiosk
sales, as compared to $218,166 and $542,728, respectively, in
product sales to third parties, $95,517 and $95,517, respectively,
in product sales to related parties, and $63,538 and $272,762,
respectively, in consulting services during the three and nine
months ended September 30, 2021. The increase in revenues during
2022, as compared to 2021, was as a result of us expanding product
sales during 2022 as compared to 2021.
Operating Costs and Expenses
The Company had total cost of goods sold of $598,627 and
$2,795,661, respectively, during the three and nine months ended
September 30, 2022, compared to total cost of goods sold of
$297,178 and $613,784, respectively, during the three and nine
months ended September 30, 2021. The increase in relative total
cost of goods sold is primarily due to increasing sales and
production in the nine months ended September 30, 2022, as compared
to the same period in 2021.
The Company incurred general and administrative expenses of
$791,562 and $1,758,561, respectively, during the three and nine
months ended September 30, 2022, which included a one-time charge
of $437,375 during the prior quarter ended March 31, 2022, for the
valuation of warrants of our parent company issued to two joint
venture partners as an inducement to enter into joint venture
agreements with us, compared to $224,926 and $736,811,
respectively, during the three and nine months ended September
30, 2021. The Company also incurred related party general and
administrative expenses of $45,000 and $195,000, respectively,
during the three and nine months ended September 30, 2022,
consisting of senior management consulting fees and rent payable on
our premises leased in San Diego, California, compared to related
party general and administrative expenses of $193,973 and $403,973,
respectively, during the three and nine months ended September 30,
2021, for related party fees and rent. The landlord, Primus
Logistics, is 90%-owned by Sandro Piancone, the Company’s CEO.
The Company’s sales and marketing expenses increased to $200,976
and $685,086, respectively, during the three and nine months ended
September 30, 2022, compared to sales and marketing expenses of
$60,538 and $96,638, respectively, during the nine months ended
September 30, 2021, as a result of us significantly expanding sales
and marketing activities during the 2021 and 2022 fiscal years as
we expanded our operations.
Net Loss
The Company had a net loss of $1,049,473 and $2,024,039,
respectively, for the three and nine months ended September 30,
2022, compared to a net loss of $467,303 and $1,196,703 for the
three and nine months ended September 30, 2021. The increase in net
loss for the nine months ended September 30, 2022, significant
additional one-off expenses were incurred in connection with our
IPO on September 1, 2022 in addition to significantly increasing
our operations during 2021 and into 2022, including the expensing
of the $437,375 valuation of warrants issued to joint venture
partners during the prior quarter ended March 31, 2022, partially
offset by decreasing interest expense to $13,080 during the nine
months ended September 30, 2022, compared to interest expense of
$206,145 during the comparative period in 2021.
Assets & Liabilities
The following table sets forth key components of our balance sheet
as of September 30, 2022, and December 31, 2021.
|
|
As of
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2022
|
|
|
2021
|
|
|
|
|
|
|
|
|
Current Assets
|
|
$ |
5,197,591 |
|
|
$ |
2,117,638 |
|
Property and Equipment
|
|
|
8,439,091 |
|
|
|
4,998,771 |
|
Total Assets
|
|
|
14,664,060 |
|
|
|
7,570,523 |
|
Current Liabilities
|
|
|
1,638,875 |
|
|
|
4,168,264 |
|
Total Liabilities
|
|
|
2,083,505 |
|
|
|
4,702,863 |
|
Stockholder’s Equity (for Hempacco)
|
|
|
12,580,555 |
|
|
|
2,867,660 |
|
Total Liabilities and Equity
|
|
$ |
14,664,060 |
|
|
$ |
7,570,523 |
|
As of September 30, 2022, current assets increased to
$5,197,591, from $2,117,638 as of December 31, 2021. This
increase was primarily due to the receipt of $5,468,812 being the
net proceeds from our IPO. As of September 30, 2022, current
liabilities decreased to $1,638,875 from $4,168,264 as of December
31, 2021, primarily due to repayment of our equipment loan of
$1,432,681 plus other short-term loans.
At
September 30, 2022, the Company had cash funds of $2,973,686.
Liquidity and Capital Resources
The table below, for the periods indicated, provides selected cash
flow information:
|
|
Nine Months
Ended
September 30,
2022
|
|
|
Nine Months
Ended
September 30,
2021
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
$ |
(3,217,684 |
) |
|
|
(966,243 |
) |
Net cash provided by (used in) investing activities
|
|
|
(282,007 |
) |
|
|
(17,289 |
) |
Net cash provided by financing activities
|
|
|
5,539,908 |
|
|
|
1,027,886 |
|
Net change in cash
|
|
$ |
(2,040,217 |
) |
|
|
44,354 |
|
Cash Flows from Operating Activities
We had cash used in operating activities of $3,217,684 in the nine
months ended September 30, 2022, as compared to cash used in
operating activities of $966,243 during the nine months ended
September 30, 2021. The increase in cash used in operating
activities of $2,251,441 for the nine months ended September 30,
2022, is primarily attributable to the increase in net operating
loss of $2,024,039 plus decreases in customer deferred revenues of
$1,115,266 and an increase of $599,572 attributable to
inventories.
Cash Flows from Investing Activities
We had cash used in investing activities of $282,007 for the nine
months ended September 30, 2022, as compared to
cash used in investing activities of $17,289 for the nine
months ended September 30, 2021. The increase was primarily due to
the purchase of additional plant and equipment of $152,109 and
franchise and license fees of $152,609 paid as a requirement of a
new product joint venture partially offset by a $40,000 cash
receipt from the sale of equipment.in the nine months ended
September 30, 2022.
Cash Flows from Financing Activities
We had cash provided by financing activities of $5,539,908 in the
nine months ended September 30, 2022, as compared to cash provided
by financing activities of $1,027,886 in the comparative period in
2021, with this increase primarily due to the receipt of $6,000,000
of gross proceeds from the sale of 1,000,000 shares of common stock
in our IPO partially offset by the costs of the offering of
$531,188 and a $300,000 cash loan repayment in the nine months
ended September 30, 2022, as compared to the nine months ended
September 30, 2021.
We anticipate that our cash needs for the next twelve months for
working capital and capital expenditures will be approximately
$1,500,000. As of September 30, 2022, we had approximately
$2,973,686 in cash, and we believe that our current cash and cash
flow from operations will be sufficient to meet anticipated cash
needs for the next twelve months for working capital and capital
expenditures. We will likely also require additional cash resources
due to possible changed business conditions or other future
developments. We plan to seek to sell additional equity securities
to generate additional cash to continue operations. We may also
sell debt securities to generate additional cash. The sale of
equity securities, or of debt securities that are convertible into
our equity, could result in additional dilution to our
shareholders. The incurrence of additional indebtedness would
result in increased debt service obligations and could result in
operating and financing covenants that would restrict our
operations and liquidity.
Our ability to obtain additional capital on acceptable terms is
subject to a variety of uncertainties, including the following:
investors’ perception of, and demand for, securities of cigarette
and hemp companies; conditions of the U.S. and other capital
markets in which we may seek to raise funds; future results of
operations, financial condition and cash flow. Therefore, our
management cannot assure that financing will be available in
amounts or on terms acceptable to us, or if at all. Any failure by
us to raise additional funds on terms favorable to us could have a
material adverse effect on our liquidity and financial
condition.
Going Concern
In the event we are not successful in reaching our sustained
revenue targets, we anticipate that depending on market conditions
and our plan of operations, we will likely incur continued
operating losses. We base this expectation, in part, on the fact
that we may not be able to generate enough gross profit to cover
our operating expenses. Consequently, despite having sufficient
cash resources for the next twelve months, there remains the
possibility that we may not continue to operate as a going concern
in the long term. As described in our description of risks
affecting our business, we are subject to many factors which could
detrimentally affect us. Many of these risk factors are outside
management's control, including demand for our products, our
ability to hire and retain talented and skilled employees and
service providers, as well as other factors.
We do not know of any trends, demands, commitments, events or
uncertainties that will result in, or that are reasonable likely to
result in, our liquidity increasing or decreasing in any material
way.
We do not know of any significant changes in expected sources and
uses of cash.
We do not have any commitments or arrangements from any person to
provide us with any equity capital.
Off-Balance Sheet Arrangements
We currently have no off-balance sheet arrangements that have or
are reasonably likely to have a current or future material effect
on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital
expenditures or capital resources.
Critical Accounting Policies
Our financial statements are based on the application of accounting
principles generally accepted in the United States ("GAAP"). GAAP
requires the use of estimates; assumptions, judgments and
subjective interpretations of accounting principles that have an
impact on the assets, liabilities, revenue, and expense amounts
reported. These estimates can also affect supplemental information
contained in our external disclosures including information
regarding contingencies, risk and financial condition. We believe
our use of estimates and underlying accounting assumptions adhere
to GAAP and are consistently and conservatively applied. We base
our estimates on historical experience and on various other
assumptions that we believe to be reasonable under the
circumstances. Actual results may differ materially from these
estimates under different assumptions or conditions. We continue to
monitor significant estimates made during the preparation of our
financial statements.
Our significant accounting policies are summarized in Note 2 to our
financial statements. While these significant accounting policies
impact our financial condition and results of operations, we view
certain of these policies as critical. Policies determined to be
critical are those policies that have the most significant impact
on our financial statements and require management to use a greater
degree of judgment and estimates. Actual results may differ from
those estimates. Our management believes that given current facts
and circumstances, it is unlikely that applying any other
reasonable judgments or estimate methodologies would cause an
effect on our results of operations, financial position or
liquidity for the periods presented in this report.
Recent Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB)
issued Accounting Standard Update No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes (ASU 2019-12),
which simplifies the accounting for income taxes. This guidance
will be effective for entities for the fiscal years, and interim
periods within those fiscal years, beginning after December 15,
2020 on a prospective basis, with early adoption permitted. We
adopted the new standard effective January 1, 2021 and do not
expect the adoption of this guidance to have a material impact on
our financial statements.
In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20
“Debt—Debt with “Conversion and Other Options” and ASC subtopic
815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard
reduced the number of accounting models for convertible debt
instruments and convertible preferred stock. Convertible
instruments that continue to be subject to separation models are
(1) those with embedded conversion features that are not clearly
and closely related to the host contract, that meet the definition
of a derivative, and that do not qualify for a scope exception from
derivative accounting; and, (2) convertible debt instruments issued
with substantial premiums for which the premiums are recorded as
paid-in capital. The amendments in this update are effective for
fiscal years beginning after December 15, 2021, including interim
periods within those fiscal years. Early adoption is permitted, but
no earlier than fiscal years beginning after December 15, 2020,
including interim periods within those fiscal years. The Company
adopted this standard effective January 1, 2021.
The Company has reviewed all other recently issued, but not yet
effective, accounting pronouncements and does not believe the
future adoption of any such pronouncements may be expected to cause
a material impact on our financial statements.
BUSINESS
Overview
We are focused on Disrupting Tobacco™ by manufacturing and selling
nicotine-free and tobacco-free alternatives to traditional
cigarettes. We utilize a proprietary, patented spraying technology
for terpene infusion and patent-pending flavored filter infusion
technology to manufacture hemp- and herb-based smokable
alternatives.
We have conducted research and development in the smokables space
and are engaged in the manufacturing and sale of smokable hemp and
herb products, including The Real Stuff™ Hemp Smokables. Our
operational segments include private label manufacturing and sales,
intellectual property licensing, and the development and sales of
inhouse brands using patented counter displays. Our inhouse brands
are currently sold in over 200 retail locations located in the San
Diego, California, area, our private label customers include
well-known and established companies in the cannabis and
tobacco-alternatives industries, and we currently own approximately
600 kiosk vending machines which we plan to refurbish and use to
distribute our smokables products in a wider fashion under our
HempBox Vending brand.
Our hemp cigarette production facility, located in San Diego,
California, has the capacity to produce up to 30 million cigarettes
monthly. From our facility, we can small-to-large quantities of
product—from single displays of product to targeted retail
locations to truckloads of product to private label customers—with
in-house processing, packing, and shipping capabilities.
We believe that our manufacturing technologies will be a critical
component of our success. We plan to continue to invest in research
and development, and we currently have one approved patent and one
patent pending with respect our critical manufacturing processes.
Our approved patent is an exclusivity patent to spray hemp with
terpenes for flavoring or to add cannabidiol, which we refer to as
CBD, or cannabigerol, which we refer to as CBG, and our pending
patent relates to our flavored filter infusion technology. We also
have several ready-to-file patent applications with respect to hemp
manufacturing, hemp processing, design patents for hemp machines
and merchandisers, and customized manufacturing equipment.
We believe that we are positioned to rapidly grow our customer and
product footprint through increasing marketing efforts, reaching
agreements with master distributors who will sell to a broad
network of retail establishments, and aggressively targeting
additional distributors throughout the United States. We plan to
drive and increase customer traffic with internet marketing to or
with the clients that carry our products.
Our Products
We have launched the production and sale of our own in-house brand
of hemp-based cigarettes, The Real Stuff™ Smokables, in three
presentations: the twenty pack, the ten pack, and the Solito™
single pack, all of which are sold in our patented counter displays
in convenience stores through master distributors.
We have launched a brand of flavored hemp rolling papers, and we
also private label manufacture hemp rolling papers for third
parties. We are currently manufacturing hemp rolling papers for HBI
International, one of the leading smoking paper producers in the
world.
We have launched a brand of flavored hemp rolling papers, and we
also private label manufacture hemp rolling papers for third
parties. We are currently manufacturing hemp rolling papers for HBI
International, one of the leading smoking paper producers in the
world, and in the fall of 2021, we received our largest purchase
order to date for approximately $9.2 million from HBI
International's Skunk and Juicy brand to manufacture hemp
rolling papers for it. This purchase order establishes initial
product pricing but is non-binding with respect to us since we are
not obligated to produce any product for HBI International under
it. We are currently negotiating a supply and manufacturing
agreement with HBI International, the terms of which have not yet
been finalized.
We have also entered into several joint ventures, described below,
to launch multiple smokables brands: Cali Vibes D8, a joint venture
focused on Delta 8 smokable products; Hemp Hop Smokables, a joint
venture with rapper Rick Ross and Rap Snack's CEO James Lindsay; a
joint venture with StickIt Ltd., an Israeli corporation, to
manufacture cannabinoid sticks for insertion into other cigarettes;
a joint venture to launch Cheech & Chong-branded hemp
smokables; Hempacco Paper Co., Inc., a joint venture with Sonora
Paper Co., Inc. focused on rolling papers; Organipure, Inc., a
joint venture with High Sierra Technologies, Inc. focused on hemp
smokables; and HPDG, LLC, a joint venture to launch smokables
products with Alfalfa Holdings, LLC.
We have a 50% interest in the Hemp Hop Smokables joint venture
entity, Hemp Hop Smokables, LLC, a Florida manager-managed limited
liability company, which is managed by five managing directors:
three managing directors appointed by us, and two managing
directors appointed by Hemp Hop Global, LLC, a Florida limited
liability company controlled by James Lindsay. Currently, the
three managing directors appointed by us are Sandro Piancone, Jorge
Olson, and Louis Pelliccia, and the two managing directors
appointed by Hemp Hop Global are James Lindsay and Taylor McCain.
The written consent of 75% of the managing directors is required
for the joint venture entity to take any of the following actions,
among others: amending the operating agreement governing the joint
venture entity, issuing additional membership interests of the
joint venture entity, entering into related party transactions,
acquiring or disposing of any joint venture entity assets other
than in the ordinary course of business, settling any lawsuit or
assuming any liability in excess $10,000, changing the number of
managing directors of the joint venture entity, changing the
business of the joint venture entity, or dissolving the joint
venture entity. We launched sales of our Hemp Hop Smokables joint
venture products in May 2022.
We have a 25% profit interest, and a 50% contribution interest in
the Cali Vibes D8 joint venture entity, Cali Vibes D8 LLC, a
Delaware member-managed limited liability company, which is
operated by Louis Pelliccia, the Chairman and CEO of the entity.
The joint venture entity shall operate until all members
unanimously vote to dissolve the Company, no further members of the
entity exist, it becomes unlawful for the entity to operate, a
judicial decree is entered to dissolve the entity, or any other
event occurs which results in dissolution of the entity under
federal or Delaware law.
In January 2022, we entered into a joint venture agreement with
StickIt Ltd. (“StickIt”), an Israeli corporation that manufactures
cannabinoid sticks which we had previously negotiated a short-form
joint venture letter agreement with in 2021, to develop and sell
hemp smokables products in the United States and Mexico utilizing
each of the parties’ respective expertise. Pursuant to the 2022
joint venture agreement, which supersedes the prior letter
agreement, we are required to fund $750,000 to the joint venture
entity, Stick-It USA, Inc., a newly formed Delaware corporation,
and we will then receive preferred shares of the joint venture
entity entitling us to 75% of distributable profits of the joint
venture entity until we have been repaid $750,000, after which our
preferred shares will convert into 750,000 shares of common stock
of the joint venture entity. StickIt will also receive 750,000
shares of common stock of the joint venture entity. We are required
to manufacture joint venture product and provide accounting,
inventory management, staff training, and trade show and marketing
services for the joint venture entity; our majority shareholder,
Green Globe International, Inc. (“Green Globe”), is required to
issue Stick-It five-year warrants to purchase 100,000,000 shares of
Green Globe common stock at an exercise price of $0.01 per share,
with the warrants issuable in three tranches (the first 25,000,000
warrants issuable upon signing the joint venture agreement, the
second 25,000,000 warrants issuable when the joint venture entity
achieves annual sales revenue in excess of $5,000,000, and the
third tranche of 50,000,000 warrants issuable upon the joint
venture entity achieving annual sales revenue in excess of
$10,000,000); and StickIt is required to license its trade name and
“CBD stick” intellectual property to the joint venture entity,
provide distribution and retailer negotiation and management
services to the joint venture entity, and supply the joint venture
entity with basic (non-CBD) sticks at an initial price of
$0.22/stick. The joint venture entity is also required to enter
into a manufacturing and supply agreement with StickIt pursuant to
which the joint venture entity shall pay StickIt $250,000, and
StickIt shall provide the joint venture entity the equipment
necessary to manufacture CBD stick products and materials to permit
the joint venture entity to manufacture an initial 30,000 stick
products. If StickIt’s ownership of the joint venture entity ever
falls below 50%, the joint venture entity is required to a name
change amendment with the State of Delaware to remove “stick” from
its name unless StickIt otherwise consents to the joint venture
entity retaining “stick” in its name. In the event that there is
dispute between us and StickIt which cannot be resolved within 28
days of the date the issue was required to be resolved by the joint
venture entity’s board of directors or shareholders, StickIt shall
have the right to purchase our interest in the joint venture entity
for a purchase price equal to the average of the joint venture
entity’s valuation as determined by two appraisers, with one
appraiser appointed by us and the other appraiser appointed by
StickIt.
In January 2022, we entered into a joint venture agreement
with Cheech and Chong’s Cannabis Company, a Nevada corporation
(“CCCC”), to form a joint venture entity in Nevada, which will
market and sell Cheech & Chong-branded hemp smokable products.
Pursuant to the agreement, the joint venture entity will be owned
50% by each of us and CCCC, we are required to fund $10,000 to the
joint venture entity, we are required to manufacture joint venture
product and provide accounting, inventory management, staff
training, and trade show and marketing services for the joint
venture entity, our majority shareholder, Green Globe, is required
to issue to CCCC a three-year warrant to purchase 100,000,000
shares of Green Globe common stock at an exercise price of $0.01
per share, and CCCC is required to provide online marketing and
promotion, design and branding, brand management and development,
trademark receipt, and sales and distribution services to the joint
venture entity. CCCC is also required to ensure that Cheech Marin
and Tommy Chong attend and make appearances at joint venture entity
events. At the Tobacco Plus Expo held in Las Vegas in January 2022,
we debuted the Cheech & Chong-branded joint venture hemp
smokables and hemp blunt wraps products, as well as a Cheech &
Chong-branded kiosk vending machine, with Tommy Chong. In July
2022, we launched sales of our Cheech & Chong-branded joint
venture products.
In October 2022, we entered into a joint venture agreement with
Sonora Paper Co., Inc., a California corporation (“Sonora”), to
form a joint venture entity in Delaware, Hempacco Paper Co., Inc.,
which will market and sell hemp rolling papers. Pursuant to the
agreement, the joint venture entity will be owned 80% by us and 20%
by Sonora, we are required to manufacture and package joint venture
product and provide accounting, inventory management, staff
training, and trade show and marketing services for the joint
venture entity, and Sonora is required to provide its patented and
patent-pending technologies for the joint venture’s use, with the
joint venture obligated to pay royalties of $0.0025 per paper cone
manufactured by the joint venture entity and provide lodging for
Sonora’s director, Daniel Kempton.
In November 2022, we entered into a joint venture agreement with
High Sierra Technologies, Inc. (“High Sierra”), a Nevada
corporation and subsidiary of High Sierra Technologies, Inc., a
Colorado corporation, to form a joint venture entity in Nevada,
Organipure, Inc., which will market and sell hemp smokables
products. Pursuant to the agreement, the joint venture entity will
be owned will be owned 50% by each of us and High Sierra, with each
of us contributing $1,000 to the joint venture initially, we are
required to manufacture joint venture product, High Sierra is
required to process raw hemp biomass initially, and each of us is
required to provide joint accounting, inventory management, staff
training, and trade show and marketing services for the joint
venture entity.
In January 2023, we entered into a joint venture agreement with
Alfalfa Holdings, LLC (“Alfalfa”), a California limited liability
company, to operate a joint venture entity in California, HPDG, LLC
(the “Joint Venture”), which will market and sell hemp smokables
products. Pursuant to the agreement, the Joint Venture will be
owned 50% by each of us and Alfalfa, we are required to fund
$10,000 to the Joint Venture, we are required to manufacture Joint
Venture product and provide accounting, inventory management, staff
training, and trade show and marketing services for the Joint
Venture, and Alfalfa is required to provide online marketing and
promotion, design and branding, and brand management and
development services to the Joint Venture, as well as Snoop Dogg
attendance and appearances at Joint Venture events subject to
professional availability, and subject to a services agreement
between Alfalfa, the Joint Venture, and Spanky’s Clothing, Inc.,
and Calvin Broadus, Jr. p/k/a “Snoop Dogg” (collectively “Talent”).
Pursuant to the services agreement, Talent will endorse the Joint
venture’s smokable hemp products and serve as a spokesperson for
the products in the United States, and the Joint Venture shall (i)
pay Talent’s legal expenses of $7,500 in connection with entering
into the Joint Venture agreement and services agreement; (ii) cause
the Company to issue to Talent a fully vested warrant to acquire
450,000 shares of Company common stock at a strike price of $1.00
per share (the “Talent Warrants”); (iii) cause the Company to issue
to Talent’s designee a fully vested warrant to acquire 50,000
shares of Company common stock at a strike price of $1.00 per share
(the “Talent Designee Warrants”); and (iv) pay Talent royalties of
10% of Joint Venture gross revenue, with minimum annual royalty
payments of $450,000 by the end of the first two years of the
initial term of the services agreement, an additional $600,000 by
the end of the third year of the initial term, and an additional
$1,200,000 by the end of the fourth year of the initial term. On or
about January 30, 2023, the Company issued the Talent Warrants and
Talent Designee Warrants as required by the services agreement
between the Joint Venture, Alfalfa, and Talent.
Our products include the following:

Industry
Smokable hemp products, which include CBD flower, hemp-CBD
pre-rolls, cigars and other inhalables, are part of a growing
sector in the hemp-CBD market. According to Hemp Industry Daily
- Sector Snapshot - Smokable Hemp, Hemp industry observers say
smokable hemp is one of the fastest growing and most lucrative
segments in the nascent hemp and CBD industry, with expectations
that the market will experience fivefold growth in the next five
years.
By 2025, Nielsen expects the smokable hemp market to reach $300
million to $400 million in size, representing roughly 5% of the
potential $6 billion to $7 billion hemp-derived CBD consumer
products category. (see
https://hempindustrydaily.com/exclusive-smokable-hemp-market-worth-up-to-80-million-for-2020-with-five-fold-growth-predicted/).
Demand for hemp-derived CBD products continues to grow, even though
market projections have fluctuated based on economic factors,
including disruptions caused by the COVID-19 pandemic and the lack
of conclusive legislation from federal authorities with respect to
consumable CBD products.
Competitive Strengths
We believe our manufacturing technologies, manufacturing facility
manufacturing capacity, and management with extensive industry
experience are strengths that set us apart from our
competitors. Our manufacturing facility can quickly scale up
production volumes, our management team has extensive experience in
the cigarette and food and beverage industries, and because of our
manufacturing technologies, which allow us to spray hemp with
terpenes for flavoring or to add CBD or CBG, and add flavoring via
our filter infusion technology, we believe our smokables products
offer consistent and unique flavor and odor profiles to consumers,
which we believe sets our products apart from competing products,
which may lack flavor and odor consistency or smell like marijuana
when smoked.
Growth Strategy
Our goal is to become the market leader in disrupting the
trillion-dollar tobacco industry with nicotine- and tobacco-free
products and technologies in connection with hemp, herb, and spice
smokables and smoking papers. We believe that our products and
technology have the potential to disrupt the Big Tobacco
industry.
We seek to become the leader in sales and distribution of
alternative smokable products. We aim to offer our products and
affiliate products in over 100,000 convenience and liquor stores in
the United States (see
https://www.convenience.org/Research/FactSheets/IndustryStoreCount),
and we also intend to build international sales and distribution
channels for our products and affiliate products. Our goal is to
build a portfolio of non-tobacco smokables brands, become the
United States market leader in the space, and subsequently build
exclusive master distribution relationships in other countries.
We plan to do this in four ways:
|
1.
|
We intend to focus on growing our fast-moving consumer goods
brands, such as our The Real Stuff™ smokables and Hempbar, our line
of liquor-flavored infused hemp smokables for sale in liquor stores
and bars.
|
In the smokables space, we plan to make strategic acquisitions of
brands to add to our portfolio of brands and products. We currently
have interests in joint ventures that have launched two new brands.
We exclusively manufacture the products for these joint ventures,
and we plan to act as a master distributor for the different joint
venture brands that we manufacture products for.
|
2.
|
We plan to build a portfolio of patents and technologies, which
should allow us to protect and grow our competitive position in the
industry.
|
We may also license some of our technologies to other cannabis
companies in the United States and hemp and cannabis companies in
other countries outside the United States. We plan to file several
applications for additional patents during the next year as
available funds permit, and we plan to evaluate opportunities to
license and/or acquire new patents and technologies that are
synergistic with our current and planned product offerings and
manufacturing plans.
|
3.
|
We intend to expand our manufacturing capabilities.
|
We believe that our inhouse manufacturing is a key capability that
will separate us from other hemp-based or tobacco-alternative
smokable brands. We are not beholden to a third-party manufacturer.
We also can produce our products anytime it is necessary, including
at night and on weekends. Because of our technologies, we believe
that we can expand private label manufacturing for other companies
and manufacture their products. We plan to charge them for use of
our patented technology, along with manufacturing costs. We plan to
continue to assess new potential technologies for acquisition or
development, and we intend to continue to design our own new
manufacturing technologies to update our production capabilities
and employ leading edge manufacturing technologies. In the future,
we will look to acquire machines, factories, and technologies to
expand our manufacturing and packaging capabilities.
|
4.
|
We plan to increase sales by focusing on master distributor
relationships, e-commerce sales, and distribution of our brands,
and joint venture brands.
|
Our sales team and brokers plan to market our entire portfolio of
brands and affiliated brands to distributors, sell our products
aggressively on e-commerce platforms, and sell our products in
kiosks.
We believe that we are positioned to rapidly grow our customer and
product footprint through increasing our marketing efforts,
reaching agreements with master distributors, and aggressively
targeting additional distributors throughout the United States. We
plan to drive and increase e-commerce customer traffic and sales
through aggressive internet marketing campaigns. It is our goal
that master distributors and other distributors will sell and
deliver to bars, liquor stores, convenience stores, smoke shops and
CBD stores.
Technology & Intellectual Property
We currently have one approved patent and one patent pending with
respect our critical manufacturing processes. Our approved patent
is an exclusivity patent to spray hemp with terpenes for flavoring
or to add cannabidiol, which we refer to as CBD, or cannabigerol,
which we refer to as CBG, and our pending patent relates to our
flavored filter infusion technology. We also have several
ready-to-file patent applications with respect to hemp
manufacturing, hemp processing, design patents for hemp machines
and merchandisers, and customized manufacturing equipment.
With regard to our patent, trademarked and referred to as
"FlorSure," it has been licensed from Open Book Extracts for three
years, and the patent expires in October of 2034 (U.S. patent no.
9532593B2, title: “Herbal Smoking Blend"). Pursuant to the license
agreement, our parent company, Green Globe International, Inc., was
obligated to issue $120,000 of its common stock to the licensor as
an initial royalty payment, it has done so, and we are obligated to
make cash royalty payments to the licensor in an amount equal to
the greater of either (i)$0.01/cigarette sold which was produced
using FlorSure, or(ii)a minimum royalty amount equal to(a) $0 for
the first year of the license (April 1, 2021–March 31, 2022), (b)
$90,000 for the second year of the license (April 1, 2022–March 31,
2023), and (c) $120,000 for the third year of the license(April 1,
2023–March 31, 2024). Such cash royalty payments are due on a
quarterly basis, and the licensor can terminate the license if the
royalty payments are not made within a 30-day cure period after
providing us notice of intent to terminate for non-payment. For
other material breaches of the license by us, the licensor can
terminate the license after the provision of 90 days’ notice to us,
provided we have not cured the breach during such 90-day cure
period. We have the right to terminate the license after the
provision of 90 days’ notice to the licensor if the licensed
intellectual property rights are rendered invalid or unenforceable
and the licensor has not remediated and made valid the licensed
rights within the 90-day cure period. The license expires on March
31, 2024, and may be renewed or extended by mutual agreement of the
parties.
FlorSure applies terpenes and cannabinoids onto smokable hemp to
enable a consistent customer experience for hemp cigarettes,
pre-rolls, and hemp flowers. FlorSure addresses one of the issues
in the hemp cigarette market—consistency. Producers of tobacco
cigarettes have developed specific tobacco blends to ensure
consistency in flavor and effect across millions of batches.
FlorSure applies terpenes and cannabinoids to hemp, enabling the
consistency in flavor profiles and physiological effects consumers
seek. With FlorSure, we believe our brands now have the ability to
create finished products with consistent, repeatable, and reliable
terpenoid profiles, delivering products that consumers can trust
and which we believe sets our products apart from competing
products.
With respect to our pending patent, the application for which was
filed in 2021, we developed and filed a patent for a new,
cutting-edge technology to infuse terpenes and aroma into the
cigarette filter. We believe this technology will also provide
greater consistency in flavor profiles for our products.
The above-described technologies include systems and methods for
infusing cigarettes with sensory additives. Sensory additives
described herein enhance the organoleptic properties, such as taste
and odor, of the cigarette, and include, for example, flavoring and
aromatic additives. A cigarette typically includes a piece of
rolling paper, a smoking substance (e.g., an herbal or plant
composition), and a filter. The rolling paper encloses the smoking
substance forming a cylindrical rod, which is coupled to a filter
to form a cigarette.
The filter is at an end of the cigarette that is placed in a
smoker's mouth. Systems and methods described herein include
infusing cigarette filters with sensory additives to enhance their
organoleptic properties.
We have applied for trademarks for "Disrupting Tobacco," "HempBox,"
"Hempbar," "The Real Stuff," "Solito," and "Cali Vibes D8," and we
recently acquired multiple smokables product trademarks in Mexico
for smokable brands including “Tijuana,” “Gladiator,” “Anchor,”
“Black Cat,” and “Solitos.”
Supplier and Fulfillment Relationships
We obtain our hemp directly from farmers in California and Oregon.
In 2022, we plan to increase our number of hemp suppliers to
support expanding sales of our hemp-based products. We source other
components and ingredients for our products from suppliers
throughout the United States and abroad, and we are not dependent
on any single supplier.
Marketing
We market our products through various sales channels, primarily
trade shows and through print and digital advertisements, focusing
on several customer types. These customers include consumers,
wholesalers, distributors, and those seeking private label
products. We repeatedly test new marketing venues, platforms and
approaches utilizing proven methods to measure results assuring our
efforts are cost effective.
Trade Shows
We exhibit at a variety of trade shows each year with differing
attendee focuses. These include hemp, cannabis, CBD and wellness,
convenience and grocery stores, consumer product distribution, and
private label.
Digital and Printed Advertisements
We utilize sophisticated digital tools to place ads primarily
through Google and Facebook (now Meta) that target likely customers
and those showing interest in our products. In addition, we have
recently begun to place traditional print ads in journals and
magazines focused on convenience stores, distributors, and private
label products.
In addition to new prospect acquisition programs, our marketing
team produces a weekly newsletter that is distributed to our
contacts with the goal of keeping the Company top-of-mind, and this
newsletter has historically resulted in conversion of contacts into
current customers.
Customers and Markets
We primarily sell our products in the United States, but we have
completed a few test orders to customers in Spain, Switzerland,
Poland, and Italy. On our e-commerce sites, we have thousands of
customers. As for our white/private label business, we have
approximately 12 customers who use us to manufacture white/private
label products for them. As to our Real Stuff™ brand, we plan to
sign up master distributors and smaller distributors to carry brand
products and increase sales of brand products. We currently sell
our products to over 200 liquor and smoke shops in the San Diego,
California area.
Competition
The smokables industry consists of a few domestic and international
tobacco and cigarette companies, most of which have existing
relationships in the markets into which we plan to sell, as well as
financial, technical, marketing, sales, manufacturing, scaling
capacity, distribution and other resources, and name recognition
substantially greater than ours. Several domestic cigarette
competitors are continuing to research hemp cigarettes.
Cigarette and filtered cigar companies compete primarily on the
basis of product quality, brand recognition, brand loyalty, taste,
innovation, packaging, service, marketing, advertising, retail
shelf space, and price. Hemp cigarette sales can be significantly
influenced by weak economic conditions, erosion of consumer
confidence, competitors' introduction of low-price products or
innovative products, higher taxes, higher absolute prices and
larger gaps between price categories, and product regulation that
diminishes the ability to differentiate hemp products.
Domestic hemp cigarette competitors included Taat International,
Wild Hemp, Pure Hemp, Colorado's Finest, and Redwood Reserve.
International hemp cigarette competitors include Heimat and Hemp
House.
Facilities
We are headquartered in San Diego, California, at the location of
our hemp cigarette and rolling paper manufacturing facility, which
location is leased from a related party (an entity controlled by
our CEO and Director, Sandro Piancone). Our management team, client
service team, marketing, operations, and sales team are all
primarily based in this location.
Our manufacturing facility at this location has the capacity to
produce up to 30 million cigarettes monthly. Our facility is
approximately 5,000 square feet in size, and we have the right to
lease up to approximately 48,000 additional square feet of
co-located manufacturing and warehouse space from the related party
as inventory and production needs expand. From our facility, we can
ship small-to-large quantities of product—from single displays of
product to targeted retail locations to truckloads of product to
private label customers—with in-house processing, packing, and
shipping capabilities.
Seasonality and Cyclicality
Although historically our product sales have not been seasonal or
cyclical to any significant degree, we expect that our sales in the
future will be greater in the summer months, when more consumers
are outdoors, than in the winter months.
Employees
As of December 31, 2022, we had 13 full-time and part-time
employees, and we consider our employee relations to be good. Our
human capital resource objectives are designed to attract, and
retain, highly motivated and well qualified employees. We have
worked diligently to provide a flexible and safe work
environment—especially during the unforeseen COVID-19 global
pandemic. The health and safety of our employees and clientele is
of the upmost importance to us. We have taken significant steps to
protect our workforce during COVID-19 including but not limited to,
working remotely, increased cleaning and sanitization of
facilities, and social distancing protocols consistent with
guidelines issued by federal, state, and local governments.
Legal Proceedings
From time to time, we may become involved in various lawsuits and
legal proceedings which arise in the ordinary course of business.
However, litigation is subject to inherent uncertainties, and an
adverse result in these or other matters may arise from time to
time that may harm our business. We are not aware of any such legal
proceedings or claims against us except as follows:
On or about October 7, 2022, the Company accepted service in a suit
filed in the United States District Court for the Southern District
of New York by Long Side Ventures LLC, R & T Sports Marketing
Inc., Sierra Trading Corp., Taconic Group LLC, KBW Holdings LLC,
Robert Huebsch and Ann E. Huebsch, Joseph Camberato, Joseph Crook,
Sachin Jamdar, Michael Matilsky, Gerard Scollan, and Daisy Arnold
(collectively “Plaintiffs”) against Hempacco Co., Inc., Mexico
Franchise Opportunity Fund, LP, Sandro Piancone, Jorge Olson,
Neville Pearson, Stuart Titus, Jerry Halamuda, Retail Automated
Concepts, Inc. f/k/a Vidbox Mexico Inc., and Vidbox Mexico S.A. De
C.V. (collectively “Defendants”) (Case No. 1:22-cv-08152 (ALC)),
alleging that (i) Plaintiffs previously received a judgment (the
“Judgment”) in a New York state court action (the “State Action”)
against Retail Automated Concepts, Inc. (“RAC”) and Vidbox Mexico
S.A. De C.V. (“Vidbox Mexico”), for breach of promissory notes
issued by RAC to Defendants in 2018 and guaranteed by Vidbox
Mexico, and (ii) prior to the filing of the State Action,
Defendants fraudulently transferred and commingled assets,
specifically 600 retail kiosks, in order to avoid enforcement of
the Judgment, with Plaintiffs seeking monetary damages from
Defendants. On or about November 29, 2022, the court granted
Defendants’ request to file a motion to dismiss the suit, and on
December 30, 2022, Defendants filed the motion to dismiss the suit
for failure to state a claim and lack of personal jurisdiction.
Defendants believe the suit is without merit and intend to defend
the matter vigorously.
Regulation
Trade Regulations
Our suppliers generally source or manufacture finished goods in
parts of the world that may be affected by the imposition of
duties, tariffs or other import regulations by the United States.
We believe that our redundant network of suppliers provide
sufficient capacity to mitigate any dependency risks on a single
supplier.
We buy necessary components or ingredients for our products from
suppliers or factories both domestically and internationally as
needed. We do not depend on any single supplier. However, if we are
unable to continue to obtain our finished products from
international locations or if our suppliers are unable to source
raw materials, it could significantly disrupt our business.
Further, we are affected by economic, political and other
conditions in the United States and internationally, including
those resulting in the imposition or increase of import duties,
tariffs and other import regulations and widespread health
emergencies, which could have a material adverse effect on our
business.
Laws and Regulations Relating to Our
Products
The production, distribution and sale in the United States of many
of our products are subject to the Federal Food, Drug, and Cosmetic
Act, the Federal Trade Commission Act, the Lanham Act, state
consumer protection laws, competition laws, federal, state and
local workplace health and safety laws, various federal, state and
local environmental protection laws, various other federal, state
and local statutes applicable to the production, transportation,
sale, safety, advertising, labeling and ingredients of such
products, and rules and regulations adopted pursuant to these laws.
Outside the United States, the distribution and sale of our many
products and related operations are also subject to numerous
similar and other statutes and regulations.
On December 20, 2018, the Agricultural Improvement Act of 2018,
which is also known as the "2018 Farm Bill," was enacted and, among
other things, further legalized hemp under U.S. federal law, but
with compliance still being required with all applicable state hemp
laws. The 2018 Farm Bill includes certain benefits for the hemp
industry in the United States, including: (i) the extension of the
protections for hemp research and researchers and the conditions in
which hemp research can be done, (ii) the protection of hemp
farmers and hemp production under federal crop insurance programs,
(iii) the permitting of the cultivation, interstate transportation
and sale of hemp and hemp products in the U.S. in compliance with
all other applicable federal and state laws, and (iv) the removal
of hemp and hemp derived products from Schedule 1 of the Controlled
Substances Act ("CSA").
As of January 1, 2021, federal law and the laws of 47 states in the
United States and the District of Columbia have legalized hemp, 36
states in the United States, the District of Columbia, Guam, Puerto
Rico, and the U.S. Virgin Islands have enacted laws and/or
regulations that recognize, in one form or another, legitimate
medical uses for cannabis/marijuana and consumer use of
cannabis/marijuana in connection with medical treatment, and 15
states in the United States, the District of Columbia, Guam, and
the Northern Mariana Islands have legalized cannabis/marijuana for
adult recreational use. Other states are considering similar
legislation. Conversely, under the federal CSA, the policies and
regulations of the federal government and its agencies are that
cannabis/marijuana has no medical benefit, and a range of
activities are prohibited, including cultivation, possession,
personal use and interstate distribution of cannabis/marijuana.
Our activities in the United States only involve legal hemp in
compliance with the CSA. The hemp and the marijuana plants are both
part of the same cannabis genus, except that hemp does not
have more than 0.3% dry weight content of
delta-9-tetrahydrocannabinol ("THC"). While 2018 Farm Bill
legalized hemp and cannabinoids extracted from hemp in the United
States, such extracts remain subject to state laws and regulation
by other U.S. federal agencies such as the FDA, U.S. Drug
Enforcement Administration ("DEA"), and the U.S. Department of
Agriculture ("USDA"). The same plant, with a higher THC content is
marijuana, which is legal under certain state laws, but which is
currently not legal under U.S. federal law. The similarities
between these plants can cause confusion.
A California law known as Proposition 65 requires a specific
warning to appear on any product containing a component listed by
the state as having been found to cause cancer or birth defects.
The state maintains lists of these substances and periodically adds
other substances to these lists. Proposition 65 exposes all food
and beverage producers to the possibility of having to provide
warnings on their products in California because it does not
provide for any generally applicable quantitative threshold below
which the presence of a listed substance is exempt from the warning
requirement. Consequently, the detection of even a trace amount of
a listed substance can subject an affected product to the
requirement of a warning label. However, Proposition 65 does not
require a warning if the manufacturer of a product can demonstrate
that the use of that product exposes consumers to a daily quantity
of a listed substance that is:
|
●
|
below a "safe harbor" threshold that may be established;
|
|
●
|
naturally occurring;
|
|
●
|
the result of necessary cooking; or
|
|
●
|
subject to another applicable exemption.
|
In January 2019, New York State's governor announced the "Consumer
Right to Know Act," a proposed law that would impose similar and
potentially more stringent labeling requirements than California
Proposition 65. The law has not yet been adopted, and to our
knowledge California Proposition 65 remains the most onerous
state-level chemical exposure labeling statutory scheme. However,
due in part to the large size of California's market, promotional
products sold or distributed anywhere in the United States may be
subject to California Proposition 65.
We are unable to predict whether a component found in a product
that we assisted a client in producing might be added to the
California list in the future. Furthermore, we are also unable to
predict when or whether the increasing sensitivity of detection
methodology may become applicable under this law and related
regulations as they currently exist, or as they may be amended.
We are subject to various federal, state and local laws and
regulations, including but not limited to, laws and regulations
relating to labor and employment, U.S. customs and consumer product
safety, including the Consumer Product Safety Improvement Act, or
the "CPSIA." The CPSIA created more stringent safety requirements
related to lead and phthalates content in children's products. The
CPSIA regulates the future manufacture of these items and existing
inventories and may cause us to incur losses if we offer for sale
or sell any non-compliant items. Failure to comply with the various
regulations applicable to us may result in damage to our
reputation, civil and criminal liability, fines and penalties and
increased cost of regulatory compliance. These current and any
future laws and regulations could harm our business, results of
operations and financial condition.
Legal requirements apply in various jurisdictions in the United
States and overseas requiring deposits or certain taxes or fees be
charged for the sale, marketing and use of certain non-refillable
beverage containers. The precise requirements imposed by these
measures vary. Other types of beverage container-related deposit,
recycling, tax and/or product stewardship statutes and regulations
also apply in various jurisdictions in the United States and
overseas. We anticipate additional, similar legal requirements may
be proposed or enacted in the future at local, state and federal
levels, both in the United States and elsewhere.
New legislation or regulation, the application of laws from
jurisdictions whose laws do not currently apply to our business, or
the application of existing laws and regulations to the Internet
and e-commerce generally could result in significant additional
taxes on our business. Further, we could be subject to fines or
other payments for any past failures to comply with these
requirements. The continued growth and demand for e-commerce is
likely to result in more laws and regulations that impose
additional compliance burdens on e-commerce companies.
Laws and Regulations Relating to Data
Privacy
In the ordinary course of our business, we might collect and store
in our internal and external data centers, cloud services and
networks sensitive data, including our proprietary business
information and that of our customers, suppliers and business
collaborators, as well as personal information of our customers and
employees. The secure processing, maintenance and transmission of
this information is critical to our operations and business
strategy. The number and sophistication of attempted attacks and
intrusions that companies have experienced from third parties has
increased over the past few years. Despite our security measures,
it is impossible for us to eliminate this risk.
A number of U.S. states have enacted data privacy and security laws
and regulations that govern the collection, use, disclosure,
transfer, storage, disposal, and protection of personal
information, such as social security numbers, financial information
and other sensitive personal information. For example, all 50
states and several U.S. territories now have data breach laws that
require timely notification to affected individuals, and at times
regulators, credit reporting agencies and other bodies, if a
company has experienced the unauthorized access or acquisition of
certain personal information. Other state laws, particularly the
California Consumer Privacy Act, as amended ("CCPA"), among other
things, contain disclosure obligations for businesses that collect
personal information about residents in their state and affords
those individuals new rights relating to their personal information
that may affect our ability to collect and/or use personal
information. The Virginia Consumer Data Protection Act ("CDPA")
also establishes rights for Virginia consumers to control how
companies use individuals' personal data. The CDPA dictates how
companies must protect personal data in their possession and
respond to consumers exercising their rights, as prescribed by the
law, regarding such personal data. The CDPA will go into effect on
January 1, 2023. Meanwhile, several other states and the federal
government have considered or are considering privacy laws like the
CCPA. We will continue to monitor and assess the impact of these
laws, which may impose substantial penalties for violations, impose
significant costs for investigations and compliance, allow private
class-action litigation and carry significant potential liability
for our business.
Outside of the U.S., data protection laws, including the EU General
Data Protection Regulation (the "GDPR"), also might apply to some
of our operations or business collaborators. Legal requirements in
these countries relating to the collection, storage, processing and
transfer of personal data/information continue to evolve. The GDPR
imposes, among other things, data protection requirements that
include strict obligations and restrictions on the ability to
collect, analyze and transfer EU personal data/information, a
requirement for prompt notice of data breaches to data subjects and
supervisory authorities in certain circumstances, and possible
substantial fines for any violations (including possible fines for
certain violations of up to the greater of 20 million Euros or 4%
of total company revenue). Other governmental authorities around
the world have enacted or are considering similar types of
legislative and regulatory proposals concerning data
protection.
The interpretation and enforcement of the laws and regulations
described above are uncertain and subject to change, and may
require substantial costs to monitor and implement and maintain
adequate compliance programs. Failure to comply with U.S. and
international data protection laws and regulations could result in
government enforcement actions (which could include substantial
civil and/or criminal penalties), private litigation and/or adverse
publicity and could negatively affect our operating results and
business.
Environmental Regulations
We use certain plastic, glass, fabric, metal and other products in
our business which may be harmful if released into the environment.
In view of the nature of our business, compliance with federal,
state, and local laws regulating the discharge of materials into
the environment, or otherwise relating to the protection of the
environment, has had no material effect upon our operations or
earnings, and we do not expect it to have a material impact in the
foreseeable future.
Tax Laws and Regulations
Changes in tax laws or regulations in the jurisdictions in which we
do business, including the United States, or changes in how the tax
laws are interpreted, could further impact our effective tax rate,
further restrict our ability to repatriate undistributed offshore
earnings, or impose new restrictions, costs or prohibitions on our
current practices and reduce our net income and adversely affect
our cash flows.
We are also subject to tax audits in the United States and other
jurisdictions and our tax positions may be challenged by tax
authorities. Although we believe that our current tax provisions
are reasonable and appropriate, there can be no assurance that
these items will be settled for the amounts accrued, that
additional tax exposures will not be identified in the future or
that additional tax reserves will not be necessary for any such
exposures. Any increase in the amount of taxation incurred as a
result of challenges to our tax filing positions could result in a
material adverse effect on our business, results of operations and
financial condition.
Other Regulations
We are subject to international, federal, national, regional,
state, local and other laws and regulations affecting our business,
including those promulgated under the Occupational Safety and
Health Act, the Consumer Product Safety Act, the Flammable Fabrics
Act, the Textile Fiber Product Identification Act, the rules and
regulations of the Consumer Products Safety Commission, the Food,
Drug, and Cosmetic Act, the Foreign Corrupt Practices Act of 1977
(FCPA), various securities laws and regulations including but not
limited to the Securities Exchange Act of 1934, the Securities
Exchange Act of 1933, and the Nasdaq Stock Market LLC Rules,
various labor, workplace and related laws, and environmental laws
and regulations. Failure to comply with such laws and regulations
may expose us to potential liability and have an adverse effect on
our results of operations.
MANAGEMENT
Directors and Executive Officers
Set forth below is information regarding our directors and
executive officers as of the date of this prospectus.
Name
|
|
Age
|
|
Position
|
Sandro Piancone
|
|
54
|
|
Chief Executive Officer, President, Treasurer, Secretary, and
Director
|
Neville Pearson
|
|
78
|
|
Chief Financial Officer
|
Jorge Olson
|
|
51
|
|
Chief Marketing Officer, Executive Vice President &
Director
|
Dr. Stuart Titus
|
|
66
|
|
Chairman of the Board
|
Jerry Halamuda
|
|
72
|
|
Independent Director
|
Miki Stephens
|
|
49
|
|
Independent Director
|
Sandro Piancone co-founded our Company and has
served as our President and Chief Executive Officer, Treasurer,
Secretary, and Director since inception. Mr. Piancone has served as
the Chief Executive Officer of Primus Logistics, a cold storage
company since January 2018. He has also served as the Chief
Executive Officer of UST Mexico, Inc, a Mexican tobacco company
since November 2013. From January 2011 to December 2017, Mr.
Piancone served as the Managing Director of Nery’s Logistics, Inc,
a foodservice and food distributor company in Mexico. From January
2012 to December 2019, he worked as the Chief Executive Officer of
Mexico Sales Made Easy-Self Promotion Platform, a marketing
company. Mr. Piancone has also been the President, Chief Executive
Officer and member of the Board of Directors of Green Globe
International, Inc., our majority owner, since March 22, 2021. Mr.
Piancone has a track record of building distribution companies with
manufacturing, sales, and distribution success. We believe that Mr.
Piancone's extensive experience in the cigarette manufacturing,
food and beverage industries makes him a valuable member of our
Board of Directors.
Jorge Olson co-founded our Company and has served
as Chief Marketing Officer since inception. Mr. Olson has helped to
develop and/or market over 1,000 consumer goods products in the USA
and Mexico. He has marketed consumer goods by creating innovative,
off-the-shelf display programs that are strategically placed in
convenience stores. Mr. Olson has worked with Sandro Piancone for
over fifteen years and is the author of Wholesale MBA and
Build Your Beverage Empire. Since 2003, Mr. Olson has been
the President of Cube17, Inc., his marketing consulting company.
Mr. Olson has also been the Chief Marketing Officer of Green Globe
International, Inc., our majority owner, since March 22, 2021. We
believe that Mr. Olson's vast consumer goods and beverage
experience makes him a valuable member of our Board of
Directors.
Neville Pearson, who served as our Interim Chief
Financial Officer from March 1, 2021-August 31, 2021, was appointed
our Chief Financial Officer as of September 1, 2021, and brings
extensive and direct experience with financial reporting,
management accounting, preparation of SEC filings, and corporate
governance and company secretarial functions. As Chief Accountant
of the UK Construction Division for John Mowlem & Co. PLC, Mr.
Pearson was responsible for over 400 active building and civil
engineering projects which include the NatWest Bank Tower in the
City financial district, and the Docklands Airport in East London.
Mr. Pearson has also been the Chief Financial Officer of Green
Globe International, Inc., our majority owner, since March 22,
2021, and he was recently appointed a director of Green Globe
International, Inc. in September of 2022. He has been the Chief
Financial Officer of ASC Biosciences, Inc. since September 2013,
and he was the Interim CFO of American Hemp Ventures, Inc. from
December 2018 to May 2020.
Dr. Stuart Titus is an expert in hemp and
cannabinoids with experience in investing and managing publicly
traded companies. He left his position as CEO of Medical Marijuana,
Inc., and joined our board in July 2021. Dr. Titus built his
financial expertise on Wall Street, where he worked as a bond
trader for 11 years, managing a trading and underwriting department
as a V.P. for Credit Suisse First Boston Corp. From March 2015
through June of 2021, Dr. Titus was the CEO and a member of the
Board of Directors of Medical Marijuana, Inc., and from June 2021
to the present, Dr. Titus has been a consultant with Seaside Sales
& Marketing, a sales and marketing consulting company focused
on the nutritional supplement industry. Dr. Titus has also been a
member of the Board of Directors of Green Globe International,
Inc., our majority owner, since March 22, 2021. We believe that Dr.
Titus's extensive experience in the cannabis industry makes him a
valuable member of our Board of Directors.
Jerry Halamuda has started over 20 businesses in
the last 50 years; one grew to have approximately $300 million in
sales. He is a business operator with agricultural, M&A and
investment experience. He founded Color Spot Nurseries Inc. in 1983
and served as its Chief Executive Officer and President through
2016 when he retired for health reasons. He has been the CEO
of King Horticulture Supply LLC, a gardening and hydroponics supply
company, since December 2019. He has been a Director of EZ Shipper
Racks, Inc., since September 2018, and he joined our board in July
2021. Mr. Halamuda has also been a member of the Board of Directors
of Green Globe International, Inc., our majority owner, since March
22, 2021. We believe that Mr. Halamuda's hands-on management
experience in connection with agricultural product sales companies
makes him a valuable member of our Board of Directors.
Miki Stephens, MBA, who joined our board on August
29, 2022, is a talented executive and entrepreneur distinguished by
her demonstrated success in mergers and acquisitions.
Strategy-driven discipline in highly complex and regulated
industries provides Ms. Stephens with a well-established background
capable of driving material business advantage. From 2017-2020, Ms.
Stephens served as Co-founder and COO of Harmony Hemp. Ms.
Stephens’ operations and financial experience played a key role in
the 2020 acquisition of Harmony Hemp by Abacus Health and
succession strategies for the company. Ms. Stephens was then the
Director of B2B Supply Planning for Charlotte’s Web from 2020 to
2022, and is currently focused on further developing her family
office through real estate and market investing. Her ability to
turn a vision into reality comes from a deep understanding of
business capabilities within an organization. Miki brings a deep
knowledge of corporate governance from years of working with
publicly traded companies.
Family Relationships
There are no family relationships among any of our officers or
directors.
Involvement in Certain Legal Proceedings
To the best of our knowledge, except as described below, none of
our directors or executive officers has, during the past ten
years:
|
·
|
been convicted in a criminal proceeding or been subject to a
pending criminal proceeding (excluding traffic violations and other
minor offences);
|
|
·
|
had any bankruptcy petition filed by or against the business or
property of the person, or of any partnership, corporation or
business association of which he was a general partner or executive
officer, either at the time of the bankruptcy filing or within two
years prior to that time;
|
|
·
|
been subject to any order, judgment, or decree, not subsequently
reversed, suspended or vacated, of any court of competent
jurisdiction or federal or state authority, permanently or
temporarily enjoining, barring, suspending or otherwise limiting,
his involvement in any type of business, securities, futures,
commodities, investment, banking, savings and loan, or insurance
activities, or to be associated with persons engaged in any such
activity;
|
|
·
|
been found by a court of competent jurisdiction in a civil action
or by the Securities and Exchange Commission or the Commodity
Futures Trading Commission to have violated a federal or state
securities or commodities law, and the judgment has not been
reversed, suspended, or vacated;
|
|
·
|
been the subject of, or a party to, any federal or state judicial
or administrative order, judgment, decree, or finding, not
subsequently reversed, suspended or vacated (not including any
settlement of a civil proceeding among private litigants), relating
to an alleged violation of any federal or state securities or
commodities law or regulation, any law or regulation respecting
financial institutions or insurance companies including, but not
limited to, a temporary or permanent injunction, order of
disgorgement or restitution, civil money penalty or temporary or
permanent cease-and-desist order, or removal or prohibition order,
or any law or regulation prohibiting mail or wire fraud or fraud in
connection with any business entity; or
|
|
·
|
been the subject of, or a party to, any sanction or order, not
subsequently reversed, suspended or vacated, of any self-regulatory
organization (as defined in Section 3(a)(26) of the Exchange Act
(15 U.S.C. 78c(a)(26))), any registered entity (as defined in
Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C.
1(a)(29))), or any equivalent exchange, association, entity or
organization that has disciplinary authority over its members or
persons associated with a member.
|
Corporate Governance
Governance Structure
We chose to appoint a separate Chairman of the Board who is not our
Chief Executive Officer. Our board of directors has made this
decision based on their belief that an independent Chairman of the
Board can act as a balance to the Chief Executive Officer, who also
serves as a non-independent director.
The Board's Role in Risk Oversight
The board of directors oversees that the assets of our company are
properly safeguarded, that the appropriate financial and other
controls are maintained, and that our business is conducted wisely
and in compliance with applicable laws and regulations and proper
governance. Included in these responsibilities is the board's
oversight of the various risks facing our company. In this regard,
our board seeks to understand and oversee critical business risks.
Our board does not view risk in isolation. Risks are considered in
virtually every business decision and as part of our business
strategy. Our board recognizes that it is neither possible nor
prudent to eliminate all risk. Indeed, purposeful and appropriate
risk-taking is essential for our company to be competitive on a
global basis and to achieve its objectives.
While the board oversees risk management, company management is
charged with managing risk. Management communicates routinely with
the board and individual directors on the significant risks
identified and how they are being managed. Directors are free to,
and indeed often do, communicate directly with senior
management.
Our board administers its risk oversight function as a whole by
making risk oversight a matter of collective consideration. Much of
this work has been delegated to committees, which will meet
regularly and report back to the full board. The audit committee
oversees risks related to our financial statements, the financial
reporting process, accounting and legal matters, the compensation
committee evaluates the risks and rewards associated with our
compensation philosophy and programs, and the nominating and
corporate governance committee evaluates risk associated with
management decisions and strategic direction.
Independent Directors
Nasdaq's rules generally require that a majority of an issuer's
board of directors must consist of independent directors. Our board
of directors currently consists of five (5) directors, Mr.
Piancone, Mr. Olson, Dr. Titus, Mr. Halamuda, and Ms. Stephens,
with Dr. Titus, Mr. Halamuda and Ms. Stephens considered
independent within the meaning of Nasdaq's rules.
Committees of the Board of Directors
Our board has established an audit committee, a compensation
committee, and a nominating and corporate governance committee,
each with its own charter approved by the board. The committee
charters have been filed as exhibits to the registration statement
of which this prospectus is a part. Upon completion of this
offering, we intend to make each committee's charter available on
our website at https://hempaccoinc.com/.
In addition, our board of directors may, from time to time,
designate one or more additional committees, which shall have the
duties and powers granted to it by our board of directors.
Audit
Committee
Ms. Stephens, Dr. Titus, and Mr. Halamuda, each of whom satisfies
the "independence" requirements of Rule 10A-3 under the Exchange
Act and Nasdaq's rules, serve on our audit committee, with Mr.
Halamuda serving as the chairperson. Our board has determined
that Mr. Halamuda qualifies as an "audit committee financial
expert." The audit committee oversees our accounting and financial
reporting processes and the audits of the financial statements of
our company.
The audit committee is responsible for, among other things: (i)
retaining and overseeing our independent accountants; (ii)
assisting the board in its oversight of the integrity of our
financial statements, the qualifications, independence and
performance of our independent auditors and our compliance with
legal and regulatory requirements; (iii) reviewing and approving
the plan and scope of the internal and external audit; (iv)
pre-approving any audit and non-audit services provided by our
independent auditors; (v) approving the fees to be paid to our
independent auditors; (vi) reviewing with our chief executive
officer and principal financial officer and independent auditors
the adequacy and effectiveness of our internal controls; (vii)
reviewing hedging transactions; and (viii) reviewing and assessing
annually the audit committee's performance and the adequacy of its
charter.
Compensation
Committee
Ms. Stephens, Dr. Titus, and Mr. Halamuda, each of whom satisfies
the "independence" requirements of Rule 10C-1 under the Exchange
Act and Nasdaq's rules, serve on our compensation committee, with
Dr. Titus serving as the chairperson. The members of the
compensation committee are also "outside directors" as defined in
Section 162(m) of the Internal Revenue Code of 1986, as amended, or
the Code, and "non-employee directors" within the meaning of
Section 16 of the Exchange Act. The compensation committee assists
the board in reviewing and approving the compensation structure,
including all forms of compensation, relating to our directors and
executive officers.
The compensation committee is responsible for, among other things:
(i) reviewing and approving the remuneration of our executive
officers; (ii) making recommendations to the board regarding the
compensation of our independent directors; (iii) making
recommendations to the board regarding equity-based and incentive
compensation plans, policies and programs; and (iv) reviewing and
assessing annually the compensation committee's performance and the
adequacy of its charter.
Nominating and
Corporate Governance Committee
Ms. Stephens, Dr. Titus, and Mr. Halamuda, each of whom satisfies
the "independence" requirements of Nasdaq's rules, serve on our
nominating and corporate governance committee, with Ms.
Stephens serving as the chairperson. The nominating and
corporate governance committee assists the board of directors in
selecting individuals qualified to become our directors and in
determining the composition of the board and its committees.
The nominating and corporate governance committee is responsible
for, among other things: (i) identifying and evaluating individuals
qualified to become members of the board by reviewing nominees for
election to the board submitted by shareholders and recommending to
the board director nominees for each annual meeting of shareholders
and for election to fill any vacancies on the board; (ii) advising
the board with respect to board organization, desired
qualifications of board members, the membership, function,
operation, structure and composition of committees (including any
committee authority to delegate to subcommittees), and
self-evaluation and policies; (iii) advising on matters relating to
corporate governance and monitoring developments in the law and
practice of corporate governance; (iv) overseeing compliance with
the our code of ethics; and (v) approving any related party
transactions.
The nominating and corporate governance committee's methods for
identifying candidates for election to our board of directors
(other than those proposed by our shareholders, as discussed below)
will include the solicitation of ideas for possible candidates from
a number of sources - members of our board of directors, our
executives, individuals personally known to the members of our
board of directors, and other research. The nominating and
corporate governance committee may also, from time-to-time, retain
one or more third-party search firms to identify suitable
candidates.
In making director recommendations, the nominating and corporate
governance committee may consider some or all of the following
factors: (i) the candidate's judgment, skill, experience with other
organizations of comparable purpose, complexity and size, and
subject to similar legal restrictions and oversight; (ii) the
interplay of the candidate's experience with the experience of
other board members; (iii) the extent to which the candidate would
be a desirable addition to the board and any committee thereof;
(iv) whether or not the person has any relationships that might
impair his or her independence; and (v) the candidate's ability to
contribute to the effective management of our company, taking into
account the needs of our company and such factors as the
individual's experience, perspective, skills and knowledge of the
industry in which we operate.
A shareholder may nominate one or more persons for election as a
director at an annual meeting of shareholders if the shareholder
complies with the notice and information provisions contained in
our bylaws. Such notice must be in writing to our Company not later
than the close of business on the ninetieth (90th) day nor earlier
than the close of business on the one-hundred-twentieth (120th) day
prior to the first anniversary of the preceding year's annual
meeting; provided, however, that in the event that the date of the
annual meeting is advanced more than thirty (30) days prior to or
delayed by more than thirty (30) days after the anniversary of the
preceding year's annual meeting, notice by the stockholder to be
timely must be so delivered not earlier than the close of business
on the one hundred twentieth (120th) day prior to such annual
meeting and not later than the close of business on the later of
the ninetieth (90th) day prior to such annual meeting or the tenth
(10th) day following the day on which public announcement of the
date of such meeting is first made or as otherwise required by the
Exchange Act. In addition, shareholders furnishing such notice must
be a holder of record on both (i) the date of delivering such
notice and (ii) the record date for the determination of
shareholders entitled to vote at such meeting.
Code of Ethics
We have adopted a code of ethics that applies to all of our
directors, officers and employees, including our principal
executive officer, principal financial officer and principal
accounting officer. Such code of ethics addresses, among other
things, honesty and ethical conduct, conflicts of interest,
compliance with laws, regulations and policies, including
disclosure requirements under the federal securities laws, and
reporting of violations of the code.
A copy of the code of ethics has been filed as an exhibit to the
registration statement of which this prospectus is a part. We are
required to disclose any amendment to, or waiver from, a provision
of our code of ethics applicable to our principal executive
officer, principal financial officer, principal accounting officer,
controller, or persons performing similar functions. We intend to
use our website as a method of disseminating this disclosure as
well as by SEC filings, as permitted or required by applicable SEC
rules. Any such disclosure will be posted to our website within
four (4) business days following the date of any such amendment to,
or waiver from, a provision of our code of ethics.
EXECUTIVE COMPENSATION
The following discussion and analysis of compensation
arrangements should be read together with the compensation tables
and related disclosures that follow. This discussion contains
forward-looking statements that are based on our current plans and
expectations regarding future compensation programs. Actual
compensation programs that we adopt may differ materially from the
programs summarized in this discussion. The following discussion
may also contain statements regarding corporate performance targets
and goals. These targets and goals are disclosed in the limited
context of our compensation programs and should not be understood
to be statements of management's expectations or estimates of
results or other guidance. We specifically caution investors not to
apply these statements to other contexts.
Summary Compensation Table – Years Ended December 31, 2022
and 2021
The following table sets forth information concerning all cash and
non-cash compensation awarded to, earned by or paid to the named
persons for services rendered in all capacities during the noted
periods. No other executive officers received total annual salary
and bonus compensation in excess of $100,000.
Summary Compensation Table
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
All Other
|
|
|
|
|
|
|
Fiscal
|
|
Salary
|
|
|
Bonus
|
|
|
Awards
|
|
|
Awards
|
|
|
Compensation
|
|
|
Total
|
|
Name and Principal Position
|
|
Year
|
|
(1)
|
|
|
(2)
|
|
|
(3)
|
|
|
(4)
|
|
|
(5)
|
|
|
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sandro Piancone
|
|
2022
|
|
$
|
120,000
|
(6)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
120,000
|
|
Chief Executive Officer, President, Treasurer & Secretary
|
|
2021
|
|
$
|
300,000
|
(6)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Neville Pearson
|
|
2022
|
|
$
|
60,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
60,000
|
|
Chief Financial Officer (7)
|
|
2021
|
|
$
|
50,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jorge Olson
|
|
2022
|
|
$
|
120,000
|
(8)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
120,000
|
|
Chief Marketing Officer & Executive Vice President
|
|
2021
|
|
$
|
120,000
|
(8)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
120,000
|
|
__________
(1)
|
The dollar value of salary (cash and non-cash) earned.
|
(2)
|
The dollar value of bonus (cash and non-cash) earned.
|
(3)
|
The value of the shares of common stock issued as compensation for
services computed in accordance with ASC 718 on the date of
grant.
|
(4)
|
The value of all stock options computed in accordance with ASC 718
on the date of grant.
|
(5)
|
All other compensation received that could not be properly reported
in any other column of the table.
|
(6)
|
Mr. Piancone's entity, Strategic Global Partners, Inc., accrued
$120,000 in consulting fees during each of the years ended December
31, 2021 and 2020, and it was issued 170,000 shares of Company
common stock in satisfaction of the $170,000 accrued balance on May
21, 2021. The remaining balance of $70,000 was paid in cash. Mr.
Piancone's entity, UST Mexico, Inc., accrued $180,000 in consulting
fees during the years ended December 31, 2021 and 2020, and its
accrued balance that had not been paid in cash was $24,600 as of
December 31, 2021, and $26,600 as of December 31, 2020. On January
20, 2022, we entered into an employment agreement with Mr.
Piancone, which replaced our prior consulting agreement with Mr.
Piancone’s entity, and pursuant to which Mr. Piancone was paid a
salary of $120,000 in 2022.
|
(7)
|
Mr. Pearson served as our Interim Chief Financial Officer from
March 1, 2021 to August 31, 2021, when he was appointed our Chief
Financial Officer. On January 20, 2022, we entered into an
employment agreement with Mr. Pearson pursuant to which Mr. Pearson
was paid a salary of $60,000 in 2022.
|
(8)
|
Mr. Olson's entity, Cube17, Inc., accrued $15,000 in consulting
fees during year ended December 31, 2019, and $120,000 during each
of the years ended December 31, 2021 and 2020, and it was issued
185,000 shares of Company common stock in satisfaction of the
$185,000 accrued balance on May 21, 2021. The remaining balance of
$70,000 was paid in cash. On February 3, 2022, we entered into an
employment agreement with Mr. Olson, which replaced our prior
consulting agreement with Mr. Olson’s entity, and pursuant to which
Mr. Olson was paid a salary of $120,000 in 2022.
|
Employment Agreements
We have not entered into employment or similar agreements with any
of our executive officers or directors except as follows:
We entered into a consulting agreement with Cube17, Inc., an entity
controlled by our founder and officer, Jorge Olson, on or about
November 6, 2019, pursuant to which the entity would provide
management, sales and marketing services to us in consideration of
the issuance of 400,000 shares of our common stock, cash fees in
the amount of $10,000/month, and sales commissions as follows: (i)
5% for direct sales, (ii) 2.5% for sales through an intermediate
broker, (iii) 5% for other retail sales (without an intermediate
broker), (iv) 5% for sales as a result of online or website leads
generated by Cube17, Inc., (v) 10% for direct retail online sales
of Company brands (such as The Real Stuff™), and (vi) 5% for
machine sales and other business opportunities. The agreement had
an initial term of one (1) year and has automatically renewed for
successive terms, although either party can terminate the agreement
for any reason by providing the other party 30 days' notice.
We entered into a consulting agreement with Strategic Global
Partners, Inc., an entity controlled by our founder and CEO, Sandro
Piancone, on or about January 3, 2020, pursuant to which the entity
would provide management, sales, marketing and logistics services
to us in consideration of cash fees of $10,000/month for an initial
term of sixty (60) months. The agreement also requires us to
reimburse the entity for reasonable and necessary expenses incurred
by the entity in performing its duties under the agreement. The
agreement is terminable by either party only upon the provision of
twelve (12) months' notice to the other party.
We entered into a consulting agreement with UST Mexico, Inc., an
entity controlled by our founder and CEO, Sandro Piancone, on or
about January 3, 2020, pursuant to which the entity would provide
manufacturing, production, supplier management, and equipment
maintenance services to us in consideration of cash fees of
$15,000/month for an initial term of sixty (60) months. The
agreement also requires us to reimburse the entity for reasonable
and necessary expenses incurred by the entity in performing its
duties under the agreement. The agreement is terminable by either
party only upon the provision of twelve (12) months' notice to the
other party.
We entered into an Interim Consulting Agreement with Neville
Pearson, our Interim Chief Financial Officer, on March 1, 2021, for
him to act as our Interim Chief Financial Officer for a period from
March 1, 2021, through August 31, 2021, and pursuant which Mr.
Pearson would be paid $5,000 per month. Beginning on September 1,
2021, Mr. Pearson entered into an agreement with our majority
shareholder, Green Globe International, Inc., pursuant to which he
would act as the Chief Financial Officer of it, would be
compensated by it instead of us, but would continue to act as our
Chief Financial Officer.
On January 20, 2022, we entered into an employment agreement with
Mr. Piancone, which supersedes and replaces our prior consulting
agreement with Mr. Piancone’s entity, Strategic Global Partners,
Inc. Pursuant to the employment agreement, which has an initial
term of three years, Mr. Piancone agreed to act as our Chief
Executive Officer, devote his full time (approximately 40 hours per
week) and attention to the performance of Company duties, and we
agreed to pay Mr. Piancone an annual base salary of $120,000, as
well as an annual bonus up to 110% of Mr. Piancone’s base salary,
based on Mr. Piancone’s and the Company’s performance, each as
determined by our Board of Directors (the “Board”). Mr. Piancone is
also eligible to receive annual grants of long-term incentive
awards (with an initial incentive award target value of 130% of Mr.
Piancone’s base salary) and participate in other Company employee
benefit plans, if any, and is entitled to take 30 days of paid
vacation during each 12-month period. Mr. Piancone is to be
reimbursed for expenses incurred in connection with his employment,
and during the period of Mr. Piancone’s employment with the Company
and for two years thereafter, Mr. Piancone is prohibited from
competing with the Company in the manufacturing of hemp smokable
products. Mr. Piancone assigned to the Company any intellectual
property rights related to our operations that he may have had
prior to the effective date of the employment agreement. Mr.
Piancone’s employment can be terminated by the Company at any time
or by Mr. Piancone upon the provision of 30 days’ notice to the
Company. If the Company terminates Mr. Piancone’s employment for a
reason other than “Cause” (as defined below), Mr. Piancone will be
entitled to a severance payment in an amount equal to 12 months of
Mr. Piancone’s base salary in effect as of the termination. If Mr.
Piancone’s employment is terminated (i) by the Company without
Cause following a “Change in Control” (as defined below), or (ii)
following a Change in Control, because Mr. Piancone has resigned
due to a material reduction in his authority, duties or
responsibilities, a material reduction in his base salary or
benefits, a mandatory relocation more than 50 miles from Mr.
Piancone’s then-current place of employment, or the Company’s
failure to obtain the assumption of the employment agreement upon
the Change in Control, then Mr. Piancone will be entitled to a
severance payment in an amount equal Mr. Piancone’s base salary in
effect as of the termination (or the highest base salary during the
three years prior to the termination) plus the average annual bonus
for the prior three years (or if the termination occurs before the
annual bonus is paid for the employee’s first year of employment,
110% of the base salary). “Cause” is generally defined as (i)
conviction or plea of no contest to the commission of a felony or
any misdemeanor that is causing substantial harm to the Company or
is a crime of moral turpitude, (ii) repeated intoxication by
alcohol or drugs that materially and adversely affects the
employee’s performance of his duties, (iii) malfeasance in the
conduct of the employee’s duties, including misuse or diversion of
Company funds, embezzlement, or misrepresentations or concealments
on any written reports submitted by or on behalf of the Company,
(iv) violation of any provision of the employment agreement, (v)
failure to perform the duties required by the employee’s employment
with the Company after the employee shall have been informed, in
writing, of the material failure, and given 30 days to remedy the
failure, or (vi) failure to follow or comply with the reasonable
and lawful written directives or policies of the Company.
“Change in Control” is generally defined as an acquisition of 40%
or more of the voting securities of the Company, the approval by
the Company’s stockholders of a complete liquidation or
dissolution, or the consummation of a reorganization, merger,
consolidation or sale of substantially all of the assets of the
Company, unless following the transaction (i) the beneficial owners
of the Company’s voting securities before the transaction continue
to beneficially own more than 60% of the voting securities of the
Company after the transaction, (ii) no beneficial owner owns more
than 40% of the voting securities of the Company after the
transaction unless that ownership existed prior to the transaction,
and (iii) at least a majority of the Board members after the
transaction were members of the Board before the transaction.
On January 20, 2022, we entered into an employment agreement with
Mr. Pearson. Pursuant to the employment agreement, which has an
initial term of three years, Mr. Pearson agreed to act as our Chief
Financial Officer, devote his full time (approximately 40 hours per
week) and attention to the performance of Company duties, and we
agreed to pay Mr. Pearson an annual base salary of $60,000, as well
as an annual bonus up to 110% of Mr. Pearson’s base salary, based
on Mr. Pearson’s and the Company’s performance, each as determined
by the Board. Mr. Pearson is also eligible to receive annual grants
of long-term incentive awards (with an initial incentive award
target value of 130% of Mr. Pearson’s base salary) and participate
in other Company employee benefit plans, if any, and is entitled to
take 30 days of paid vacation during each 12-month period. Mr.
Pearson is to be reimbursed for expenses incurred in connection
with his employment, and during the period of Mr. Pearson’s
employment with the Company and for two years thereafter, Mr.
Pearson is prohibited from competing with the Company in the
manufacturing of hemp smokable products. Mr. Pearson assigned to
the Company any intellectual property rights related to our
operations that he may have had prior to the effective date of the
employment agreement. Mr. Pearson’s employment can be terminated by
the Company at any time or by Mr. Pearson upon the provision of 30
days’ notice to the Company. If the Company terminates Mr.
Pearson’s employment for a reason other than “Cause” (as defined
below), Mr. Pearson will be entitled to a severance payment in an
amount equal to 12 months of Mr. Pearson’s base salary in effect as
of the termination. If Mr. Pearson’s employment is terminated (i)
by the Company without Cause following a “Change in Control” (as
defined below), or (ii) following a Change in Control, because Mr.
Pearson has resigned due to a material reduction in his authority,
duties or responsibilities, a material reduction in his base salary
or benefits, a mandatory relocation more than 50 miles from Mr.
Pearson’s then-current place of employment, or the Company’s
failure to obtain the assumption of the employment agreement upon
the Change in Control, then Mr. Pearson will be entitled to a
severance payment in an amount equal Mr. Pearson’s base salary in
effect as of the termination (or the highest base salary during the
three years prior to the termination) plus the average annual bonus
for the prior three years (or if the termination occurs before the
annual bonus is paid for the employee’s first year of employment,
110% of the base salary). “Cause” is generally defined as (i)
conviction or plea of no contest to the commission of a felony or
any misdemeanor that is causing substantial harm to the Company or
is a crime of moral turpitude, (ii) repeated intoxication by
alcohol or drugs that materially and adversely affects the
employee’s performance of his duties, (iii) malfeasance in the
conduct of the employee’s duties, including misuse or diversion of
Company funds, embezzlement, or misrepresentations or concealments
on any written reports submitted by or on behalf of the Company,
(iv) violation of any provision of the employment agreement, (v)
failure to perform the duties required by the employee’s employment
with the Company after the employee shall have been informed, in
writing, of the material failure, and given 30 days to remedy the
failure, or (vi) failure to follow or comply with the reasonable
and lawful written directives or policies of the Company.
“Change in Control” is generally defined as an acquisition of 40%
or more of the voting securities of the Company, the approval by
the Company’s stockholders of a complete liquidation or
dissolution, or the consummation of a reorganization, merger,
consolidation or sale of substantially all of the assets of the
Company, unless following the transaction (i) the beneficial owners
of the Company’s voting securities before the transaction continue
to beneficially own more than 60% of the voting securities of the
Company after the transaction, (ii) no beneficial owner owns more
than 40% of the voting securities of the Company after the
transaction unless that ownership existed prior to the transaction,
and (iii) at least a majority of the Board members after the
transaction were members of the Board before the transaction.
On February 3, 2022, we entered into an employment agreement with
Mr. Olson, which supersedes and replaces our prior consulting
agreement with Mr. Olson’s entity, Cube17, Inc. Pursuant to the
employment agreement, which has an initial term of three years, Mr.
Olson agreed to act as our Chief Marketing Officer, devote his full
time (approximately 40 hours per week) and attention to the
performance of Company duties, and we agreed to pay Mr. Olson an
annual base salary of $120,000, as well as an annual bonus up to
500% of Mr. Olson’s base salary, based on Mr. Olson’s and the
Company’s performance, each as determined by the Board. Mr. Olson
is also eligible to receive annual grants of long-term incentive
awards (with an initial incentive award target value of 1,000% of
Mr. Olson’s base salary) and participate in other Company employee
benefit plans, if any, and is entitled to take 30 days of paid
vacation during each 12-month period. Mr. Olson is to be reimbursed
for expenses incurred in connection with his employment, and to
receive $350 per diem for Company-related travel outside San Diego,
California, and during the period of Mr. Olson’s employment with
the Company and for two years thereafter, Mr. Olson is prohibited
from competing with the Company in the manufacturing of hemp
smokable products. Mr. Olson assigned to the Company any
intellectual property rights he developed for the Company that he
may have had prior to the effective date of the employment
agreement (but specifically not including rights to Mr. Olson’s
literary works; marketing funnels; LinkedIn groups, Facebook
groups, or other social media contacts and accounts; audios,
podcasts, videos and courses not connected to the Company; and
websites not connected to the Company). Mr. Olson’s employment can
be terminated by the Company or by Mr. Olson upon the provision of
30 days’ notice to the other party. If (i) the Company terminates
Mr. Olson’s employment for a reason other than “Cause” (as defined
below), or (ii) Mr. Olson’s employment is terminated following a
“Change in Control” (as defined below) because Mr. Olson has
resigned due to a material reduction in his authority, duties or
responsibilities, a material reduction in his base salary or
benefits, a mandatory relocation more than 50 miles from Mr.
Olson’s then-current place of employment, or the Company’s failure
to obtain the assumption of the employment agreement upon the
Change in Control, then Mr. Olson will be entitled to a severance
payment in an amount equal two times the sum of (i) Mr. Olson’s
base salary in effect as of the termination (or the highest base
salary during the three years prior to the termination), and (ii)
the average annual bonus for the prior three years (or if the
termination occurs before the annual bonus is paid for the
employee’s first year of employment, 110% of the base salary).
“Cause” is generally defined as (i) conviction or plea of no
contest to the commission of a felony or any misdemeanor that is
causing substantial harm to the Company or is a crime of moral
turpitude, (ii) repeated intoxication by alcohol or drugs that
materially and adversely affects the employee’s performance of his
duties, (iii) malfeasance in the conduct of the employee’s duties,
including misuse or diversion of Company funds, embezzlement, or
misrepresentations or concealments on any written reports submitted
by or on behalf of the Company, (iv) violation of any provision of
the employment agreement, (v) failure to perform the duties
required by the employee’s employment with the Company after the
employee shall have been informed, in writing, of the material
failure, and given 30 days to remedy the failure, or (vi) failure
to follow or comply with the reasonable and lawful written
directives or policies of the Company. “Change in Control” is
generally defined as an acquisition of 40% or more of the voting
securities of the Company, the approval by the Company’s
stockholders of a complete liquidation or dissolution, or the
consummation of a reorganization, merger, consolidation or sale of
substantially all of the assets of the Company, unless following
the transaction (i) the beneficial owners of the Company’s voting
securities before the transaction continue to beneficially own more
than 60% of the voting securities of the Company after the
transaction, (ii) no beneficial owner owns more than 40% of the
voting securities of the Company after the transaction unless that
ownership existed prior to the transaction, and (iii) at least a
majority of the Board members after the transaction were members of
the Board before the transaction.
On August 29, 2022, we entered into an independent director
agreement with Ms. Stephens, pursuant to which she would serve as
an independent director on our Board of Directors, but pursuant to
which Ms. Stephens’ compensation terms were to be determined as of
a later date.
Outstanding Equity Awards at Fiscal Year-End
No executive officer named above had any unexercised options, stock
that has not vested or equity incentive plan awards outstanding as
of December 31, 2022 and 2021.
Director Compensation
No member of our board of directors received any compensation for
his or her services as a director during the fiscal years ending
December 31, 2022 and 2021, nor do they currently receive any
compensation for such services.
Effective September 2, 2022, we determined to begin compensating
each of our directors as follows: (i) during the first year
(September 2, 2022-September 1, 2023), no cash compensation will be
paid; (ii) during the second year, the directors will be paid
$12,000 for the year, prorated and paid monthly; (iii) during the
third year, the directors will be paid $24,000 for the year,
prorated and paid monthly; and (iv) each director shall receive
options to purchase 75,000 shares of our common stock at
$2.00/share, which shall vest monthly over three years and shall be
exercisable for seven years from the date of grant. No written
agreements have been entered into to implement this director
compensation structure.
Equity Incentive Plans
Long-Term Incentive Plans. The Company does not provide
its officers or employees with pension, stock appreciation rights,
long-term incentive or other plans, nor does it provide
non-qualified deferred compensation to its officers or employees,
and therefore, the Summary Compensation Table above does not
include columns for nonequity incentive plan compensation and
nonqualified deferred compensation earnings since there were
none.
Employee Pension, Profit Sharing or other Retirement
Plans. The Company does not have a defined benefit, pension
plan, profit sharing or other retirement plan, although it may
adopt one or more of such plans in the future.
CERTAIN RELATIONSHIPS AND RELATED PARTY
TRANSACTIONS
Transactions with Related Persons
The following includes a summary of transactions during the fiscal
years ending December 31, 2021 and 2020, or any currently proposed
transaction, in which we were or are to be a participant and the
amount involved exceeded or exceeds the lesser of $120,000 or one
percent of the average of our total assets at year-end for the last
three completed fiscal years, and in which any related person had
or will have a direct or indirect material interest (other than
compensation described under "Executive Compensation"
above). We believe the terms obtained or consideration that we paid
or received, as applicable, in connection with the transactions
described below were comparable to terms available or the amounts
that would be paid or received, as applicable, in arm's-length
transactions.
On October 22, 2019, we entered into a Kiosk Acquisition Agreement
with Mexico Franchise Opportunity Fund LP ("MFOF"), a related party
entity owned approximately 31% by our founder and CEO, Sandro
Piancone, and approximately 25% by our founder and officer, Jorge
Olson, to purchase 600 vending kiosks for total consideration of
$3,638,357, payable by the issuance of 8,000,000 shares of Series A
Preferred Shares to MFOF. Due to the related party status of MFOF,
and since the entities were under common control, we used the
carryover basis of accounting, and the 600 kiosks were recorded at
net book value of $3,638,357 upon acquisition.
As of December 31, 2021 and 2020, we owed $29,000 and $53,877,
respectively, to UST Mexico, Inc. (“UST”), an entity controlled by
our founder and CEO, Mr. Piancone, which manufactures tobacco
cigarettes in Mexico, for consulting fees payable to UST for
manufacturing, production, supplier management, and equipment
maintenance services. As of December 31, 2021 and 2020, we were
owed $132,147 and $0, respectively, by UST for products we sold to
UST and for equipment parts provided to UST. The value of goods and
services we provided to UST was $152,147 and $62,174 for the years
ended December 31, 2021 and 2020, respectively, and the value of
goods and services provided by UST to us was $251,000 and $205,127
for the years ended December 31, 2021 and 2020, respectively. The
value of goods and services provided by UST to us was $147,182 for
the nine months ended September 30, 2022. As of September 30, 2022,
we were owed $134,534 by UST for products we sold to UST and for
equipment parts provided to UST. The value of goods and services we
provided to UST was $31,840 for the nine months ended September 30,
2022, and as of September 30, 2022, we owed $12,181 to UST.
As of December 31, 2020, we owed $120,000 to Strategic Global
Partners, Inc. ("SGP"), Mr. Piancone's entity, for consulting fees
payable to the entity for Mr. Piancone's management, sales and
other services to us during 2020. We accrued another $50,000 in
consulting fees to SGP through May of 2021, and on May 21, 2021, we
issued 170,000 shares of common stock to SGP in satisfaction of the
total accrued fees of $170,000. As of December 31, 2021, we owed
$70,000 to SGP for services rendered by SGP to us. Consulting
expenses of $60,000 were recorded for the nine months ended
September 30, 2022, and as of September 30, 2022, we owed $28,000
to SGP for services rendered by SGP to us.
As of December 31, 2019, we owed $15,000 to Cube17, Inc. ("Cube"),
Mr. Olson's entity, for consulting fees payable to the entity for
Mr. Olson's sales, marketing and other services to us during 2019.
We accrued another $120,000 in consulting fees to Cube in 2020, and
another $50,000 through May of 2021, and on May 21, 2021, we issued
185,000 shares of common stock to Cube in satisfaction of the total
accrued fees of $185,000. As of December 31, 2021 and 2020, we owed
$63,404 and $135,000, respectively to Cube for services rendered by
Cube to us. Consulting expenses to Cube of $30,000 were
recorded for the nine months ended September 30, 2022. As of
September 30, 2022, we owed $47,738 to Cube for services rendered
by Cube to us.
As of December 31, 2021 and 2020, we owed Primus Logistics, our
landlord and an entity which is owned 90% by Mr. Piancone, $0 and
$116,940, respectively, for rent, inventory and product storage. As
of December 31, 2021, Primus Logistics had been paid $14,764 in
advance for rent. As of September 30, 2022, we owed Primus
Logistics $9. As of September 30, 2022, Primus Logistics had been
paid $17,752 in advance for rent.
Lake Como is also owned and controlled by Mr. Piancone. This entity
is used by us primarily as a sales company for our products, and it
sometimes sells products it purchases from us. As of December 31,
2021 and 2020, we had receivables of $150 and $5,586, respectively,
from Lake Como for sales of our products made by Lake Como. As of
September 30, 2022, we had receivables of $150 from Lake Como for
sales of our products made by Lake Como.
On or about March 18, 2022, we borrowed $50,000 from Jerry
Halamuda, one of our directors, and issued Mr. Halamuda a $50,000
promissory note, accruing interest at 8% per annum, which
originally matured on June 18, 2022, and was extended to mature on
December 18, 2022. The note is secured by 50,000 shares of our
common stock.
Transactions in
Connection with Green Globe International, Inc.
In February 2021, we negotiated the acquisition from an unrelated
third party of 100 shares of super-voting Series A Preferred Stock
(the “Control Block”) of Green Globe International, Inc., a
Delaware corporation (“Green Globe”), for a purchase price of
$50,000, with the understanding that the officers and directors of
Green Globe at the time would resign and our officers and directors
and nominees would be appointed as the officers and directors of
Green Globe upon payment of the $50,000 acquisition purchase price.
The Control Block was entitled to approximately 80% of the voting
rights of the capital stock of Green Globe, and there were
approximately 3,700,640,356 shares of Green Globe common stock
outstanding at the time. Green Globe had not filed any quarterly or
annual reports with OTCMarkets.com since May 16, 2019, and we
viewed Green Globe as insolvent because, at that time, its
liabilities exceeded its assets, it had no current assets and had a
working capital deficit, it was not generating revenues, and
it was not generating any cash flows from operations, investing
activities, or financing activities. Subsequent reports filed by
Green Globe with OTCMarkets.com indicated that it was a shell
company (i.e., a company with no or nominal non-cash assets and no
or nominal operations) at that time. We also determined that upon
acquiring control of Green Globe, we would cancel the Control Block
and have Green Globe acquire Hempacco in a share exchange
transaction by issuing 70,312,160,174 shares of Green Globe common
stock in exchange for all outstanding shares of Hempacco, such that
(i) Hempacco would become a wholly-owned subsidiary of Green Globe,
(ii) Hempacco’s shareholders immediately prior to acquiring
Hempacco would receive 95% of the common stock of Green Globe
(70,312,160,174 shares out of 74,012,800,530 that would be
outstanding following the share exchange), and (iii) Green Globe’s
common shareholders immediately prior to acquiring Hempacco would
retain 5% of Green Globe’s common stock (3,700,640,356 shares out
of 74,012,800,530 shares that would be outstanding following the
share exchange). We also determined at the time that we did not
want to effect the share exchange with Green Globe until we had
resolved as many of our outstanding liabilities as practicable. We
did not obtain any fairness opinion or other valuation of either
Green Globe or Hempacco at the time, and the 70,312,160,174-share
number (the number of shares of Green Globe we determined would be
issued to Hempacco’s shareholders in the share exchange
transaction) was arbitrarily determined by us without reference to
any particular valuation or book value.
On or about March 22, 2021, we paid the $50,000 purchase price for
the Control Block and acquired it, the officers and directors of
Green Globe resigned, and our officers, our sole director at the
time, and two other director nominees selected by us were appointed
as the officers and directors of Green Globe as follows: (i) our
CEO and sole director, Sandro Piancone, was appointed as CEO and
director of Green Globe; (ii) Neville Pearson, our Chief Financial
Officer, was appointed as the Chief Financial Officer, Secretary
and Treasurer of Green Globe; (iii) Jorge Olson, our Chief
Marketing Officer, was appointed as the Chief Marketing Officer of
Green Globe; and (iv) Jerry Halamuda and Dr. Stuart Titus, who at
the time had no positions with us, were appointed as directors of
Green Globe at our direction.
As of March 22, 2021, we had outstanding approximately 8,478,000
shares of common stock and 8,000,000 Series A Preferred Shares.
Between March 22, 2021, and May 21, 2021, we negotiated with
counterparties owed funds by us, including the related parties
described below, with the goal of resolving as much of our
outstanding obligations as possible prior to effecting the share
exchange with Green Globe. We then issued 9,917,532 shares of our
common stock, and then closed the share exchange with Green Globe
on May 21, 2021, with all 18,395,532 shares of our outstanding
common stock transferred to Green Globe in consideration of Green
Globe’s issuance of an aggregate of 70,312,160,174 shares to our
shareholders. The 9,917,532 shares of common stock we issued on May
21, 2021, are described below. Between March 22, 2021, and May 21,
2021, Mr. Piancone was our CEO and sole director, he was the CEO
and one of the directors of Green Globe, he was the officer and
control person of several of the related party entities described
below, and he functionally controlled both us and Green
Globe.
On October 22, 2019, we had entered into a Kiosk Acquisition
Agreement with Mexico Franchise Opportunity Fund LP ("MFOF") (a
related party entity of which approximately 31% is owned by our
founder and CEO, Sandro Piancone, and approximately 25% is owned by
our founder and CMO, Jorge Olson) to purchase 600 vending kiosks
for total consideration of $3,638,357, payable by the issuance of
8,000,000 shares of our Series A Preferred Shares to MFOF. On May
21, 2021, we issued 8,757,479 shares of common stock to MFOF upon
conversion of the 8,000,000 shares of Series A Preferred Shares
into common stock at $1.00 per share, and payment of 757,479 shares
of common stock for accrued dividends of $757,479, due on the
preferred shares, at $1.00 per share.
On May 21, 2021, we issued 357,006 shares of common stock to eight
third-party lenders shares for conversion of debt owed to the
lenders at $1.00 per share, with 336,500 of such shares issued upon
conversion of principal of $336,500, and 20,506 of such shares
issued upon conversion of accrued interest of $20,506.
On May 21, 2021, we issued 127,016 shares of common stock to Mr.
Halamuda (now considered a related party as he was appointed as a
member of our Board of Directors in July 2021) for conversion of
debt owed to Mr. Halamuda at $1.00 per share, with 125,000 of such
shares issued upon conversion of principal of $125,000, and 2,016
of such shares issued upon conversion of accrued interest of
$2,016.
On May 21, 2021, we issued 51,030 shares of common stock to a
lender (Dr. Stuart Titus, now considered a related party as he was
appointed as our Chairman of the Board of Directors in July 2021)
for conversion of debt owed to Dr. Titus at $1.00 per share, with
50,000 of such shares issued upon conversion of principal of
$50,000, and 1,030 of such shares issued upon conversion of accrued
interest of $1,030.
On May 21, 2021, we issued 170,000 shares of common stock to an
entity (Strategic Global Partners, Inc.) controlled by our founder
and CEO, Mr. Piancone, in satisfaction of $170,000 of accrued fees
for management services owed to the entity by us.
On May 21, 2021, we issued 185,000 shares of common stock to an
entity (Cube17, Inc.) controlled by our founder and CMO, Mr. Olson,
in satisfaction of $185,000 of accrued fees for management services
owed to the entity by us.
On May 21, 2021, we issued 170,000 shares of common stock to an
entity (Primus Logistics) controlled by our founder and CEO, Mr.
Piancone, for rent of our manufacturing and office facility from
January 1, 2020, to May 31, 2021, valued at $170,000.
On May 21, 2021, we issued 100,000 shares of common stock to a
third party for information technology, software development, and
kiosk technical services provided by them to us valued at
$100,000.
On or about March 1, 2022, we entered into a mutual line of credit
agreement with Green Globe to facilitate our short-term borrowing
needs on an interest-free basis, with advances being subject to
repayment within 90 days with a maximum of $500,000 allowed to be
outstanding within any 90-day period. During the nine months ended
September 30, 2022, Green Globe and its other subsidiaries advanced
or paid $621,755 to us under the line of credit, and we advanced or
paid $683,100 to Green Globe and its subsidiaries under the line of
credit. As of September 30, 2022, the balance owed to us by Green
Globe was $61,345.
Promoters and Certain Control Persons
Each of our executive officers may be deemed a "promoter" as
defined by Rule 405 of the Securities Act. For information
regarding compensation, including items of value, that have been
provided or that may be provided to these individuals, please refer
to "Executive Compensation" above.
PRINCIPAL SHAREHOLDERS
The following table sets forth certain information with respect to
the beneficial ownership of our common stock as of the date of this
prospectus for (i) each of our named executive officers and
directors; (ii) all of our named executive officers and directors
as a group; and (iii) each other shareholder known by us to be the
beneficial owner of more than 5% of our outstanding common stock.
The following table assumes that the underwriters have not
exercised the over-allotment option.
Beneficial ownership is determined in accordance with SEC rules and
generally includes voting or investment power with respect to
securities. For purposes of this table, a person or group of
persons is deemed to have "beneficial ownership" of any shares of
common stock that such person or any member of such group has the
right to acquire within sixty (60) days of the date of this
prospectus. For purposes of computing the percentage of outstanding
shares of our common stock held by each person or group of persons
named above, any shares that such person or persons has the right
to acquire within sixty (60) days of the date of this prospectus
are deemed to be outstanding for such person, but not deemed to be
outstanding for the purpose of computing the percentage ownership
of any other person. The inclusion herein of any shares listed as
beneficially owned does not constitute an admission of beneficial
ownership by any person.
The percentages below are calculated based
on 23,477,999 shares of our common stock, and 0 shares of
our preferred stock, issued and outstanding as of December 31,
2022. We do not have any outstanding options, warrants exercisable
for, or other securities convertible into shares of our common
stock within the next 60 days which are deemed beneficially owned
by the holder thereof. Unless otherwise indicated, the address of
each beneficial owner listed in the table below is c/o our company,
Hempacco Co., Inc., 9925 Airway Road, San Diego, CA, 92154.
Name of Beneficial Owner
|
|
Title of Class
|
|
Amount and Nature of Beneficial Ownership
|
|
|
Percent of Class Before This Offering
|
|
|
Percent of Class After This Offering
|
|
Sandro Piancone (1)
|
|
Common Stock
|
|
|
17,609,688
|
(2)
|
|
|
75.0
|
%
|
|
|
%
|
Dr. Stuart Titus (3)
|
|
Common Stock
|
|
|
17,709,688
|
(4)(5)
|
|
|
75.4
|
%
|
|
|
%
|
Jerry Halamuda (3)
|
|
Common Stock
|
|
|
17,659,688
|
(4)(6)
|
|
|
75.2
|
%
|
|
|
%
|
Neville Pearson (7)
|
|
Common Stock
|
|
|
17,659,688
|
(4)(8)
|
|
|
75.2
|
%
|
|
|
%
|
Jorge Olson(9)
|
|
Common Stock
|
|
|
-
|
(10)
|
|
|
-
|
|
|
|
|
All Officers and Directors as a Group
|
|
Common Stock
|
|
|
17,809,688
|
(11)
|
|
|
75.9
|
%
|
|
|
%
|
Rafael Rojas(12)
|
|
Common Stock
|
|
|
1,400,000
|
|
|
|
6.0
|
%
|
|
|
%
|
(1)
|
CEO and Director of Hempacco; CEO and Director of our majority
shareholder, Green Globe International, Inc.
|
(2)
|
Mr. Piancone does not directly own any shares of our common stock.
However, he is one of the directors of our majority shareholder,
Green Globe International, Inc. (the majority of its directors are
also directors or officers of us), and he owns approximately 31% of
Mexico Franchise Opportunities Fund LP, which is the holder of
approximately 25% of the common stock and a majority of the Series
C preferred stock of Green Globe International, Inc. Accordingly,
Mr. Piancone may be deemed to be the beneficial owner of shares
held in the name of Green Globe International, Inc. As of December
31, 2022, 17,609,688 shares of our common stock were owned by Green
Globe International, Inc.
|
(3)
|
Director of Hempacco; director of our majority shareholder, Green
Globe International, Inc.
|
(4)
|
Dr. Titus, Mr. Halamuda and Neville Pearson are directors of our
majority shareholder, Green Globe International, Inc., and
therefore they share voting and dispositive power with respect to
shares held in the name of Green Globe International, Inc., and may
be deemed to be beneficial owners of shares held in the name of
Green Globe International, Inc. As of December 31, 2022,
17,609,688 shares of our common stock were owned by Green Globe
International, Inc.
|
(5)
|
Includes 100,000 shares held by Dr. Titus, as well as 17,609,688
shares held by Green Globe International, Inc.
|
(6)
|
Includes 50,000 shares held in the name of the Halamuda Family
Trust, which shares are deemed to be beneficially owned by Mr.
Halamuda, as well as 17,609,688 shares held by Green Globe
International, Inc.
|
(7)
|
CFO of Hempacco; CFO and director of our majority shareholder,
Green Globe International, Inc.
|
(8)
|
Includes 50,000 shares held jointly with his spouse, as well as
17,609,688 shares held by Green Globe International, Inc.
|
(9)
|
CMO and Director; CMO of our majority shareholder, Green Globe
International, Inc.
|
(10)
|
Mr. Olson is the CMO of our majority shareholder, Green Globe
International, Inc., but he is not a director of it, he does not
have or share voting or dispositive power with respect to shares
held in the name of Green Globe International, Inc., and he
beneficially owns no other shares of our stock.
|
(11)
|
Includes 17,609,688 shares held by Green Globe International, Inc.,
100,000 shares held by Dr. Titus, 50,000 shares held in the name of
the Halamuda Family Trust, and 50,000 shares held by Mr. Pearson
with his spouse.
|
(12)
|
Held in the name of Nery’s Logistics, Inc. The Company believes
that Mr. Rojas has voting and dispositive power of shares held in
the name of Nery’s Logistics, Inc., as he is its sole director and
majority shareholder.
|
We do not currently have any arrangements which if consummated may
result in a change of control of our company.
DESCRIPTION OF SECURITIES
General
Our authorized capital stock currently consists of 250,000,000
shares, consisting of 200,000,000 shares of common stock, par value
$0.001 per share, and 50,000,000 shares of "blank check" preferred
stock, par value $0.001 per share.
The following description summarizes important terms of the classes
of our capital stock following the filing of our articles of
incorporation. This summary does not purport to be complete and is
qualified in its entirety by the provisions of our articles of
incorporation and our bylaws which have been filed as exhibits to
the registration statement of which this prospectus is a part.
As
of the date of this prospectus, there were 23,477,999 shares of
common stock and no shares of preferred stock issued and
outstanding. Upon closing of this offering, we will have 28,207,728
shares of common stock issued and outstanding (or 28,917,187 shares
if the underwriters exercise the over-allotment option in full),
and no shares of preferred stock will be issued and
outstanding.
Common Stock
Voting Rights. The holders of common stock are entitled to
one vote for each share held of record on all matters submitted to
a vote of the shareholders. Under our articles of incorporation and
bylaws, any corporate action to be taken by vote of shareholders
other than for election of directors shall be authorized by the
affirmative vote of the majority of votes cast. Directors are
elected by a plurality of votes. Shareholders do not have
cumulative voting rights.
Dividend Rights. Subject to preferences that may be
applicable to any then-outstanding preferred stock, holders of
common stock are entitled to receive ratably those dividends, if
any, as may be declared from time to time by the board of directors
out of legally available funds.
Liquidation Rights. In the event of our liquidation,
dissolution or winding up, holders of common stock will be entitled
to share ratably in the net assets legally available for
distribution to shareholders after the payment of all of our debts
and other liabilities and the satisfaction of any liquidation
preference granted to the holders of any then-outstanding shares of
preferred stock.
Other Rights. Holders of common stock have no preemptive,
conversion or subscription rights and there are no redemption or
sinking fund provisions applicable to the common stock. The rights,
preferences and privileges of the holders of common stock are
subject to, and may be adversely affected by, the rights of the
holders of shares of any series of preferred stock.
Preferred Stock
Our articles of incorporation authorize our board to issue up to
50,000,000 shares of preferred stock in one or more series, to
determine the designations and the powers, preferences and rights
and the qualifications, limitations and restrictions thereof,
including the dividend rights, conversion or exchange rights,
voting rights (including the number of votes per share), redemption
rights and terms, liquidation preferences, sinking fund provisions
and the number of shares constituting the series. Our board of
directors could, without shareholder approval, issue preferred
stock with voting and other rights that could adversely affect the
voting power and other rights of the holders of common stock and
which could have the effect of making it more difficult for a third
party to acquire, or of discouraging a third party from attempting
to acquire, a majority of our outstanding voting stock.
Warrants
Upon the closing of this offering, there will be up to 331,081
shares of common stock issuable upon exercise of the
Representatives’ warrants (up to 380,743 shares if the underwriters
exercise their over-allotment option in full). See
“Underwriting” below for a description of the
Representatives’ warrants.
Options
Although we may issue options to purchase our capital stock in the
future, there are no outstanding options to purchase our capital
stock, nor do we anticipate issuing options to purchase our common
stock immediately after consummation of this offering.
Anti-Takeover Provisions
Provisions of the Nevada Revised Statutes, our articles of
incorporation and our bylaws could have the effect of delaying or
preventing a third-party from acquiring us, even if the acquisition
would benefit our stockholders. Such provisions of the Nevada
Revised Statutes, our articles of incorporation and our bylaws are
intended to enhance the likelihood of continuity and stability in
the composition of our board of directors and in the policies
formulated by the board of directors and to discourage certain
types of transactions that may involve an actual or threatened
change of control of our company. These provisions are designed to
reduce our vulnerability to an unsolicited proposal for a takeover
that does not contemplate the acquisition of all of our outstanding
shares, or an unsolicited proposal for the restructuring or sale of
all or part of our company.
Nevada Anti-Takeover Statutes
Pursuant to our articles of incorporation, we have elected not to
be governed by the terms and provisions of Nevada's control share
acquisition laws (Nevada Revised Statutes 78.378–78.3793), which
prohibit an acquirer, under certain circumstances, from voting
shares of a corporation's stock after crossing specific threshold
ownership percentages, unless the acquirer obtains the approval of
the issuing corporation's stockholders. The first such threshold is
the acquisition of at least one-fifth but less than one-third of
the outstanding voting power.
Pursuant to our articles of incorporation, we have also elected not
to be governed by the terms and provisions of Nevada's combination
with interested stockholder statutes (Nevada Revised Statutes §§
78.411–78.444), which prohibit an "interested stockholder" from
entering into a "combination" with the corporation, unless certain
conditions are met. An "interested stockholder" is a person who,
together with affiliates and associates, beneficially owns (or
within the prior two years, did beneficially own) 10 percent or
more of the corporation's voting stock, or otherwise has the
ability to influence or control such corporation's management or
policies.
Bylaws
In addition, various provisions of our bylaws may also have an
anti-takeover effect. These provisions may delay, defer or prevent
a tender offer or takeover attempt of the Company that a
stockholder might consider in his or her best interest, including
attempts that might result in a premium over the market price for
the shares held by our stockholders. Our bylaws may be adopted,
amended or repealed by the affirmative vote of the holders of at
least a majority of our outstanding shares of capital stock
entitled to vote for the election of directors, and except as
provided by Nevada law, our board of directors shall have the power
to adopt, amend or repeal the bylaws by a vote of not less than a
majority of our directors. Any bylaw provision adopted by the board
of directors may be amended or repealed by the holders of a
majority of the outstanding shares of capital stock entitled to
vote for the election of directors. Our bylaws also contain
limitations as to who may call special meetings as well as require
advance notice of stockholder matters to be brought at a meeting.
Additionally, our bylaws also provide that no director may be
removed by less than a two-thirds vote of the issued and
outstanding shares entitled to vote on the removal. Our bylaws also
permit the board of directors to establish the number of directors
and fill any vacancies and newly created directorships. These
provisions will prevent a shareholder from increasing the size of
our board of directors and gaining control of our board of
directors by filling the resulting vacancies with its own
nominees.
Our bylaws establish an advance notice procedure for shareholder
proposals to be brought before an annual meeting of our
shareholders, including proposed nominations of persons for
election to the board of directors. Shareholders at an annual
meeting will only be able to consider proposals or nominations
specified in the notice of meeting or brought before the meeting by
or at the direction of the board of directors or by a shareholder
who was a shareholder of record on the record date for the meeting,
who is entitled to vote at the meeting and who has given us timely
written notice, in proper form, of the shareholder's intention to
bring that business before the meeting. Although our bylaws do not
give the board of directors the power to approve or disapprove
shareholder nominations of candidates or proposals regarding other
business to be conducted at a special or annual meeting, our bylaws
may have the effect of precluding the conduct of certain business
at a meeting if the proper procedures are not followed or may
discourage or deter a potential acquirer from conducting a
solicitation of proxies to elect its own slate of directors or
otherwise attempting to obtain control of our company.
Authorized but Unissued Shares
Our authorized but unissued shares of common stock are available
for our board of directors to issue without stockholder approval.
We may use these additional shares for a variety of corporate
purposes, including raising additional capital, corporate
acquisitions and employee stock plans. The existence of our
authorized but unissued shares of common stock could render it more
difficult or discourage an attempt to obtain control of the Company
by means of a proxy context, tender offer, merger or other
transaction since our board of directors can issue the Company
large amounts of capital stock as part of a defense to a take-over
challenge. In addition, we have authorized in our articles of
incorporation 50,000,000 shares of preferred stock, none of which
are currently designated or outstanding. However, the board acting
alone and without approval of our stockholders can designate and
issue one or more series of preferred stock containing super-voting
provisions, enhanced economic rights, rights to elect directors, or
other dilutive features, that could be utilized as part of a
defense to a take-over challenge.
Supermajority Voting Provisions
Nevada Law provides generally that the affirmative vote of a
majority of the shares entitled to vote on any matter is required
to amend a corporation's articles of incorporation or bylaws,
unless a corporation's articles of incorporation or bylaws, as the
case may be, require a greater percentage. Although our articles of
incorporation and bylaws do not currently provide for such a
supermajority vote on any matters, our board of directors can amend
our bylaws and we can, with the approval of our stockholders, amend
our articles of incorporation to provide for such a super-majority
voting provision.
Cumulative Voting
Furthermore, neither the holders of our common stock nor the
holders of our preferred stock have cumulative voting rights in the
election of our directors. The combination of the present ownership
by a few shareholders of a significant portion of our issued and
outstanding common stock and lack of cumulative voting makes it
more difficult for other shareholders to replace our board of
directors or for a third party to obtain control of our company by
replacing its board of directors.
Transfer Agent and Registrar
Transfer Online, Inc., 512 SE Salmon Street, Portland, Oregon,
97214, telephone (503) 227-2950, is the transfer agent for our
common stock.
SHARES ELIGIBLE FOR FUTURE
SALE
Before this offering, there has not been a public market for shares
of our common stock. Future sales of substantial amounts of shares
of our common stock, including shares issued upon the conversion of
convertible notes, the exercise of outstanding options and
warrants, in the public market after this offering, or the
possibility of these sales occurring, could cause the prevailing
market price for our common stock to fall or impair our ability to
raise equity capital in the future.
Immediately following the closing of this offering, we will
have 28,207,728 shares of common stock issued and
outstanding. In the event the underwriters exercise in full the
over-allotment option to purchase additional shares of common
stock, we will have 28,917,187 shares of common stock issued and
outstanding. The common stock sold in this offering will be freely
tradable without restriction or further registration or
qualification under the Securities Act.
Previously issued shares of common stock that were not offered and
sold in this offering, as well as shares issuable upon the exercise
of warrants and subject to employee stock options, are or will be
upon issuance, "restricted securities," as that term is defined in
Rule 144 under the Securities Act. These restricted securities are
eligible for public sale only if such public resale is registered
under the Securities Act or if the resale qualifies for an
exemption from registration under Rule 144 or Rule 701 under the
Securities Act, which are summarized below.
Rule 144
In general, a person who has beneficially owned restricted shares
of our common stock for at least twelve months, or at least six
months in the event we have been a reporting company under the
Exchange Act for at least ninety (90) days before the sale, would
be entitled to sell such securities, provided that such person is
not deemed to be an affiliate of ours at the time of sale or to
have been an affiliate of ours at any time during the ninety (90)
days preceding the sale. A person who is an affiliate of ours at
such time would be subject to additional restrictions, by which
such person would be entitled to sell within any three-month period
only a number of shares that does not exceed the greater of the
following:
|
·
|
1% of the number of shares of our common stock then outstanding;
or
|
|
·
|
1% of the average weekly trading volume of our common stock during
the four calendar weeks preceding the filing by such person of a
notice on Form 144 with respect to the sale;
|
provided that, in each case, we are subject to the periodic
reporting requirements of the Exchange Act for at least 90 days
before the sale. Rule 144 trades must also comply with the manner
of sale, notice and other provisions of Rule 144, to the extent
applicable.
Rule 701
In general, Rule 701 allows a shareholder who purchased shares of
our capital stock pursuant to a written compensatory plan or
contract and who is not deemed to have been an affiliate of ours
during the immediately preceding 90 days to sell those shares in
reliance upon Rule 144, but without being required to comply with
the public information, holding period, volume limitation or notice
provisions of Rule 144. All holders of Rule 701 shares, however,
are required to wait until ninety (90) days after the date of this
prospectus before selling shares pursuant to Rule 701.
Lock-Up Agreements
Our executive officers, directors and our security
holder(s) of five percent (5%) or more of our securities have
agreed not to offer, sell, agree to sell, directly or indirectly,
or otherwise dispose of any shares of our common stock for a
lock-up period through August 30, 2023, subject to certain
exceptions, and we have agreed not to offer or sell any shares of
stock until September 1, 2023. See the "Underwriting"
section below for more information.
MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR
NON-U.S. HOLDERS OF OUR SECURITIES
The following is a summary of the material U.S. federal income and
estate tax consequences of the ownership and disposition of our
common stock that is being issued pursuant to this offering. This
summary is limited to Non-U.S. Holders (as defined below) that hold
our common stock as a capital asset (generally, property held for
investment) for U.S. federal income tax purposes. This summary does
not discuss all of the aspects of U.S. federal income and estate
taxation that may be relevant to a Non-U.S. Holder in light of the
Non-U.S. Holder's particular investment or other circumstances.
Accordingly, all prospective Non-U.S. Holders should consult their
own tax advisors with respect to the U.S. federal, state, local and
non-U.S. tax consequences of the ownership and disposition of our
common stock.
This summary is based on provisions of the Code, applicable U.S.
Treasury regulations and administrative and judicial
interpretations, all as in effect or in existence on the date of
this prospectus. Subsequent developments in U.S. federal income or
estate tax law, including changes in law or differing
interpretations, which may be applied retroactively, could alter
the U.S. federal income and estate tax consequences of owning and
disposing of our common stock as described in this summary. There
can be no assurance that the Internal Revenue Service, or IRS, will
not take a contrary position with respect to one or more of the tax
consequences described herein and we have not obtained, nor do we
intend to obtain, a ruling from the IRS with respect to the U.S.
federal income or estate tax consequences of the ownership or
disposition of our common stock.
As used in this summary, the term "Non-U.S. Holder" means a
beneficial owner of our common stock that is not, for U.S. federal
income tax purposes:
|
·
|
an individual who is a citizen or resident of the United
States;
|
|
·
|
a corporation (or other entity treated as a corporation) created or
organized in or under the laws of the United States, any state
thereof, or the District of Columbia;
|
|
·
|
an entity or arrangement treated as a partnership;
|
|
·
|
an estate whose income is includible in gross income for U.S.
federal income tax purposes regardless of its source; or
|
|
·
|
a trust, if (1) a U.S. court is able to exercise primary
supervision over the trust's administration and one or more "United
States persons" (within the meaning of the Code) has the authority
to control all of the trust's substantial decisions, or (2) the
trust has a valid election in effect under applicable U.S. Treasury
regulations to be treated as a United States person.
|
If an entity or arrangement treated as a partnership for U.S.
federal income tax purposes holds our common stock, the tax
treatment of a partner in such a partnership generally will depend
upon the status of the partner, the activities of the partnership
and certain determinations made at the partner level. Partnerships,
and partners in partnerships, that hold our common stock should
consult their own tax advisors as to the particular U.S. federal
income and estate tax consequences of owning and disposing of our
common stock that are applicable to them.
This summary does not consider any specific facts or circumstances
that may apply to a Non-U.S. Holder and does not address any
special tax rules that may apply to particular Non-U.S. Holders,
such as:
|
·
|
a Non-U.S. Holder that is a financial institution, insurance
company, tax-exempt organization, pension plan, broker, dealer or
trader in securities, dealer in currencies, U.S. expatriate,
controlled foreign corporation or passive foreign investment
company;
|
|
·
|
a Non-U.S. Holder holding our common stock as part of a conversion,
constructive sale, wash sale or other integrated transaction or a
hedge, straddle or synthetic security;
|
|
·
|
a Non-U.S. Holder that holds or receives our common stock pursuant
to the exercise of any employee stock option or otherwise as
compensation; or
|
|
·
|
a Non-U.S. Holder that at any time owns, directly, indirectly or
constructively, 5% or more of our outstanding common stock.
|
In addition, this summary does not address any U.S. state or local,
or non-U.S. or other tax consequences, or any U.S. federal income
or estate tax consequences for beneficial owners of a Non-U.S.
Holder, including shareholders of a controlled foreign corporation
or passive foreign investment company that holds our common
stock.
Each Non-U.S. Holder should consult its own tax advisor
regarding the U.S. federal, state, local and non-U.S. income and
other tax consequences of owning and disposing of our common
stock.
Distributions on Our Common Stock
We do not currently expect to pay any cash dividends on our common
stock. If we make distributions of cash or property (other than
certain pro rata distributions of our common stock) with respect to
our common stock, any such distributions generally will constitute
dividends for U.S. federal income tax purposes to the extent paid
from our current or accumulated earnings and profits, as determined
under U.S. federal income tax rules. If a distribution exceeds our
current and accumulated earnings and profits, the excess will be
treated as a nontaxable return of capital to the extent of the
Non-U.S. Holder's adjusted tax basis in our common stock and will
reduce (but not below zero) such Non-U.S. Holder's adjusted tax
basis in our common stock. Any remaining excess will be treated as
gain from a disposition of our common stock subject to the tax
treatment described below in "— Dispositions of Our Common
Stock."
Distributions on our common stock that are treated as dividends and
that are effectively connected with a Non-U.S. Holder's conduct of
a trade or business in the United States will be taxed on a net
income basis at the regular graduated rates and in the manner
applicable to United States persons. An exception may apply if the
Non-U.S. Holder is eligible for, and properly claims, the benefit
of an applicable income tax treaty and the dividends are not
attributable to a permanent establishment or fixed base maintained
by the Non-U.S. Holder in the United States. In such case, the
Non-U.S. Holder may be eligible for a lower rate under an
applicable income tax treaty between the United States and its
jurisdiction of tax residence. Dividends that are effectively
connected with a Non-U.S. Holder's conduct of a trade or business
in the United States will not be subject to the U.S. withholding
tax if the Non-U.S. Holder provides to the applicable withholding
agent a properly executed IRS Form W-8ECI (or other applicable
form) in accordance with the applicable certification and
disclosure requirements. A Non-U.S. Holder treated as a corporation
for U.S. federal income tax purposes may also be subject to a
"branch profits tax" at a 30% rate (unless the Non-U.S. Holder is
eligible for a lower rate under an applicable income tax treaty) on
the Non-U.S. Holder's earnings and profits (attributable to
dividends on our common stock or otherwise) that are effectively
connected with the Non-U.S. Holder's conduct of a trade or business
within the United States. The amount of taxable earnings and
profits is generally reduced by amounts reinvested in the
operations of the U.S. trade or business and increased by any
decline in its equity.
The certifications described above must be provided to the
applicable withholding agent prior to the payment of dividends and
must be updated periodically. A Non-U.S. Holder may obtain a refund
or credit of any excess amounts withheld by timely filing an
appropriate claim for a refund with the IRS. Non-U.S. Holders
should consult their own tax advisors regarding their eligibility
for benefits under any relevant income tax treaty and the manner of
claiming such benefits.
The foregoing discussion is subject to the discussions below under
"Backup Withholding and Information Reporting" and
"FATCA Withholding."
Dispositions of Our Common Stock
A Non-U.S. Holder generally will not be subject to U.S. federal
income tax (including U.S. withholding tax) on gain recognized on
any sale or other disposition of our common stock unless:
|
·
|
the gain is effectively connected with the Non-U.S. Holder's
conduct of a trade or business in the United States (and, if
required by an applicable income tax treaty, is attributable to a
permanent establishment or fixed base maintained by the Non-U.S.
Holder in the United States); in such case, the gain would be
subject to U.S. federal income tax on a net income basis at the
regular graduated rates and in the manner applicable to United
States persons (unless an applicable income tax treaty provides
otherwise) and, if the Non-U.S. Holder is treated as a corporation
for U.S. federal income tax purposes, the "branch profits tax"
described above may also apply;
|
|
·
|
the Non-U.S. Holder is an individual who is present in the United
States for 183 days or more in the taxable year of the disposition
and meets certain other requirements; in such case, except as
otherwise provided by an applicable income tax treaty, the gain,
which may be offset by certain U.S. source capital losses,
generally will be subject to a flat 30% U.S. federal income tax,
even if the Non-U.S. Holder is not treated as a resident of the
United States under the Code; or
|
|
·
|
we are or have been a "United States real property holding
corporation" for U.S. federal income tax purposes at any time
during the shorter of (i) the five-year period ending on the date
of disposition and (ii) the period that the Non-U.S. Holder held
our common stock.
|
Generally, a corporation is a "United States real property holding
corporation" if the fair market value of its "United States real
property interests" equals or exceeds 50% of the sum of the fair
market value of its worldwide real property interests plus its
other assets used or held for use in a trade or business. We
believe that we are not currently, and we do not anticipate
becoming in the future, a United States real property holding
corporation. However, because the determination of whether we are a
United States real property holding corporation is made from time
to time and depends on the relative fair market values of our
assets, there can be no assurance in this regard. If we were a
United States real property holding corporation, the tax relating
to disposition of stock in a United States real property holding
corporation generally will not apply to a Non-U.S. Holder whose
holdings, direct, indirect and constructive, constituted 5% or less
of our common stock at all times during the applicable period,
provided that our common stock are "regularly traded on an
established securities market" (as provided in applicable U.S.
Treasury regulations) at any time during the calendar year in which
the disposition occurs. However, no assurance can be provided that
our common stock will be regularly traded on an established
securities market for purposes of the rules described above.
Non-U.S. Holders should consult their own tax advisors regarding
any possible adverse U.S. federal income tax consequences to them
if we are, or were to become, a United States real property holding
corporation.
The foregoing discussion is subject to the discussions below under
"Backup Withholding and Information Reporting" and
"FATCA Withholding."
Federal Estate Tax
Any shares of our common stock that are owned (or treated as owned)
by an individual who is not a U.S. citizen or resident of the
United States (as specially defined for U.S. federal estate tax
purposes) at the time of death will be included in that
individual's gross estate for U.S. federal estate tax purposes,
unless an applicable estate tax or other treaty provides otherwise
and, therefore, may be subject to U.S. federal estate tax.
Backup Withholding and Information Reporting
Backup withholding (currently at a rate of 24%) may apply to
dividends paid by U.S. corporations in some circumstances, but will
not apply to payments of dividends on our common stock to a
Non-U.S. Holder if the Non-U.S. Holder provides to the applicable
withholding agent a properly executed IRS Form W-8BEN or W-8BEN-E
(or other applicable form) certifying under penalties of perjury
that the Non-U.S. Holder is not a United States person or is
otherwise entitled to an exemption. However, the applicable
withholding agent generally will be required to report to the IRS
(and to such Non-U.S. Holder) payments of dividends on our common
stock and the amount of U.S. federal income tax, if any, withheld
from those payments. In accordance with applicable treaties or
agreements, the IRS may provide copies of such information returns
to the tax authorities in the country in which the Non-U.S. Holder
resides.
The gross proceeds from sales or other dispositions of our common
stock may be subject, in certain circumstances discussed below, to
U.S. backup withholding and information reporting. If a Non-U.S.
Holder sells or otherwise disposes of any of our common stock
outside the United States through a non-U.S. office of a non-U.S.
broker and the disposition proceeds are paid to the Non-U.S. Holder
outside the United States, the U.S. backup withholding and
information reporting requirements generally will not apply to that
payment. However, U.S. information reporting, but not U.S. backup
withholding, will apply to a payment of disposition proceeds, even
if that payment is made outside the United States, if a Non-U.S.
Holder sells our common stock through a non-U.S. office of a broker
that is a United States person or has certain enumerated
connections with the United States, unless the broker has
documentary evidence in its files that the Non-U.S. Holder is not a
United States person and certain other conditions are met or the
Non-U.S. Holder otherwise qualifies for an exemption.
If a Non-U.S. Holder receives payments of the proceeds of a
disposition of our common stock to or through a U.S. office of a
broker, the payment will be subject to both U.S. backup withholding
and information reporting unless the Non-U.S. Holder provides to
the broker a properly executed IRS Form W-8BEN or W-8BEN-E (or
other applicable form) certifying under penalties of perjury that
the Non-U.S. Holder is not a United States person, or the Non-U.S.
Holder otherwise qualifies for an exemption.
Backup withholding is not an additional tax. Any amounts withheld
under the backup withholding rules may be credited against the
Non-U.S. Holder's U.S. federal income tax liability (which may
result in the Non-U.S. Holder being entitled to a refund), provided
that the required information is timely furnished to the IRS.
FATCA Withholding
The Foreign Account Tax Compliance Act and related Treasury
guidance (commonly referred to as FATCA) impose U.S. federal
withholding tax at a rate of 30% on payments to certain foreign
entities of (i) U.S.-source dividends (including dividends paid on
our common stock) and (ii) the gross proceeds from the sale or
other disposition of property that produces U.S.-source dividends
(including sales or other dispositions of our common stock). This
withholding tax applies to a foreign entity, whether acting as a
beneficial owner or an intermediary, unless such foreign entity
complies with (i) certain information reporting requirements
regarding its U.S. account holders and its U.S. owners and (ii)
certain withholding obligations regarding certain payments to its
account holders and certain other persons. Accordingly, the entity
through which a Non-U.S. Holder holds its common stock will affect
the determination of whether such withholding is required. While
withholding under FATCA would have also applied to payments of
gross proceeds from the sale or other disposition of our common
stock on or after January 1, 2019, U.S. Treasury regulations
proposed in December 2018 eliminate such withholding on payments of
gross proceeds entirely. Taxpayers generally may rely on these
proposed U.S. Treasury regulations until final U.S. Treasury
regulations are issued. Non-U.S. Holders are encouraged to consult
their tax advisors regarding FATCA.
UNDERWRITING
In connection with this offering, we expect to enter an
underwriting agreement with Boustead Securities, LLC and EF Hutton
(which we refer to as the Representatives), as representatives of
the underwriters named in this prospectus, with respect to the
common stock in this offering. Under the terms and subject to the
conditions contained in the underwriting agreement, the
Representatives will agree to purchase from us on a firm commitment
basis the respective number of shares of commons stock at the
public price less the underwriting discounts and commissions set
forth on the cover page of this prospectus, and each of the
underwriters has severally agreed to purchase, and we have agreed
to sell to the underwriters, at the public offering price per
shares less the underwriting discounts and commissions set forth on
the cover page of this prospectus, the number of shares of common
stock listed next to its name in the following table.
Underwriters
|
|
Number
of Shares
|
|
Boustead Securities, LLC
|
|
|
___
|
|
EF
Hutton, division of Benchmark Investments, Inc.
|
|
|
___
|
|
Total
|
|
|
|
|
The shares of common stock sold by the underwriters to the public
will initially be offered at the initial public offering price set
forth on the cover page of this prospectus. Any shares of common
stock sold by the underwriters to securities dealers may be sold at
a discount from the initial public offering price not to exceed $__
per share. If all of the shares are not sold at the initial
offering price, the Representatives may change the offering price
and the other selling terms. The Representatives have advised us
that the underwriters do not intend to make sales to discretionary
accounts. The underwriting agreement will provide that the
obligations of the underwriters to pay for and accept delivery of
the shares of common stock are subject to the passing upon certain
legal matters by counsel and certain conditions such as
confirmation of the accuracy of representations and warranties by
us about our financial condition and operations and other matters.
The obligation of the underwriters to purchase the shares of common
stock is conditioned upon our receiving approval to list the shares
of common stock on NASDAQ.
If
the underwriters sell more shares of common stock than the total
number set forth in the table above, we have granted to the
Representatives an option, exercisable one or more times in whole
or in part, not later than 45 days after the date of this
prospectus, to purchase up to 709,459 additional shares
of common stock at the public offering price less the underwriting
discounts and commissions set forth on the cover page of this
prospectus, constituting 15% of the total number of shares of
common stock to be offered in this offering (excluding shares
subject to this option). The Representatives may exercise this
option solely for the purpose of covering over-allotments in
connection with this offering. This offering is being conducted on
a firm commitment basis. Any shares of common stock issued or sold
under the option will be issued and sold on the same terms and
conditions as the other shares of common stock that are the subject
of this offering.
Discounts and Commissions; Expenses
The underwriting discounts and commissions are a cash fee equal to:
(i) seven percent (7%) of gross proceeds from the sale of
securities in this offering. We have been advised by the
Representatives that the underwriters propose to offer the common
stock to the public at the public offering price set forth on the
cover of this prospectus and to dealers at a price that represents
a concession not in excess of $__ per share under the public
offering price. After the offering, the Representatives may change
the public offering price and other selling terms.
The following table summarizes the public offering price and the
underwriting discounts and commissions payable to the underwriters
by us in connection with this offering (assuming both the exercise
in full and non-exercise of the over-allotment option that we have
granted to the Representatives):
|
|
Per Share
|
|
|
Total
Without
Over-
Allotment
Option
|
|
|
Total With
Full Over-
Allotment
Option
|
|
Assumed public offering price
|
|
$ |
|
|
|
$ |
5,250,000 |
|
|
$ |
6,037,500 |
|
Underwriting discounts and commissions (1)
|
|
$ |
|
|
|
$ |
367,500 |
|
|
$ |
422,625 |
|
Non-accountable expense allowance (1%)
|
|
$ |
|
|
|
$ |
52,500 |
|
|
$ |
60,375 |
|
Proceeds, before expenses, to us
|
|
$ |
|
|
|
$ |
4,830,000 |
|
|
$ |
5,554,500 |
|
(1)
|
Does not include (i) the warrant to purchase a number of shares of
common stock equal to 7% of the number of shares sold in the
offering, or (ii) amounts representing reimbursement of certain
out-of-pocket expenses, each as described below.
|
Representatives’ Warrants
We have agreed to issue to the Representatives (or their permitted
assignees) warrants to purchase up to a total number of shares of
common stock equal to 7% of the total number of shares of common
stock sold in this offering at an exercise price equal to 100% of
the public offering price of the common stock sold in this
offering. The Representatives’ warrants will be exercisable at any
time, and from time to time, in whole or in part, commencing from
the closing of the offering and expiring five (5) years from the
effectiveness of the offering, will have a cashless exercise
provision and will terminate on the fifth anniversary of the
effective date of the registration statement of which this
prospectus is a part. The Representatives’ warrants are not
exercisable or convertible for more than five years from the
commencement of sales of the public offering. The Representatives’
warrants also provide for customary anti-dilution provisions and
immediate "piggyback" registration rights with respect to the
registration of the shares underlying the warrants for a period of
seven years from commencement of sales of this offering. We have
registered the Representatives’ warrants and the shares underlying
the Representatives’ warrants in this offering.
The Representatives’ warrants and the underlying shares are deemed
to be compensation by FINRA, and therefore will be subject to a
180-day lock-up period pursuant to FINRA Rule 5110(e)(1). In
accordance with FINRA Rule 5110(e)(1), neither the Representatives’
warrants nor any of our common stock issued upon exercise of the
Representatives’ warrants may be sold, transferred, assigned,
pledged or hypothecated, or be the subject of any hedging, short
sale, derivative, put or call transaction that would result in the
effective economic disposition of such securities by any person,
for a period of 180 days immediately following commencement of sale
of this offering subject to certain exceptions permitted by FINRA
Rule 5110(e)(2).
We have agreed to pay the Representatives a non-accountable expense
allowance equal to 1% of the gross proceeds received at the closing
of this offering.
We have agreed to reimburse the Representatives for reasonable
out-of-pocket expenses incurred by the Representatives in
connection with this offering, regardless of whether the offering
is consummated, up to $55,000. The Representatives out-of-pocket
expenses include but are not limited to: (i) road show and travel
expenses, (ii) reasonable fees of Representatives’ legal counsel,
(iii) the cost of background check on our officers, directors and
major shareholders and due diligence expenses. Any such
out-of-pocket expenses described in the preceding sentence above
$5,000 shall have been pre-approved by the Company. Any advance
payments made by the Company to the Representatives to be applied
against their actual out-of-pocket accountable expenses will be
returned to us to the extent any portion of the advance is not
actually incurred, in accordance with FINRA Rule 5110(g)(4)(A).
In connection with the offering, the underwriters may purchase and
sell shares in the open market. Purchases and sales in the open
market may include short sales, purchases to cover short positions,
which may include purchases pursuant to the over-allotment option,
and stabilizing purchases.
|
●
|
Short sales involve secondary market sales by an underwriter of a
greater number of shares than they are required to purchase in the
offering.
|
|
|
|
|
●
|
“Covered” short sales are sales of shares in an amount up to the
number of shares represented by the over-allotment option.
|
|
|
|
|
●
|
“Naked” short sales are sales of shares in an amount in excess of
the number of shares represented by the over-allotment option.
|
|
|
|
|
●
|
Covering transactions involve purchases of shares either pursuant
to the over-allotment option or in the open market after the
distribution has been completed in order to cover short
positions.
|
|
|
|
|
●
|
To
close a naked short position, an underwriter must purchase shares
in the open market after the distribution has been completed. A
naked short position is more likely to be created if an underwriter
is concerned that there may be downward pressure on the price of
the shares in the open market after pricing that could adversely
affect investors who purchase in the offering.
|
|
|
|
|
●
|
To
close a covered short position, an underwriter must purchase shares
in the open market after the distribution has been completed or
must exercise the over-allotment option. In determining the source
of shares to close the covered short position, the underwriters
will consider, among other things, the price of shares available
for purchase in the open market as compared to the price at which
they may purchase shares through the over-allotment option.
|
|
|
|
|
●
|
Stabilizing transactions involve bids to purchase shares so long as
the stabilizing bids do not exceed a specified maximum.
|
Purchases to cover short positions and stabilizing purchases, as
well as other purchases by an underwriter for its own account, may
have the effect of preventing or retarding a decline in the market
price of the common stock. They may also cause the price of the
common stock to be higher than the price that would otherwise exist
in the open market in the absence of these transactions. The
underwriters may conduct these transactions in the over-the-counter
market or otherwise. If the underwriters commence any of these
transactions, they may discontinue them at any time.
Determination of Offering Price
In determining the initial public offering price, we and the
Representatives have considered a number of factors, including:
|
●
|
the information set forth in this prospectus and otherwise
available to the Representatives;
|
|
●
|
our prospects and the history and prospects for the industry in
which we compete;
|
|
●
|
an assessment of our management;
|
|
●
|
our prospects for future revenue and earnings;
|
|
●
|
the general condition of the securities markets at the time of this
offering;
|
|
●
|
the recent prices of, and demand for, shares sold by us prior to
this offering;
|
|
●
|
the recent market prices of, and demand for, publicly traded
securities of generally comparable companies; and
|
|
●
|
other factors deemed relevant by the Representatives and us.
|
The initial public offering price set forth on the cover page of
this preliminary prospectus is subject to change as a result of
market conditions and other factors. Neither we nor the
Representatives can assure investors that an active trading market
will develop for our common stock, or that the shares will trade in
the public market at or above the initial public offering
price.
Indemnification
We have agreed to indemnify the Representatives and the other
underwriters against certain liabilities, including liabilities
under the Securities Act. If we are unable to provide this
indemnification, we will contribute to payments that the
Representatives and the other underwriters may be required to make
for these liabilities.
Right of First Refusal
The Representatives have the right of first refusal for two (2)
years following the consummation of this offering or the
termination or expiration of the engagement with the
Representatives to act as financial advisor or to act as joint
financial advisor on at least equal economic terms on any public or
private financing (debt or equity), merger, business combination,
recapitalization or sale of some or all of our equity or our
assets, whether in conjunction with another broker-dealer or on the
Company’s own volition (collectively, “Future Services”). In the
event that we engage the Representatives to provide such Future
Services, the Representatives will be compensated consistent with
the engagement agreement with the Representatives, unless we
mutually agree otherwise. To the extent we are approached by a
third party to lead any public or private financing (debt or
equity), merger, business combination, recapitalization or sale of
some or all of our equity or assets, the Representatives will be
notified of the transaction and be granted the right to participate
in such transaction under any syndicate formed by such third
party.
No Sales of Similar Securities
We have agreed not to offer, issue, sell, contract to sell,
encumber, grant any option for the sale of or otherwise dispose of
any shares of our common stock or other securities convertible into
or exercisable or exchangeable for shares of common stock, or
modify the terms of any existing securities, whether in conjunction
with another broker-dealer or on the Company’s own volition until
September 1, 2023, without the prior written consent of the
Representatives.
Lock-Up Agreements
Our officers, directors, Green Globe International, Inc. (our
majority shareholder which owns approximately 78.7% of our common
stock as of December 31, 2022), and Nery’s Logistics, Inc. (which
owns approximately 6.0% of our common stock as of December 31,
2022) have each agreed not to offer, sell, agree to sell,
directly or indirectly, or otherwise dispose of any shares of our
common stock for a period through August 30, 2023 (the “Lock-Up
Period”), except that the shareholders are permitted to transfer
shares so long as (a) the transferee executes a lock-up agreement
for the balance of the Lock-Up Period, (b) the transfer is not a
disposition for value, (c) the transfer is not required to be
reported in any public report or filing with the SEC, and (d) the
shareholder does not voluntarily effect any public filing or report
regarding such transfer: (i) as a gift, (ii) to any immediate
family member, (iii) if the shareholder is a business entity that
transfers the shares to another entity that is an affiliate of the
shareholder or if the shareholder is a business entity that
transfers the shares to its limited partners, members or
stockholders, (iv) if the shareholder is a trust that transfers the
shares to a trust beneficiary, or (v) by will or other testamentary
document or intestate succession, or by operation of law pursuant
to a domestic order or in connection with a divorce settlement.
Additionally, our investors, who purchased in the aggregate
1,508,000 shares of our common stock in December of 2021 and April
of 2022 (and which shares constitute in the aggregate approximately
6.5% of our outstanding common stock as of December 31, 2022) (such
shareholders the “Pre-IPO Shareholders,” and such shares the
“Pre-IPO Shares”), have agreed not to sell, transfer or otherwise
dispose of any of the Pre-IPO Shares until the 180th day after August 30, 2022 (the
“Lock-Up Trigger Date”). Between 181 and 270 days after the Lock-Up
Trigger Date, each of the Pre-IPO Shareholders has agreed not to
sell, transfer or otherwise dispose of more than one-third of their
Pre-IPO Shares, subject to a maximum sale on any trading day of 3%
of the daily trading volume. Between 271 and 365 days
after the Lock-Up Trigger Date, each of the Pre-IPO Shareholders
has agreed not to sell, transfer or otherwise dispose of more than
one-third of their Pre-IPO Shares, subject to a maximum sale on any
trading day of 3% of the daily trading volume. After 365 days after
the Lock-Up Trigger Date, the Pre-IPO Shareholders can sell their
remaining Pre-IPO Shares without contractual restriction.
Additionally, commencing 90 days after the Lock-Up Trigger Date, if
the price per share of the Company’s common stock is at least 50%
higher than the price per share in this offering and trades at
least 100,000 shares daily, both for ten (10) consecutive trading
days, each Pre-IPO Shareholder may sell one-third of its shares
subject to a maximum sale on any trading day of 3% of the daily
volume; and if the Company’s common share price is at least 100%
higher than the price per share in this offering and trades at
least 100,000 shares daily, both for ten (10) consecutive trading
days, each Pre-IPO Shareholder may sell up to an additional
one-third of its shares subject to a maximum sale on any trading
day of 3% of the daily volume; and if the Company common share
price is at least 150% higher than the price per share in this
offering and trades at least 100,000 shares daily, both for ten
(10) consecutive trading days, each Pre-IPO Shareholder may sell an
additional one-third constituting a maximum total of all of its
shares subject to a maximum sale on any trading day of 3% of the
daily volume.
The underwriters of this offering may engage in stabilization
activities as described above. The Representatives may in its sole
discretion and at any time without notice release some or all of
the shares subject to lock-up agreements prior to the expiration of
the Lock-Up Period. When determining whether or not to release
shares from the lock-up agreements, the Representatives will
consider, among other factors, the security holder’s reasons for
requesting the release, the number of shares for which the release
is being requested and market conditions at the time.
Electronic Offer, Sale and Distribution of Common
Stock
A prospectus in electronic format may be made available on the
websites maintained by the Representatives. In addition, shares of
common stock may be sold by the Representatives to securities
dealers who resell our common stock to online brokerage account
holders. Other than the prospectus in electronic format, the
information on the Representatives’ website and any information
contained in any other website maintained by the Representatives is
not part of the prospectus or the registration statement of which
this prospectus forms a part, has not been approved and/or endorsed
by us or the Representatives in its capacity as Representatives and
should not be relied upon by investors.
Selling Restrictions
No action has been taken in any jurisdiction (except in the United
States) that would permit a public offering of our common stock, or
the possession, circulation or distribution of this prospectus or
any other material relating to us or our common stock, where action
for that purpose is required. Accordingly, our common stock may not
be offered or sold, directly or indirectly, and neither this
prospectus nor any other offering material or advertisements in
connection with our common stock may be distributed or published,
in or from any country or jurisdiction except in compliance with
any applicable rules and regulations of any such country or
jurisdiction.
Offer Restrictions Outside the United States
Other than in the United States, no action has been taken by us or
the underwriters that would permit a public offering of the
securities offered by this prospectus in any jurisdiction where
action for that purpose is required. The securities offered by this
prospectus may not be offered or sold, directly or indirectly, nor
may this prospectus or any other offering material or
advertisements in connection with the offer and sale of any such
securities be distributed or published in any jurisdiction, except
under circumstances that will result in compliance with the
applicable rules and regulations of that jurisdiction. Persons into
whose possession this prospectus comes are advised to inform
themselves about and to observe any restrictions relating to this
offering and the distribution of this prospectus. This prospectus
does not constitute an offer to sell or a solicitation of an offer
to buy any securities offered by this prospectus in any
jurisdiction in which such an offer or a solicitation is unlawful.
In particular, our common stock has not been qualified for
distribution by prospectus in Canada and may not be offered or sold
in Canada during the course of their distribution hereunder except
pursuant to a Canadian prospectus or prospectus exemption.
LEGAL MATTERS
Brunson Chandler & Jones, PLLC, has acted as our counsel in
connection with the preparation of this prospectus. The validity of
the securities offered, shares of common stock, and warrants
covered by this prospectus will be passed upon for us by Brunson
Chandler & Jones, PLLC. The underwriters have been represented
in connection with this offering by Bevilacqua PLLC.
EXPERTS
The financial statements of our company included in this
registration statement and have been audited by dbbmckennon, an
independent registered public accounting firm, as indicated in its
report with respect thereto, and have been so included in reliance
upon the report of such firm given on the authority of said firm as
experts in accounting and auditing.
WHERE YOU CAN FIND MORE
INFORMATION
We have filed a registration statement, of which this prospectus is
a part, on Form S-1 with the SEC relating to this offering. This
prospectus does not contain all of the information in the
registration statement and the exhibits included with the
registration statement. For further information pertaining to us
and the securities to be sold in this offering, you should refer to
the registration statement and its exhibits, portions of which have
been omitted as permitted by SEC rules and regulations. References
in this prospectus to any of our contracts, agreements or other
documents are not necessarily complete, and you should refer to the
exhibits attached to the registration statement for copies of the
actual contracts, agreements or documents. You may read and copy
the registration statement, the related exhibits and other material
we file with the SEC at the SEC’s public reference room in
Washington, D.C. at 100 F Street, Room 1580, N.E., Washington, D.C.
20549. You can also request copies of those documents, upon payment
of a duplicating fee, by writing to the SEC. Please call the SEC at
1-800-SEC-0330 for further information on the operation of the
public reference rooms. The SEC also maintains an internet site
that contains reports, proxy and information statements and other
information regarding issuers that file with the SEC. The website
address is http://www.sec.gov.
Upon the effectiveness of the registration statement, we will be
subject to the informational requirements of the Exchange Act, and,
in accordance with the Exchange Act, will file reports, proxy and
information statements and other information with the SEC. Such
annual, quarterly and special reports, proxy and information
statements and other information can be inspected and copied at the
locations set forth above. We also anticipate making these
documents publicly available, free of charge, on our website at
https://hempaccoinc.com/ as soon as reasonably practicable after
filing such documents with the SEC. Information on, or accessible
through, our website is not part of this prospectus.
HEMPACCO CO., INC.
(FORMERLY THE HEMPACCO CO., INC.)
INDEX TO CONSOLIDATED FINANCIAL
STATEMENTS
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
To the Board of Directors and
Stockholders of Hempacco Co., Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of
Hempacco Co., Inc. (the “Company”) as of December 31, 2021 and
2020, the related consolidated statements of operations,
stockholders’ equity, and cash flows, for the years then ended and
the related notes (collectively referred to as the “financial
statements”). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the
Company as of December 31, 2021 and 2020, and the results of its
operations and its cash flows for the years then ended, in
conformity with accounting principles generally accepted in the
United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on the
Company’s financial statements based on our audit. We are a public
accounting firm registered with the Public Company Accounting
Oversight Board (United States) (“PCAOB”) and are required to be
independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial
reporting. As part of our audit, we are required to obtain an
understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of
the Company’s internal control over financial reporting.
Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial
statements. Our audit also included evaluating the accounting
principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial
statements. We believe that our audit provides a reasonable basis
for our opinion.
Going Concern
The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in
Note 1 to the financial statements, the Company has suffered
recurring losses from operations and has used cash in operating
activities, which raises substantial doubt about its ability to
continue as a going concern. Management’s plans in regard to these
matters are also described in Note 1. The financial statements do
not include any adjustments that might result from the outcome of
this uncertainty.
Critical Audit Matters
The critical audit matter communicated below is a matter arising
from the current period audit of the financial statements that was
communicated or required to be communicated to the audit committee
and that: (1) relates to accounts or disclosures that are material
to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of
the critical audit matter does not alter in any way our opinion on
the financial statements, taken as a whole, and we are not, by
communicating the critical audit matter below, providing separate
opinions on the critical audit matter or on the accounts or
disclosures to which it relates.
Revenue Recognition
Description of the Matter:
As disclosed in Note 2 and 11, the Company recognizes revenue when
or as the Company satisfies a customer agreement performance
obligation by transferring control of a product or service to a
customer, in an amount that reflects the consideration the Company
expects to receive in exchange for those products or services. In
determining revenue recognition for certain customer agreements,
significant judgment was exercised by the Company, and included the
following: 1) An assessment of the products and services promised
in contracts or customer agreements, and the identification of a
performance obligation for each promise to transfer to the customer
a product or service that is distinct. 2) Determination of relative
standalone selling price for distinct performance obligations. 3)
The timing of product or service delivery for performance
obligations. Given these factors, the related audit effort in
evaluating management’s judgments in determining revenue
recognition for these customer agreements was extensive, which led
us to determine this as a critical audit matter
How We Addressed the Matter in our Audit:
Our principal audit procedures related to the Company’s revenue
recognition for these customer agreements included an evaluation of
the controls related to the identification of distinct performance
obligations and the determination of the timing of revenue
recognition. We also evaluated management’s significant accounting
policies related to certain customer agreements. In addition, we
selected customer agreements and performed the following
procedures: 1) Obtained and read the customer agreements or
contracts for each selected agreement. 2) Evaluated and tested
management’s identification of significant terms for completeness,
including the identification of distinct performance obligations.
3) Evaluated the appropriateness of management’s application of
their accounting principles, in their determination of revenue
recognition conclusions. 4) Tested he mathematical accuracy of
management’s calculations of revenue and the associated timing of
revenue recognized in the financial statements.
/s/ dbbmckennon
PCAOB #3501
We have served as the Company’s auditors since 2021
San Diego, California
March 23, 2022
Hempacco Co., Inc.
|
(Formerly The Hempacco Co., Inc.)
|
|
|
|
|
|
|
|
CONSOLIDATED BALANCE SHEETS
|
|
|
December 31,
2021
|
|
|
December 31,
2020
|
|
ASSETS
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
Cash
|
|
$ |
933,469 |
|
|
$ |
500 |
|
Accounts Receivable – Related Parties
|
|
|
137,297 |
|
|
|
5,587 |
|
Accounts Receivable
|
|
|
144,246 |
|
|
|
10,390 |
|
Less: Receivables Impairment Allowance
|
|
|
- |
|
|
|
(10,290 |
) |
Inventory at Cost Less Obsolescence Allowance
|
|
|
198,936 |
|
|
|
92,699 |
|
Deposits & Prepayments
|
|
|
703,690 |
|
|
|
2,576 |
|
Total Current Assets
|
|
|
2,117,638 |
|
|
|
101,462 |
|
|
|
|
|
|
|
|
|
|
Property and Equipment
|
|
|
|
|
|
|
|
|
Leasehold Improvements
|
|
|
12,431 |
|
|
|
12,431 |
|
Furniture, Fixtures & Equipment
|
|
|
5,147,693 |
|
|
|
5,067,730 |
|
Accumulated Depreciation
|
|
|
(161,353 |
) |
|
|
(74,852 |
) |
Total Property and Equipment
|
|
|
4,998,771 |
|
|
|
5,005,309 |
|
|
|
|
|
|
|
|
|
|
Other Assets
|
|
|
|
|
|
|
|
|
Operating Lease – Right of Use Asset
|
|
|
642,752 |
|
|
|
642,752 |
|
Right of Use Assets – Accumulated Amortization
|
|
|
(188,638 |
) |
|
|
(91,629 |
) |
Total Other Assets
|
|
|
454,114 |
|
|
|
551,123 |
|
|
|
|
|
|
|
|
|
|
Total Assets
|
|
$ |
7,570,523 |
|
|
$ |
5,657,894 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
Accounts Payable & Accrued Expenses
|
|
$ |
97,800 |
|
|
$ |
70,828 |
|
Accounts Payable – Related Parties
|
|
|
162,405 |
|
|
|
425,817 |
|
Accrued Interest on Long Term Notes
|
|
|
9,416 |
|
|
|
- |
|
Long Term Promissory Notes Payable
|
|
|
175,000 |
|
|
|
- |
|
Customer Pre-paid Invoices & Deferred Revenue
|
|
|
2,128,393 |
|
|
|
756,971 |
|
Loans Payable – Related Parties
|
|
|
9,600 |
|
|
|
26,600 |
|
Equipment Loan
|
|
|
1,482,681 |
|
|
|
1,469,535 |
|
Other Short-Term Loans
|
|
|
- |
|
|
|
85,000 |
|
Operating Lease – Right of Use Liability – Short Term Portion
|
|
|
102,969 |
|
|
|
97,010 |
|
Total Current Liabilities
|
|
|
4,168,264 |
|
|
|
2,931,761 |
|
|
|
|
|
|
|
|
|
|
Long Term Liabilities
|
|
|
|
|
|
|
|
|
Other Long-Term Loans
|
|
|
168,328 |
|
|
|
- |
|
Long Term Promissory Notes Payable
|
|
|
- |
|
|
|
11,500 |
|
Long Term Promissory Notes Payable – Related Parties
|
|
|
- |
|
|
|
25,000 |
|
Accrued Interest on Long Term Notes
|
|
|
- |
|
|
|
3,590 |
|
Right of Use Liability – Straight-Line Rent Rule – Deferred
Rent
|
|
|
15,126 |
|
|
|
9,362 |
|
Right of Use Liability – Long Term Portion
|
|
|
351,145 |
|
|
|
454,113 |
&n |